Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2021

The CB1 Receptor Positive Allosteric Modulator, ZCZ011,
Attenuates Naloxone-Precipitated Withdrawal Signs in
Oxycodone-Dependent Mice and Inhibits Small Intestinal Transit
in Mice
Julien Dodu
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Pharmacology Commons
© Julien Dodu

Downloaded from
https://scholarscompass.vcu.edu/etd/6846

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

© Julien Dodu
2021
All Rights Reserved

The CB1 Receptor Positive Allosteric Modulator, ZCZ011,
Attenuates Naloxone-Precipitated Withdrawal Signs in OxycodoneDependent Mice and Inhibits Small Intestinal Transit in Mice

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy
at Virginia Commonwealth University.

By
Julien C. Dodu
Bachelor of Science,
East Carolina University, 2016

Director: Dr. Aron H. Lichtman, Ph.D., Professor, Department of Pharmacology and Toxicology, and
Associate Dean of Research and Graduate Studies, Department of Medicinal Chemistry

Virginia Commonwealth University
Richmond, Virginia
December 2021

Acknowledgements
I first like to thank my advisor, Dr. Aron Lichtman. He has taught me several life-lessons I know
I will use for the rest of my life. His continued support, guidance, and expertise in and out of the lab has
taught me to critically think about the science I conducted and I have him to thank for making me the
scientist I am today. Even though we have had our roller coaster moments, I know I have become a
stronger individual for it, making me more resilient and flexible when things go wrong. I learned the true
importance of following the data when I had to pivot my project countless times and, in the end, I
established my work and learned to prioritize what needed to be done to accomplish everything I needed
to do in spite of having to deal with the COVID pandemic.
I would also like to thank my committee members, Dr. Steve Negus, Dr. Imad Damaj, Dr. John
Bigbee, and Dr. Egidio Del Fabbro for their incredible guidance, input, and suggestions during my time
as a graduate student.
I would also like to personally thank Dr. Hamid Akbarali for his invaluable knowledge and
expertise in teaching me everything I know about the gastrointestinal system. I would not have been able
to grasp the complexity of the GI system without you.
I also would like to thank Dr. William Dewey for being such an incredible inspiration for students
throughout the Pharmacology and Toxicology Department and for providing me the opportunity to
conduct my studies in this highly regarded Department. I would also like to thank Dr. Krista Scoggins and
Dr. Keith Shelton for your continued support as my advisors throughout my first few years of my Ph.D.
training.
And of course, a huge thank you goes out to all current and past lab mates I was honored to work
with. Dr. Lesly O’Brien, you were the first person I ever met in Richmond and from the lab and you
continue to inspire me to become a well-rounded scientist and overall kind person. I also want to say
thank you to Rebecca Moncayo and Aidan Jones for not only being an amazing people and always having
fun in lab, but also being willing to help me score my withdrawal videos with me. Mohammed, I can’t
believe that these 4.5 years have gone by so quickly because I remember like it was yesterday when you
first trained me on the tetrad procedure and the drug discrimination paradigm, I know you are going to do
incredible things during and after your Ph.D. training. I’d also like to thank Kennedy Goldsborough and
Kimmie Karin for being amazing friends and lab mates whenever I had my long days in the lab.
I also want to thank my family. My parents, Coca and George Dodu, thank you so much for the
continued support as I went through this stage of my life. Your love and support meant everything to me
and I don’t know what I’d do without you. Also, my sister, Alex Dodu, I thank you for being the best big
sister a little brother could ask for. Even though I got on your nerves when we were young, I love how
close we have become despite the long distance. Lastly, and certainly not least, Lauren Moncayo; thank
iii

you for everything. Thank you for being so supportive over these years and always being there when I
needed you. I can’t wait to see what’s next for us in our lives together.

iv

Table of Contents
Acknowledgements .................................................................................................................................... iii
List of Figures............................................................................................................................................. ix
List of Tables .............................................................................................................................................. xi
List of Abbreviations ............................................................................................................................... xiii
Abstract..................................................................................................................................................... xvi
1. Chapter 1: Introduction ....................................................................................................................... 1
1.1.

Introduction to Cannabinoids....................................................................................................... 1

1.1.1.

Medical history of Cannabis ............................................................................................................ 1

1.1.2.

FDA-approved Cannabis-derived and Cannabis-related compounds ............................................. 1

1.1.3.

Cannabis use disorder ...................................................................................................................... 2

1.2.

The endogenous cannabinoid system (ECS) ............................................................................... 3

1.2.1.

Cannabinoid receptors ..................................................................................................................... 3

1.2.2.

Endocannabinoids and their regulatory enzymes............................................................................. 4

1.3.

The ECS regulates homeostatic functions ................................................................................... 6

1.3.1.

Modulation of CB1 receptors in the gastrointestinal tract ................................................................ 7

1.4.

CB1 receptor effects in pathological models from pre-clinical research ................................. 10

1.4.1.

Pre-clinical effects of ∆9-THC and synthetic cannabinoids in pathological models...................... 10

1.4.2.

Pre-clinical effects of inhibiting MAGL and FAAH in pathological models ................................ 15

1.5.

CB1 receptor allosteric modulation ............................................................................................ 16

1.5.1.

Definition and types of allosteric modulators ................................................................................ 16

1.5.2.

Identifying and quantifying allosteric modulators ......................................................................... 16

1.5.3.

Therapeutic potential of allosteric modulators............................................................................... 18

1.5.4.

CB1 receptor NAMs and PAMs ..................................................................................................... 19

1.5.5.

Pre-clinical effects of CB1 receptor PAMs .................................................................................... 20

1.6.

Natural opiates and opioid receptors ......................................................................................... 25

v

1.7.

Opioid use disorder ...................................................................................................................... 26

1.8.

Opioid tolerance and withdrawal in humans ............................................................................ 27

1.8.1.

Opioid withdrawal symptoms in humans....................................................................................... 28

1.8.2.

Treatments for opioid withdrawal symptoms ................................................................................ 28

1.9.

Neuroadaptive changes of opioid tolerance and withdrawal in rodent models...................... 31

1.10.

Opioid withdrawal in rodent models.......................................................................................... 34

1.11.

Targeting the endocannabinoid system to ameliorate opioid withdrawal signs in rodents .. 35

1.12.

Hypothesis and Rationale ............................................................................................................ 41

1.12.1. Overall Hypothesis......................................................................................................................... 41
1.12.2. Objectives ...................................................................................................................................... 41
1.12.3. Rationale ........................................................................................................................................ 41
2. Chapter 2: The CB1 Receptor Positive Allosteric Modulator, ZCZ011, Attenuates NaloxonePrecipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice...................................... 43
2.1.

Introduction .................................................................................................................................. 43

2.2.

Methods......................................................................................................................................... 45

2.2.1.

Animals .......................................................................................................................................... 45

2.2.2.

Drugs.............................................................................................................................................. 46

2.2.3.

Naloxone-precipitated oxycodone withdrawal model ................................................................... 47

2.2.4.

Treatment schedule for experiments .............................................................................................. 48

2.2.5.

Statistical Analyses ........................................................................................................................ 49

2.3.

Results ........................................................................................................................................... 50

2.3.1.

Naloxone precipitates withdrawal signs in oxycodone-dependent male and female mice ............ 50

2.3.2.

Withdrawal scoring between observers ......................................................................................... 53

2.3.3.

The CB1 receptor PAM, ZCZ011, attenuates naloxone-precipitated withdrawal signs in
oxycodone-dependent male and female mice without affecting saline-treated mice..................... 53

vi

2.3.4.

Acute oxycodone administration dose-dependently attenuates naloxone-precipitated withdrawal
signs in oxycodone-dependent male and female mice ................................................................... 58

2.3.5.

ZCZ011 dose-dependently attenuates naloxone-precipitated withdrawal signs in oxycodonedependent male and female mice ................................................................................................... 59

2.3.6.

Rimonabant, not SR144528, reverses the anti-withdrawal effects of ZCZ011 ............................. 67

2.3.7.

The anti-withdrawal effects of ZCZ011 are absent in CB1 (-/-) mice............................................ 67

2.4.

Discussion .................................................................................................................................... 77

3. Chapter 3: The CB1 Receptor Positive Allosteric Modulator, ZCZ011, Inhibits Small Intestinal
Transit in Oxycodone-Dependent Mice Undergoing Precipitated Withdrawal and in Naïve Mice
.............................................................................................................................................................. 82
3.1.

Introduction .................................................................................................................................. 82

3.2.

Methods......................................................................................................................................... 84

3.2.1.

Animals .......................................................................................................................................... 84

3.2.2.

Drugs.............................................................................................................................................. 85

3.2.3.

Measuring small intestinal transit in mice ..................................................................................... 85

3.2.4.

Modified naloxone-precipitated oxycodone withdrawal model .................................................... 86

3.2.5.

Treatment schedule for experiments .............................................................................................. 87

3.2.6.

Statistical Analyses ....................................................................................................................... 89

3.3.

Results ........................................................................................................................................... 90

3.3.1.

Naloxone enhances small intestinal transit and precipitates fecal output and diarrhea in
oxycodone-dependent male and female mice ................................................................................ 90

3.3.2.

Withdrawal scoring between observers ......................................................................................... 93

3.3.3.

The CB1 receptor PAM, ZCZ011, inhibits naloxone-enhanced small intestinal transit in salinetreated and oxycodone-dependent male and female mice.............................................................. 93

3.3.4.

ZCZ011 dose-dependently inhibits naloxone-enhanced small intestinal transit in oxycodonedependent mice .............................................................................................................................. 97
vii

3.3.5.

Rimonabant dose-dependently enhances small intestinal transit in naïve mice............................. 97

3.3.6.

The inhibition of naloxone-enhanced small intestinal transit and naloxone-precipitated diarrhea
by ZCZ011 is mediated by CB1, not CB2, receptors .................................................................... 103

3.3.7.

The inhibition of naloxone-enhanced small intestinal transit by ZCZ011 in oxycodone-dependent
mice requires CB1 receptor activation ......................................................................................... 104

3.3.8.

ZCZ011 inhibits small intestinal transit in saline-treated and oxycodone-dependent mice in the
absence of naloxone ..................................................................................................................... 109

3.3.9.

The inhibition of small intestinal transit by ZCZ011 was absent in naïve CB1 (-/-) mice ........... 112

3.3.10. The inhibition of small intestinal transit by ZCZ011 undergoes tolerance following repeated
administration .............................................................................................................................. 115
3.4.

Discussion ................................................................................................................................... 119

4. Chapter 4: Discussion ...................................................................................................................... 126
4.1.

Summary..................................................................................................................................... 126

4.2.

Anti-weight loss mechanisms of ZCZ011 ................................................................................ 128

4.3.

Anti-transit and anti-diarrheal mechanisms of ZCZ011........................................................ 130

4.3.1.

Possible peripheral mechanisms of anti-diarrheal and anti-transit effects ................................... 130

4.3.2.

Possible central mechanisms of anti-diarrheal and anti-transit effects ........................................ 135

4.4.

Sex differences in models of opioid dependence ...................................................................... 139

4.5.

Advantages of CB1 receptor positive allosteric modulation .................................................. 139

4.6.

Implications of CB1 receptor positive allosteric modulation in other models of developing

diarrhea and gastrointestinal disorders and diseases .......................................................................... 141
4.7.

Overall conclusions and future directions ............................................................................... 142

5. References ......................................................................................................................................... 144

viii

List of Figures
Figure 1. Naloxone (1 mg/kg s.c.) precipitates withdrawal signs in oxycodone-dependent male and female
mice. ............................................................................................................................................................ 51
Figure 2. Two observers blinded to treatment conditions produced high inter-rater reliability for jumps,
paw flutters, and head shakes. .................................................................................................................... 54
Figure 3. The CB1 receptor PAM, ZCZ011 (40 mg/kg i.p.), attenuates naloxone-precipitated withdrawal
signs in oxycodone-dependent male and female mice. ............................................................................... 55
Figure 4. Acute oxycodone (17-75 mg/kg s.c.) dose-dependently attenuates naloxone-precipitated
withdrawal signs in oxycodone-dependent male and female mice. ............................................................ 60
Figure 5. ZCZ011 (5-40 mg/kg i.p.) dose-dependently attenuates naloxone-precipitated withdrawal signs
in oxycodone-dependent male and female mice. ........................................................................................ 63
Figure 6. Rimonabant (SR1; 3mg/kg i.p.), but not SR144528 (SR2; 3 mg/kg i.p.), reversed the antiwithdrawal effects of ZCZ011 (40 mg/kg i.p.) in oxycodone-dependent male and female mice undergoing
naloxone-precipitated withdrawal. .............................................................................................................. 69
Figure 7. The anti-withdrawal effects of ZCZ011 (40 mg/kg i.p.) were absent in oxycodone-dependent
male and female CB1 (-/-) mice undergoing naloxone-precipitated withdrawal......................................... 73
Figure 8. Naloxone (1 mg/kg s.c.) enhances small intestinal transit and precipitates fecal output and
diarrhea in oxycodone-dependent male and female mice. .......................................................................... 91
Figure 9. Two trained observers that were blind to treatment conditions displayed high inter-rater
reliability for naloxone-precipitated fecal output........................................................................................ 94
Figure 10. The CB1 receptor PAM, ZCZ011 (40 mg/kg i.p.), inhibits small intestinal transit in salinetreated and oxycodone-dependent male and female mice and attenuates naloxone-precipitated fecal output
and diarrhea in oxycodone-dependent male and female mice. ................................................................... 95
Figure 11. ZCZ011 inhibits naloxone-enhanced small intestinal transit and attenuates naloxoneprecipitated fecal output and diarrhea in oxycodone-dependent male and female mice in a dose-dependent
manner. ....................................................................................................................................................... 99
ix

Figure 12. The CB1 inverse agonist/antagonist, rimonabant, dose-dependently enhances small intestinal
transit in naïve male and female mice. ...................................................................................................... 101
Figure 13. A subthreshold dose of rimonabant (0.3 mg/kg i.p.), but not SR144528 (3 mg/kg i.p.), reversed
the inhibition of ZCZ011 (40 mg/kg i.p.) on naloxone-enhanced small intestinal transit and naloxoneprecipitated diarrhea in oxycodone-dependent male and female mice. .................................................... 105
Figure 14. The inhibition of ZCZ011 (40 mg/kg i.p.) on naloxone-enhanced small intestinal transit and
the attenuation on naloxone-precipitated diarrhea was absent in CB1 (-/-) oxycodone-dependent male and
female mice. .............................................................................................................................................. 107
Figure 15. ZCZ011 (40 mg/kg i.p.) inhibits small intestinal transit in saline-treated and oxycodonedependent male and female mice in the absence of naloxone administration. ......................................... 110
Figure 16. The inhibition of small intestinal transit by ZCZ011 (40 mg/kg i.p.) was absent in CB1 (-/-)
naïve male and female mice. ..................................................................................................................... 113
Figure 17. The inhibition of small intestinal transit by ZCZ011 (40 mg/kg i.p.) in naïve male and female
mice undergoes tolerance following repeated administration. .................................................................. 116
Figure 18. Potential anti-transit and anti-diarrheal mechanism of action of the CB1 PAM, ZCZ011 in the
small intestine ........................................................................................................................................... 138

x

List of Tables
Table 1. In vitro effects of CB1 receptor positive allosteric modulators in radioligand binding assays ..... 22
Table 2. In vitro effects of CB1 receptor positive allosteric modulators in functional assays .................... 23
Table 3. Effects of cannabinoids targeting the CB1 receptor on precipitated-withdrawal in opioiddependent animals....................................................................................................................................... 38
Table 4. Summary of statistical results from Fisher exact tests and two-way ANOVA analyses for Figure
3 ................................................................................................................................................................. 57
Table 5. Summary of statistical results from Fisher exact tests and two-way ANOVA analyses for Figure
4 .................................................................................................................................................................. 62
Table 6. Summary of statistical results from Fisher exact tests and two-way ANOVA analyses for Figure
5 .................................................................................................................................................................. 65
Table 7. Summary of statistical results from Fisher exact tests and three-way ANOVA analyses for Figure
6 .................................................................................................................................................................. 71
Table 8. Summary of statistical results from Fisher exact tests and three-way ANOVA analyses for Figure
7 .................................................................................................................................................................. 75
Table 9. Summary of statistical results from Fisher exact tests and three-way ANOVA analyses for Figure
10 ................................................................................................................................................................ 96
Table 10. Summary of statistical results from Fisher exact tests and two-way ANOVA analyses for Figure
11 .............................................................................................................................................................. 100
Table 11. Summary of statistical results from two-way ANOVA analyses for Figure 12........................ 102
Table 12. Summary of statistical results from Fisher exact tests and three-way ANOVA analyses for
Figure 13 ................................................................................................................................................... 106
Table 13. Summary of statistical results from Fisher exact tests and two-way ANOVA analyses for Figure
14 .............................................................................................................................................................. 108
Table 14. Summary of statistical results from two-way ANOVA analyses for Figure 15........................ 111
Table 15. Summary of statistical results from two-way ANOVA analyses for Figure 16........................ 114
xi

Table 16. Summary of statistical results from two-way ANOVA analyses for Figure 17........................ 118

xii

List of Abbreviations
2-AG

2-arachidonoyl glycerol

AA

Arachidonic Acid

ABHD

Alpha/beta hydrolase

ACh

Acetylcholine

AEA

Anandamide

ANOVA

Analysis of variance

cAMP

Cyclic adenosine monophosphate

CB1

Cannabinoid receptor, subtype 1

CB2

Cannabinoid receptor, subtype 2

CPA

Conditioned Place Aversion

CPP

Conditioned Place Preference

CP55,940

5-(1,1-Dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol

CREB

cAMP response element binding protein

DAGL

Diacylglycerol lipase

DMV

Dorsal motor nucleus of the vagus

DOR

∂ (delta) opioid receptor

DSM-V

Diagnostic and statistical manual of mental disorders, 5th edition

ECS

Endogenous cannabinoid system

Emax

Maximum possible effect of an agonist

FAAH

Fatty acid amide hydrolase

GABA

Gamma-aminobutyric acid

GAT211

3-(2-nitro-1-phenylethyl)-2-phenyl-1H-indole

GAT228

R-(+)-3-(2-Nitro-1-phenylethyl)-2-phenyl-1H-indole

GAT229

S-(-)-3-(2-Nitro-1-phenylethyl)-2-phenyl-1H-indole

xiii

G-protein

Guanine nucleotide binding protein

Gi

cAMP inhibitory G-protein

GI

Gastrointestinal

GRK

G-protein receptor kinase

i.c.v.

Intracerebroventricular

i.p.

Intraperitoneal

JZL184

4-nitrophenyl-4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl) piperidine1carboxylate

KOR

κ (kappa) opioid receptor

LC

Locus coeruleus

MAGL

Monoacylglycerol lipase

MAPK

Mitogen activated protein kinase

MJN110

2,5-dioxopyrrolidin-1-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate

MHb

Medial habenula

MOR

µ (mu) opioid receptor

NAc

Nucleus accumbens

NAPE-PLD

N-acyl phosphatidylethanolamine phospholipase D

NTS

Nucleus tractus solitarii

PAG

Periaqueductal grey

PF-3845

N-(pyridin-3-yl)-4-(3-(5-(trifluoromethyl)pyridin-2-yloxy)benzyl)
piperdine-1-carboxamide

p.o.

Per os, oral administration

POMC

Proopiomelanocortin

SAMHSA

Substance Abuse and Mental Health Services Administration

Sal

Saline (0.9% NaCl)

xiv

SA-57

2-(Methylamino)-2-oxoethyl 4-(4-chlorophenethyl)piperidine-1Carboxylate

s.c.

Subcutaneous

SR1

Rimonabant, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4methyl-1H-pyrazole-3-carboxamide HCl

SR2

SR144528, N-[(1S)-endo-1,3,3,-trimethylbicyclo[2.2.1]heptan-2-yl]-5-(4-chloro3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide

THC

Δ9-tetrahydrocannabinol

VTA

Ventral tegmental area

WIN55,212-2

(R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone

ZCZ011

6-methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole

xv

Abstract

The CB1 Receptor Positive Allosteric Modulator, ZCZ011, Attenuates Naloxone-Precipitated
Withdrawal Signs in Oxycodone-Dependent Mice and Inhibits Small Intestinal Transit in Mice
By Julien C. Dodu
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy
at Virginia Commonwealth University.
Virginia Commonwealth University, 2021.
Director: Dr. Aron H. Lichtman, Ph.D., Professor, Department of Pharmacology and Toxicology, and
Associate Dean of Research and Graduate Studies, Department of Medicinal Chemistry

The endogenous cannabinoid system tightly regulates a myriad of physiological and
pathophysiological functions. Effects of cannabinoids in ameliorating opioid withdrawal signs has been
known for decades. Naloxone precipitates several withdrawal signs (e.g., diarrhea, weight loss, jumps,
paw flutters, and head shakes) in opioid dependent rodents. ∆9-tetrahydrocannabinol (THC) has been
shown to ameliorate opioid withdrawal in mice through the activation of cannabinoid type-1 (CB1)
receptors. Inhibition of the endocannabinoid degradative enzymes also attenuates these withdrawal signs
(i.e., diarrhea, weight loss, jumps, paw flutters, and head shakes) in opioid-dependent mice. Specifically,
inhibition of fatty acid amide hydrolase (FAAH), the primary metabolic enzyme for the endocannabinoid
N-arachidonoylethanolamide (AEA; anandamide), or inhibition of monoacylglycerol lipase (MAGL), the
primary degradative metabolic enzyme for the endocannabinoid 2-arachidonoylglycerol (2-AG), reduces
opioid withdrawal in mice. Notably, FAAH inhibition attenuates a subset of withdrawal signs (i.e.,
jumping and paw fluttering) but not diarrhea or weight loss, whereas full MAGL inhibition completely
reduces withdrawal signs in mice. MAGL inhibition also produces similar acute cannabimimetic side
effects as THC as well as cannabinoid dependence following repeated administration. Additionally, the
combination of minimal MAGL inhibition with maximal FAAH inhibition results in a greater reduction
xvi

of withdrawal signs than inhibiting each enzyme alone; however, mice trained in the drug discrimination
paradigm exhibited full discrimination of a dual FAAH-MAGL inhibitor, SA-57, where the CB1 receptor
agonist, CP55,940, fully substituted for SA-57 suggesting intrinsic subjective effects to a direct CB1
receptor orthosteric agonist. Thus, a selective approach targeting the CB1 receptor without
cannabimimetic side effects is needed. CB1 receptor positive allosteric modulators (PAMs) target and
bind to a topographically distinct site, i.e., an allosteric site, that is less conserved than the prototypical
orthosteric site where THC, other synthetic cannabinoids (i.e., CP55,940), and the endocannabinoids, 2AG and AEA, readily bind and elicit a conformational change that results in enhanced efficacy and
potency of CB1 receptor orthosteric ligands when bound to CB1 receptors simultaneously. This alternative
approach of enhancing CB1 receptor activation has promising therapeutic potential in rodent models by
eliciting antinociceptive effects in pain models and anti-withdrawal effects in THC-dependent mice
without producing acute cannabimimetic effects (i.e., impaired locomotion, catalepsy, or hypothermia), or
antinociceptive tolerance or cannabinoid dependence following repeated administration. Furthermore, the
CB1 receptor PAM, ZCZ011, does not substitute for the synthetic cannabinoid, CP55,940, in C57BL/6J
mice or AEA in FAAH (-/-) mice in the drug discrimination paradigm. Therefore, the objectives of this
dissertation are to (1) assess the efficacy of the CB1 receptor PAM, ZCZ011, to reduce withdrawal signs
in opioid dependent male and female mice, (2) identify complementary dependent measures that reflect
enhanced transit effects associated with the severe withdrawal sign of diarrhea, and (3) determine whether
the anti-diarrheal effect of ZCZ011 ameliorates these processes of enhanced transit during opioid
withdrawal through CB1 or CB2 receptors. We found that ZCZ011 fully attenuates a subset of naloxoneprecipitated withdrawal signs, i.e., diarrhea and weight loss, in oxycodone-dependent male and female
mice through the activation of CB1, not CB2, receptors. Moreover, ZCZ011 partially attenuates paw
flutters and head shakes, while no effect on jumping was observed. Additionally, we determined that
when an oral gavage of a non-absorbable charcoal solution was administered before naloxone in
oxycodone-dependent mice, there was a profound enhancement of small intestinal transit during
naloxone-precipitated withdrawal. ZCZ011 inhibits transit in oxycodone-dependent mice undergoing
xvii

withdrawal. Subsequent studies demonstrated that, indeed, the CB1, not CB2, receptor is required for this
inhibition of naloxone-enhanced small intestinal transit. Furthermore, an unforeseen finding revealed that
ZCZ011 reduces transit in non-dependent mice and merited additional experiments to (1) discern whether
CB1 receptors mediate this effect and (2) whether the effect undergoes tolerance following repeated
administration. These studies found that ZCZ011 inhibits small intestinal transit by activating CB1
receptors and this anti-transit effect undergoes tolerance after six days of repeated administration of
ZCZ011 twice a day. These studies suggest that the CB1 receptor PAM, ZCZ011, may be an alternative
treatment for withdrawal-induced diarrhea; however, it is limited due to its inhibition of small intestinal in
non-dependent mice. Considering the inhibitory transit effects of ZCZ011 underwent tolerance, further
research is needed to determine whether maintained anti-withdrawal effects of ZCZ011 under conditions
of opioid withdrawal remain or dissipate.

xviii

Chapter 1: Introduction
1.1. Introduction to Cannabinoids
1.1.1.

Medical history of Cannabis
Archeological evidence for the medicinal and ritualistic uses of Cannabis dates 10,000-2,000

years ago in early Japanese, Chinese, and Indian culture (Bonini et al., 2018; Pisanti and Bifulco, 2019).
In the 19th century, William Brooke O’Shaughnessy investigated the pharmacological and toxic properties
of Cannabis and used it to treat tetanus, rabies, and other convulsive diseases (O’Shaughnessy, 1843). In
1851, the third edition of the United States Pharmacopoeia stated Cannabis had uses as an analgesic,
anticonvulsant, and hypnotic agent (Russo, 2007). In 1889, Edward Birch published in the Lancet that a
tincture extract from Cannabis sativa was able to treat opioid abstinence such as lack of appetite,
anorexia, disordered bowels and conscious delusions in a middle-aged man (Birch, 1889). It was only
until 1940 when Roger Adams isolated the first constituent from Cannabis, commonly known today as
cannabidiol (CBD), where research on the pharmacological properties of Cannabis began to be explored
(Adams et al., 1940). After Raphael Mechoulam confirmed the structure of CBD in 1963 (Mechoulam
and Shvo, 1963) he and his team extracted and isolated the primary compound responsible for Cannabis’s
psychoactive activity, ∆9-tetrahydrocannabinol (THC) (Gaoni and Mechoulam, 1964). From this point
forward exploration into much of the pharmacological properties of the Cannabis plant eventually led to
several FDA-approved medications for a variety of diseases and disorders.
1.1.2.

FDA-approved Cannabis-derived and Cannabis-related compounds
Currently the United States has approved three Cannabis-related compounds and one Cannabis-

derived compound. In 1985, the FDA approved the first Cannabis-related compound, Marinol® (synthetic
∆9-THC, also known as dronabinol), which is dissolved in sesame oil and encapsulated in soft gelatin
capsules for the treatment of nausea and vomiting associated with chemotherapy and anorexia associated
with HIV/AIDS. In 2006, Cesamet®, also known as nabilone, which is a synthetic analog of ∆9-THC, the
FDA approved it for the same indications as Marinol®. In 2016, Syndros® was FDA-approved as the first
liquid formulation of dronabinol as an alternative to oral capsules and again had the same indications as
1

Cesamet® and Marinol®. In 2018, the first Cannabis-derived compound, Epidiolex® (plant-derived
cannbidiol), was FDA-approved to treat seizures associated with Lennox-Gastaut syndrome, Dravet
syndrome, and tuberous sclerosis complex in patients one year of age or older and comes as an oral
solution. Notably, in Canada and Europe, Sativex® was approved in 2010 as the first Cannabis-derived
compound that contains equal ratios of THC and CBD (1:1) to manage cancer pain and neuropathic pain
associated with multiple sclerosis. While several non-approved uses of Cannabis are also known, such as
managing chronic pain, treating abuse disorders, managing sleep disturbances, and producing anxiolysis,
prolonged use of Cannabis and related cannabinoid compounds can produce dependency and a
withdrawal syndrome following cessation of use thereby limiting its clinical use.
1.1.3.

Cannabis use disorder
According to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5)

(American Psychiatric Association, 2013) the criteria for Cannabis use disorder (CUD) is classified as
having at least two of the following symptoms, accompanied by significant impairment of functioning
and distress, within a one year period: (1) continuing to use Cannabis over a longer period than intended
and/or taking larger amounts; (2) repeated failed attempts to discontinue or reduce the amount of
Cannabis consumed; (3) reallocating much of your time to acquire, use, or recover from the effects of
Cannabis; (4) cravings or desires to use Cannabis that can include intrusive thoughts and images or
olfactory perceptions from the smell of Cannabis; (5) recurrent Cannabis use despite failing to fulfill
obligations at work, school, or home; (6) continued Cannabis use despite persistent social or interpersonal
problems caused or exacerbated by the effects of Cannabis; (7) recurrent Cannabis use while in
hazardous situations such as operating a motor vehicle; (8) continued Cannabis use despite being aware
of physical or psychological problems, such as a chronic cough and lack of motivation; (9) tolerance; and
(10) withdrawal. Tolerance is defined as either having a need for markedly increased amounts of
Cannabis to achieve intoxication or the desired effect, or a markedly diminished effect with continued use
of the same amount of Cannabis. Withdrawal manifests from chronic Cannabis use where cessation of
use results in behavioral, physiological, and psychological symptoms, including anger, aggression,
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irritability, anxiety and nervousness, decreased appetite or weight loss, and sleep difficulties with strange
dreams (Bonnet and Preuss, 2017). The severity of CUD is noted as mild (2-3 symptoms), moderate (4-5
symptoms), or severe (6 or more symptoms).
Currently, no medications have been approved for the treatment of CUD or withdrawal symptoms
(Kesner and Lovinger, 2021), but several medications have been studied in humans to alleviate Cannabis
withdrawal such as zolpidem (GABA-A receptor agonist) (Vandrey et al., 2011), mirtazapine
(norepinephrine and serotonin reuptake inhibitor) (Haney et al., 2010), gabapentin (blocks Na+ channels
and is a GABA-A receptor modulator) (Mason et al., 2012), dronabinol (Haney et al., 2004; Budney et
al., 2007; Levin et al., 2011), rimonabant (the selective cannabinoid receptor 1 antagonist) (Huestis et al.,
2007), and PF-04457845 (a selective fatty acid amide hydrolase inhibitor) (D’Souza et al., 2019) [for a
comprehensive review see Brezing and Levin (2018)]. Although there are several limitations of using
Cannabis as a medication due to its euphoric effects, abuse liability, and a risk of dependence, it also led
to the discovery of the endogenous cannabinoid system, which provides a plethora of therapeutic targets
to treat diseases and disorders.
1.2. The endogenous cannabinoid system (ECS)
1.2.1.

Cannabinoid receptors
The existence of cannabinoid receptors was first suggested when THC and other cannabinoids

were shown to inhibit adenylyl cyclase activity (Howlett and Fleming, 1984) and demonstrate specific
binding of the highly potent bicyclic cannabinoid compound, [3H]CP55,940, in rat brain (Devane et al.,
1988). Subsequently, two subtypes of cannabinoid receptors, cannabinoid 1 (CB1; Matsuda et al., 1990)
and cannabinoid 2 (CB2; (Munro et al., 1993) receptors, were characterized and cloned in the rat brain
and immune cells, such as macrophages in the rat spleen, respectively. Both CB1 and CB2 receptors were
determined to be Gi/o-protein coupled receptors (GPCRs) and upon activation will lead to (1) inhibition of
adenylyl cyclase which leads to decreased levels of cAMP (Howlett et al., 1990) and L-, N-, and P/Q-type
voltage-gated Ca2+ channels which inhibits synaptic vesicle fusion to the nerve terminal resulting in
reduced neurotransmitter release (Caulfield and Brown, 1992; Mackie and Hille, 1992; Twitchell et al.,
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1997); and (2) activation of inwardly-rectifying K+ channels via the Gβγ subunits (Mackie et al., 1995;
Mcallister et al., 1999; Guo and Ikeda, 2004) and p38-mediated mitogen-activated protein kinase
(Derkinderen et al., 2001). CB1 receptors are heterogeneously expressed throughout the central nervous
system (CNS) and periphery (e.g., liver and adipocytes) (Herkenham et al., 1990; Matsuda et al., 1990;
Felder and Michelle, 1998), as well as within the enteric nervous system (ENS) in both the myenteric and
submucosal plexuses (Izzo and Sharkey, 2010; Sharkey and Wiley, 2016), while CB2 receptors are
localized primarily on immune cells and microglia and are highly associated with modulating immune
function, particularly in a pathological inflammatory state (Galiègue et al., 1995; Gong et al., 2006). CB1
receptors are localized to the presynaptic membrane where it is predominantly expressed on GABAergic
neurons (Katona et al., 1999; Marsicano and Lutz, 1999) and to a lesser extent on glutamatergic neurons
in the CNS (Tsou et al., 1998; Huang et al., 2001; Szabo and Schlicker, 2005). In the ENS, CB1 receptors
localize to excitatory neurons that release acetylcholine and substance P (Coutts et al., 2002; Maguma et
al., 2010). Notably, CB1 receptors can also localize to postsynaptic neurons (Maroso et al., 2016), glial
cells such as astrocytes (Han et al., 2012; Navarrete et al., 2014; Robin et al., 2018), oligodendrocytes
(Molina-Holgado et al., 2002), and microglia (Stella, 2009; Mecha et al., 2015), and on the outer
membrane of mitochondria (Bénard et al., 2012) which highlights the increased complexity of CB1
receptor modulation on synaptic transmission.
1.2.2.

Endocannabinoids and their regulatory enzymes
Two main endogenous ligands (i.e., endocannabinoids) bind and activate CB1 and CB2 receptors,

2-arachidonoylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura et al., 1995) and Narachidonoylethanolamide (anandamide; AEA) (Devane et al., 1992). Both endocannabinoids are derived
from phospholipid precursors in the postsynaptic neuron, but unlike traditional neurotransmitters,
endocannabinoids are not stored in vesicles and are released on-demand when the postsynaptic membrane
becomes depolarized where they subsequently travel in a retrograde manner from postsynaptic terminals
and act on presynaptic cannabinoid receptors found on the neuronal plasma membrane (Ahn et al., 2008).
While both endocannabinoids share similarities in binding to CB1 and CB2 receptors, there are distinct
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differences that make each unique. First, AEA acts as a partial agonist in vitro whereas 2-AG acts as a full
agonist as demonstrated by increases in intracellular Ca2+ in NG108-15 cells (Sugiura et al., 1999) and
through inhibition of cAMP levels (Ignatowska-Jankowska, Baillie, et al., 2015). Also, AEA is an agonist
at the capsaicin receptor, TRPV1 (Ross, 2003), and the nuclear receptor, peroxisome proliferatoractivated receptor-α (PPARα) (Jhaveri et al., 2008). Another key difference is that 2-AG levels are
approximately 100-1000 fold higher than AEA levels in the CNS (Sugiura et al., 2002; Ahn et al., 2009;
Long, Li, et al., 2009). Of note, other less characterized cannabinoids also exist which include noladin
ether (Hanus et al., 2001), virodhamine (Porter et al., 2002), and N-arachidonoyl dopamine (Huang et al.,
2002).
Biosynthetic and degradative enzymes tightly regulate AEA and 2-AG levels in the body. With
respect to AEA production, several biosynthetic pathways exist (Hussain et al., 2017), including the
conversion of N-acyl-phosphatidylethanolamine (NAPE) by NAPE-phospholipase D (NAPE-PLD) to
AEA (Liu et al., 2008); however, a rate-limiting biosynthetic enzyme(s) remains to be identified
(Blankman and Cravatt, 2013). In contrast, diacylglycerol lipase (DAGL) isoforms α (DAGLα) and β
(DAGLβ) convert diacylglycerols into 2-AG (Bisogno et al., 2003; Gao et al., 2010; Tanimura et al.,
2010). DAGLα is primarily expressed on postsynaptic membranes of dendritic spines (Yoshida et al.,
2006) and astrocytes (Viader et al., 2016), whereas DAGLβ is primarily abundant on immune cells such
as macrophages in the periphery and resident microglia of the CNS (Hsu et al., 2012). Importantly,
DAGLα has also been shown to be expressed on myenteric neurons, specifically acetylcholine-,
substance P-, and nitric oxide-producing neurons in both the ileum and the colon (Bashashati et al., 2015)
suggesting a local endocannabinoid tone present in the gut. In regards to degradative enzymes, AEA and
2-AG are rapidly metabolized by their respective degradative enzymes, fatty acid amide hydrolase
(FAAH) (Cravatt et al., 1996, 2001) and monoacylglycerol lipase (MAGL) (Dinh et al., 2002). FAAH is
predominantly localized on postsynaptic neurons, whereas MAGL is predominantly expressed on
presynaptic axonal terminals (Gulyas et al., 2004). Notably, FAAH also serves as a major catabolic
enzyme for two other bioactive lipids, N-palmitoylethanolamine (PEA) and oleoylethanolamide (OEA),
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which do not bind CB1 or CB2 receptors (Lo Verme et al., 2005; Sagar et al., 2009; Donvito et al., 2016).
Moreover, FAAH expression has also been shown to localize to cell bodies of the myenteric plexus
(Duncan et al., 2005) and throughout the small and large intestine (Capasso et al., 2005). MAGL serves
as the rate-limiting enzyme for free arachidonic acid (AA) levels in the brain, liver, and lung, but not in
the gastrointestinal tract or other organs (De Petrocellis and Di Marzo, 2009). MAGL expression is also
found throughout the small intestine (i.e., duodenum, jejunum, and ileum) and colon of myenteric neurons
(Taschler et al., 2015). Furthermore, the minor enzymes ABHD6 and ABHD12 also play roles in the
metabolism of 2-AG (Blankman et al., 2007). In addition, cyclooxygenase-2 and 12- and 15lipoxygenases are also known to oxidize 2-AG and AEA (Matias and Marzo, 2006).
1.3. The ECS regulates homeostatic functions
The ECS exhibits a wide array of physiological and cognitive functions that underlie homeostatic
processes, including but not limited to mood, fear and stress, appetite, pain, and gastrointestinal function
(Sharkey and Wiley, 2016; de Melo Reis et al., 2021). Activation of CB1 receptors is primarily the
mechanism by which homeostatic processes are altered, whereas CB2 receptors are more readily
expressed during pathological states. CB1 receptor activation can modulate natural rewards, such as social
interaction, sexual desire, and palatable foods, as well as induce desirable drug effects by activating the
well characterized mesolimbic pathway in the brain (Parsons and Hurd, 2015). Natural rewards and drugs
of abuse (i.e., cocaine, nicotine, alcohol, opiates, and cannabinoids) activate the ventral tegmental area
(VTA) in the midbrain to increase levels of the neurotransmitter, dopamine (DA), to the ventral striatal
brain region, the nucleus accumbens (NAc), which results in subjective reward and positive reinforcement
(Salamone et al., 2005). THC and other CB1 receptor agonists activate CB1 receptors on GABAergic
neurons innervating the VTA which leads to an increased release of dopamine in the NAc thereby
implicating the ECS in the treatment of mood and anxiety disorders (Vlachou and Panagis, 2014). With
respect to fear and stress, administration of CB1 receptor agonists in various brain regions, including the
amygdala, prefrontal cortex (PFC), or hippocampus, can lead to fear extinction (Lin et al., 2006),
disruption of reconsolidation of fear memories (Sachser et al., 2015), and can suppress stress-induced
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corticosterone secretion (Hill et al., 2009). This can be therapeutic for patients and veterans with posttraumatic stress disorder (Mayo et al., 2021). As described above, dronabinol in various forms has been
FDA-approved to help stimulate appetite in HIV patients. Additionally, the ECS can modulate pain
responses through supraspinal, spinal, and peripheral mechanisms of action. CB1 receptor activation,
either through direct CB1 receptor agonists or MAGL and/or FAAH inhibition, produces effective
antinociception in animal models and pain relief in humans (Hill et al., 2017; Lötsch et al., 2018;
Anthony et al., 2020). Moreover, there is a plethora of literature that dates back to the 1970’s where
evidence demonstrates strong regulation of gastrointestinal function, predominantly through the
modulation of CB1 receptors.
1.3.1.

Modulation of CB1 receptors in the gastrointestinal tract
Early studies used guinea pigs, mice, rats, and even human tissue, to study the effects of

cannabinoids on gastrointestinal (GI) function. Some of the first work studied the contractile effects of
THC (Gill et al., 1970), CP55,940, WIN55,212-2 (each are pan CB1 and CB2 receptor agonists), and
anandamide on isolated guinea pig small intestinal longitudinal and circular muscle where the inhibition
of contractions did not alter acetylcholine (Pertwee et al., 1996; Coutts and Pertwee, 1997), carbachol,
substance P, or histamine (Izzo et al., 1998) addition. This suggested that CB1 receptors inhibit
contractions through a neuronal mechanism and not by directly inhibiting smooth muscle cells of the GI
tract. In the whole animal, one of the most common assays to measure small intestinal transit is through
the use of an orally administered non-absorbable charcoal where the leading edge of the charcoal solution
is measured relative to the entire small intestine. Mice pre-treated with THC, AEA, and WIN55,212-2
have readily shown to inhibit transit between 30-60% compared to vehicle-treated mice (Dewey et al.,
1970, 1972; Chesher et al., 1973; Anderson et al., 1974, 1975; Jackson et al., 1976; Calignano et al.,
1997; Colombo et al., 1998; Izzo, Mascolo, et al., 1999; Izzo et al., 2000). Moreover, rimonabant (a
selective CB1 receptor antagonist) has also been shown to enhance small intestinal transit in the charcoal
transit model (Calignano et al., 1997; Colombo et al., 1998; Izzo, Mascolo, et al., 1999; Izzo et al., 2000;
Carai et al., 2006) indicating a bidirectional effect of CB1 receptors on small intestinal transit. Izzo et al.
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(2000) aimed to elucidate whether central or enteric CB1 receptors mediate the modulation of small
intestinal transit effects by WIN55,212-2 and rimonabant. The study administered each compound
through intraperitoneal (i.p.) and intracerebroventricular (i.c.v.) injections and found they modulate small
intestinal transit regardless of the route of administration. This suggested a role of central CB1 receptors
play in modulating small intestinal transit. More importantly, Izzo et al. (2000) treated mice with
hexamethonium, a ganglionic blocker, and found that i.p.-administered mice continued to show similar
inhibition of transit suggesting a peripheral site of action. In other words, even though central CB1
receptors can modulate small intestinal transit, it is likely that when cannabinoid drugs are given i.p. they
modulate small intestinal transit through enteric neurons expressing CB1 receptors. This inhibition of
small intestinal transit and motility by CB1 receptor agonists has also been shown to reduce gastric
emptying (Calignano et al., 1997; Izzo, Macolo, et al., 1999; Landi et al., 2002; Di Marzo et al., 2008;
Abalo et al., 2009) and colonic propulsion (Pinto et al., 2002). Additional studies investigated FAAH and
MAGL functionality on GI transit and motility. The FAAH inhibitor, N-arachidonoylserotonin (AA-5HT), elicited inhibitory effects in the small intestine and this effect was abolished in both FAAH (-/-) and
CB1 (-/-) mice suggesting the elevation of anandamide inhibits small intestinal transit through the
activation of CB1 receptors (Capasso et al., 2005). Moreover, the inhibition of small intestinal transit by
AA-5-HT was reversed by rimonabant and not SR144528, the selective CB2 receptor antagonist, or
5’iodoresiniferatoxin, the TRPV1 receptor antagonist, further supporting the notion that anandamide
controls small intestinal transit through CB1 receptors. MAGL deficiency, as evidenced through MAGL (/-) mice or the MAGL inhibitor, JZL184, demonstrate delayed whole gut transit (Taschler et al., 2015). In
addition, MAGL (-/-) mice show delayed colonic transit as measured by the time needed for a bead to be
expelled from the colon. Importantly, MAGL (-/-) mice display an accumulation of CB1 receptors in
intracellular vesicles along the myenteric plexus of colonic neurons (Taschler et al., 2015).
Fluid secretion is another critical function of the GI tract where it serves to facilitate normal
passage of gut contents along the bowels. The cannabinoid agonists, CP55,940 and ACEA (selective CB1
receptor agonist), both dose-dependently inhibited hypersecretion through the activation of CB1 receptors
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in the mouse small intestine while rimonabant enhanced fluid hypersecretion in a cholera toxin-induced
hypersecretion model (Izzo et al., 2003; Izzo and Capasso, 2006). Moreover, WIN55,212-2 dosedependently diminishes and rimonabant dose-dependently enhances intraluminal fluid accumulation
within rat small intestines, respectively (Izzo, Mascolo, et al., 1999). Importantly, a subthreshold dose of
rimonabant reversed the inhibition of fluid secretion by WIN55,212-2 revealing a CB1-mediated action on
modulating fluid secretion (Izzo, Mascolo, et al., 1999). Additionally, rimonabant can also enhance
gastric acid secretion in vitro in rodents (Coruzzi et al., 2006; Borrelli, 2007) and enhance secretion in
humans (Fernandez and Allison, 2004). In fact, the enhancement of intestinal transit and secretion by
rimonabant in part suggested that CB1 receptor antagonism may be a therapeutic target as an anti-obesity
medication. In 2006, rimonabant was approved as an anti-obesity medication in Europe; however, it was
quickly withdrawn in 2008 for serious psychiatric side effects, including insomnia, depressive disorders,
mood alterations, and even suicidal ideation (Nathan et al., 2011).
The modulation of gastrointestinal effects by CB1 receptor agonists can also produce tolerance
following repeated administration. The inhibition of transit by THC elicits tolerance just after four days of
treatment (Anderson et al., 1975) and to fecal defecation (Masur et al., 1971). In a recent study, Abalo et
al. (2009) demonstrated that the inhibition of small and large intestinal transit by WIN55,212-2
underwent tolerance following repeated administration whereas delayed gastric emptying was resistant to
tolerance. This highlights an important feature that tolerance is highly contextual upon the tissue of
interest, and more generally to the effect being measured (e.g., tolerance to antinociceptive versus
inhibitory transit effects), and that it is likely there are multiple and unique mechanisms that underlie the
differential tolerance observed. Moreover, repeated administration of rimonabant (3 and 5.6 mg/kg) leads
to tolerance of its enhancement of small intestinal transit as early as three days over the course of an 8day treatment schedule in mice (Carai et al., 2004). Additionally, the inhibition of whole gut transit by the
MAGL inhibitor, JZL184, also demonstrated tolerance following a 7-day daily injection procedure
(Taschler et al., 2015). Furthermore, the inhibition of gastrointestinal motility by CB1 receptor agonists in
isolated tissue models were used to test whether prolonged incubation would shift the concentration9

response curves. A concentration-response of WIN55,212-2 produced a rightward shift in its inhibition of
electrically-evoked contractions in isolated guinea pig myenteric plexus-longitudinal muscle preparations
when incubated with WIN55,212-2 for five hours suggesting that the inhibitory effect of WIN55,212-2
underwent tolerance (Basilico et al., 1999). Another study found a similar rightward shift of the
concentration-response curve of WIN55,212-2 on electrically-evoked contractions of longitudinal muscle
strips from guinea pig and human small intestinal tissue when incubated with WIN55,212-2 for 48 hours
thereby inferring the development of tolerance even at the level of isolated organ bath tissue models
(Guagnini et al., 2006). Importantly, rimonabant reversed the inhibition of contractions in both guinea pig
and human tissue revealing a CB1-dependent mechanism.
Overall, the modulation of transit, motility, and secretion by the cannabinoid system,
predominantly through CB1 receptors, has been extensively studied and seems to reveal a bidirectional
tone on the GI tract suggesting that the endocannabinoid system is tonically active in the gut; however,
the inhibitory GI effects of CB1 receptor agonists and MAGL inhibitors often develop tolerance following
repeated administration. Pre-clinical literature demonstrates that targeting the CB1 receptor elicits a wide
spectrum of potential therapeutic effects in pathological animal models.
1.4. CB1 receptor effects in pathological models from pre-clinical research
1.4.1.

Pre-clinical effects of ∆9-THC and synthetic cannabinoids in pathological models
Ever since the discovery of THC (a partial CB1 and CB2 receptor agonist) (Pertwee, 2008) in

1964, several synthetic cannabinoids were created including classical (e.g., compounds structurally
similar to THC such as dronabinol and the full CB1 and CB2 receptor agonist, HU-210) (Mechoulam et
al., 1988), non-classical (e.g., the full CB1 and CB2 receptor agonist, CP55,940) (Wiley et al., 1995),
aminoalkylindoles (e.g., the full CB1 and CB2 receptor agonist, WIN55,212-2) (Kuster et al., 1993),
eicosanoids (e.g., derivatives of endocannabinoids such as AEA including methanandamide) (Abadji et
al., 1994), and selective CB1 receptor agonists (e.g., arachidonyl-2’-chloroethylamide (ACEA) and
arachidonylcyclopropylamide (ACPA)) (Hillard et al., 1999). One manor of determining whether CB1
receptors mediate certain effects of drugs in animal models was from the discovery and characterization
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of the selective CB1 receptor antagonist, SR141716A, better known as rimonabant (Rinaldi-Carmona et
al., 1994). This was essential to begin differentiating the myriad of effects that THC and synthetic
cannabinoids elicit in animal models. Importantly, the creation of CB1 constitutive (transgenic) knockout
mice provided a complementary tool for pharmacologists to use and discern the involvement of CB1mediated effects (Zimmer et al., 1999). THC and synthetic cannabinoids produce a myriad of potential
therapeutic effects, particularly antinociceptive effects in models of inflammatory (Sofia et al., 1973;
Clayton et al., 2002; Jayamanne et al., 2006; Cox et al., 2007; Gutierrez et al., 2007; Naidu et al., 2010;
Kinsey, Mahadevan, et al., 2011; Booker et al., 2012; Anderson et al., 2014; Auh et al., 2016) and nerve
injury- or chemotherapy-induced neuropathic pain models (Mao et al., 2000; Fox et al., 2001; De Vry et
al., 2004; LaBuda and Little, 2005; Rahn et al., 2007; Williams et al., 2008; Sain et al., 2009; Kinsey,
Mahadevan, et al., 2011; Vera et al., 2013; Deng et al., 2015; Xie et al., 2016; Harris et al., 2016) where
CB1 receptors are expressed in relevant pain neurocircuitry including the periaqueductal grey (PAG;
(Tsou et al., 1998)), dorsal horn of the spinal cord (Farquhar-Smith et al., 2000), and the dorsal root
ganglion (Hohmann and Herkenham, 1999).
Additionally, anorexia (i.e., loss of appetite/aversion to food) and cachexia (i.e., extreme weight
loss and muscle wasting due to a disease state such as cancer) have been studied in animal models since
activation of the CB1 receptor can increase feeding behavior in animals (see review by (Koch, 2017)).
However, it has been shown that low to moderate doses of CB1 receptor agonists stimulate food intake in
mice whereas moderate to high doses can decrease feeding behavior producing a bimodal control of food
intake (Bellocchio et al., 2010). In fact, it was found that the hyperphagia effects were mediated by the
inhibition of glutamatergic neurons and hypophagia occurs through the inhibition of GABAergic neurons
(Bellocchio et al., 2010). Specifically, hypothalamic neurons, a brain region that regulates feeding
behavior, shows that direct infusion of CB1 receptor agonists into discrete hypothalamic nuclei leads to
enhanced feeding behavior (Jamshidi and Taylor, 2001; Koch et al., 2015). Additionally, CB1 receptor
signaling interferes with signal transmission of metabolic hormones such as leptin (Di Marzo et al., 2001)
and ghrelin (Kola et al., 2008), which regulate satiation and hunger, respectively. Furthermore, blockade
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of the CB1 receptor is a viable target to treat visceral obesity. Repeated administration of CB1 receptor
antagonists or genetic knockout of CB1 receptors results in decreased food intake, body weight, and
adiposity, increased insulin and lipid sensitivity, as well as improved glucose and lipid homeostasis, and
hepatic steatosis in rodent models of obesity (Trillou et al., 2003, 2004; Fong et al., 2007; Bell-Anderson
et al., 2011; Jourdan et al., 2012; Nam et al., 2012). In fact, Tam et al. (2014) demonstrated that daily
treatment of rimonabant improved diminished glucose homeostasis and insulin sensitivity, as well as
hepatic steatosis and fibrosis when mice are treated with a high fat diet (HFD). Moreover, when the
biologically active substance, adiponectin, which is implicated in the maintenance of energy homeostasis,
is genetically knocked out, the antisteatotic and fibrotic effects of rimonabant were abolished suggesting
that the reversal of HFD-induced hepatic steatosis and fibrosis by repeated CB1 receptor blockade is
mediated by adiponectin (Tam et al., 2014). Another study examined the role of peripheral CB1 receptor
blockade in hypothalamic leptin signaling (Tam et al., 2017). It was determined that peripheral CB1
receptor blockade reverses hyperleptinemia observed in diet-induced obese mice by restoring leptinmediated pro-opiomelanocortin neuronal activation in the hypothalamus (Tam et al., 2017).
Targeting the CB1 receptor can also ameliorate disease progression in animal models of multiple
sclerosis (MS) including the experimental autoimmune encephalomyelitis (EAE) and Theiler
murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD), which serves to model the
demyelination phenotype in MS, as well as the chronic relapsing EAE (CREAE) model, which represents
relapsing-remitting MS (Cabranes et al., 2005, 2006; Constantinescu et al., 2011). In the CREAE model,
THC, WIN55,212-2, and methanandamide all reduced tremors and spasticity in diseased mice whereas
rimonabant and SR144528 both exacerbated these measures in diseased mice suggesting the endogenous
cannabinoid system is tonically active in the control of tremor and spasticity (Baker et al., 2000).
Regarding the TMEV-IDD model, WIN55,212-2 improved motor coordination, and reduced microglial
activation and CD4+ T cell infiltration as far out as 25 days post-treatment (Arévalo-Martín et al., 2003).
Another study found that THC ameliorates the neurological score used to assess the severity of EAE in
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mice and that CB1 receptors on neurons, not T-cells, abolished the THC-meditated EAE suppression
(Maresz et al., 2007).
Studies also demonstrate how CB1 receptor stimulation can produce gastroprotective effects from
non-steroidal anti-inflammatory drug(NSAID)-induced ulcers (Pertwee, 2001; Carai et al., 2006;
Trautmann and Sharkey, 2015; Dipatrizio, 2016; Cohen and Neuman, 2020). NSAIDs have been used for
decades for their analgesic properties, but they are also a leading cause of gastric ulcers which limits their
clinical utility (Musumba et al., 2009). While patients are readily prescribed proton pump inhibitors
(PPIs) to reduce the production of stomach acid associated with ulcer formation, PPIs also exhibit side
effects including an increased risk of gastric polyps, development of cancer, bone fractures, and bacterial
infections (Lodato et al., 2010). THC, however, elicits gastroprotective effects by attenuating the severity
of diclofenac-induced ulcers in mice through the activation of CB1 receptors by using the CB1 selective
antagonist, rimonabant (Kinsey, Nomura, et al., 2011). A follow-up study showed that THC dosedependently attenuated diclofenac-induced ulcers both through i.p. and oral routes of administration
(Kinsey and Cole, 2013).
Although all these studies outline the therapeutic effects of CB1 receptor agonists in animal
models, there are several side effects associated with targeting the CB1 receptor through direct means (i.e.,
the orthosteric site of action). Indeed, phytocannabinoids and synthetic cannabinoids all elicit a multitude
of potential therapeutic effects as described above; however, many of these studies also investigate the
well-characterized tetrad assay that was developed by Dr. Billy Martin to examine cannabimimetic side
effects in rodent models (Martin et al., 1991). The test investigates locomotor activity, catalepsy as
assessed in the ring or bar test, antinociception using the tail-flick and/or hot plate test, and hypothermia
as measured by a rectal thermometer. Indeed, THC, CP55,940, WIN55,212-2 all produce the cardinal
signs of the tetrad assay (Kinsey and Cole, 2013; Grim, Morales, et al., 2016); however, other central
nervous system (CNS) acting drugs can also produce one or more of these effects. For instance, Wiley
and Martin, (2003) examined a psychomotor stimulant (amphetamine), a tricyclic antidepressant
(desipramine), an antimuscarinic agent (scopolamine), an opioid (morphine), several antipsychotics
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(pimozide, clozapine, chlorpromazine, thioridazine, and haloperidol), and CNS depressants (diazepam,
pentobarbital, and ethanol) in the tetrad assay. While many of the drugs only displayed one or more of the
tetrad effects, clozapine, chlorpromazine, thioridazine, and haloperidol elicited dose-dependent effects in
all four measures. The use, however, of the selective CB1 receptor antagonist, rimonabant, was critical in
revealing that the tetrad effects of THC were completely blocked by rimonabant indicating CB1 receptor
involvement, whereas rimonabant failed to completely block activity of the other drugs (i.e., clozapine,
chlorpromazine, thioridazine, and haloperidol) in all four tests, even though it significantly reversed the
effects of some drugs in one or two of the tests (Wiley and Martin, 2003). Furthermore, drug
discrimination is readily used to discern pharmacologically selective differences of centrally acting
psychoactive drugs like THC in rodent behavioral phenotypes. Mice can be trained to make one response,
often by lever presses or nose pokes, when administered a psychoactive drug (i.e., the training drug) and
another response when administered vehicle or a drug that does not share the same psychoactive
properties. The FDA classifies drug discrimination as one of the assays to assess potential abuse liability
of centrally acting drugs (Gauvin et al., 2021). When other drugs, either in the same class as the training
drug or not, can substitute for the training drug, it is inferred they share similar intrinsic subjective effects.
In fact, mice trained with various CB1 receptor agonists, including THC or other synthetic cannabinoids
like CP55,940 and WIN55,212-2, readily produce a discriminative stimulus in rodents and can substitute
for THC thereby inferring intrinsic subjective effects consistent with the potential for abuse liability
(Compton et al., 1993; Wiley et al., 1995, 2017, 2018; Vann et al., 2009; Gatch and Forster, 2018).
Furthermore, repeated administration of CB1 receptor agonists readily produce antinociceptive tolerance
(Fan et al., 1994; Smith et al., 2007; Wakley et al., 2014) and physical dependence (Lichtman et al.,
2001; Schlosburg et al., 2009, 2010; Trexler et al., 2018, 2019) thereby diminishing enthusiasm for their
clinical development. As such, pharmacologists and medicinal chemists developed inhibitors for
endocannabinoid degradative enzymes, MAGL and FAAH, as an alternative approach to mitigate the side
effect profile of direct CB1 receptor agonists while still retaining the therapeutic benefits of activating CB1
receptors.
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1.4.2.

Pre-clinical effects of inhibiting MAGL and FAAH in pathological models
MAGL and FAAH inhibition has become a promising alternative approach to targeting CB1

receptors for a variety of therapeutic effects. Notably, both MAGL and FAAH inhibitors or their genetic
deletion respectively elevate brain levels of AEA (Lichtman et al., 2004) and 2-AG (Long, Li, et al.,
2009; Schlosburg et al., 2010). The MAGL inhibitors, JZL184 and MJN110, and the FAAH inhibitor, PF3845, have shown antinociceptive effects in inflammatory (Ahn et al., 2009; Naidu et al., 2010; Kinsey,
Mahadevan, et al., 2011; Booker et al., 2012; Ghosh et al., 2013) and nerve- and chemotherapy-induced
neuropathic pain models (Guindon et al., 2013; Crowe et al., 2015; Ghosh et al., 2015; IgnatowskaJankowska, Wilkerson, et al., 2015; Wilkerson et al., 2016). MAGL and FAAH inhibitors also produce
gastroprotective effects in NSAID-induced ulcer models. For example, JZL184, attenuates the severity of
ulcer development from treating mice with diclofenac (Kinsey et al., 2013; Crowe and Kinsey, 2017;
Trexler et al., 2019) as well as the FAAH inhibitor, URB597 (Naidu et al., 2009).
Although full blockade of MAGL inhibition is also associated with several side effects, such as
hypo-locomotion (Long, Li, et al., 2009), as well as antinociceptive tolerance and physical dependence
upon repeated administration (Schlosburg et al., 2010, 2014; Slivicki et al., 2017), the combination of
FAAH and MAGL inhibitors can produce additive and/or synergistic effects. Moreover, dual
MAGL/FAAH inhibitors, such as SA-57, were also investigated to determine whether they produce
therapeutic effects without a myriad of side effects. Dual inhibition of MAGL and FAAH also show
similar antinociceptive effects in models of inflammatory and neuropathic pain models (Ghosh et al.,
2015; Wilkerson et al., 2017); however, dual MAGL/FAAH inhibitors (i.e., SA-57), and the selective
MAGL inhibitor, MJN110, can elicit a discriminative stimulus on their own (Owens et al., 2017).
Furthermore, SA-57 and combinations of JZL184 and PF-3845 can substitute for the discriminative
stimulus of THC in mice (Hruba et al., 2015). Moreover, the combination of MJN110 and PF-3845 also
substitutes for discriminative stimulus of THC (Owens et al., 2017). In contrast, exogenous
administration of AEA or FAAH inhibitors do not substitute in rodents trained to discriminate THC,
unless a combination of AEA and FAAH inhibition is conducted or in mice that lack the FAAH enzyme
15

(Solinas et al., 2007; Walentiny et al., 2011, 2015; Wiley et al., 2014; Hruba et al., 2015). In sum, it
seems selective increases of 2-AG using MAGL inhibitors and increases of both AEA and 2-AG using
dual MAGL/FAAH inhibitors or combinations of both inhibitors mimic the discriminative stimulus
effects of THC, whereas selective elevation of AEA can only substitute for THC when exogenous
administration and/or concomitant inhibition of its metabolism by FAAH are performed. Thus, increasing
endocannabinoid levels through the inhibition of their respective metabolic enzymes can elicit some side
effects that deter their use in the clinic. Alternatively, to circumvent this approach of indirectly elevating
endogenous cannabinoids, medicinal chemists have developed compounds that improve selectivity by
targeting CB1 receptor allosteric sites.
1.5. CB1 receptor allosteric modulation
1.5.1.

Definition and types of allosteric modulators
Research on G-protein coupled receptors (GPCRs) have now turned to developing ligands that

bind to topographically distinct site(s) (i.e., allosteric site(s)) compared to where traditional endogenous
ligands bind (i.e., orthosteric site). The International Union of Basic and Clinical Pharmacology defines
an allosteric site as a “binding site on a receptor macromolecule that is nonoverlapping and spatially
distinct from but conformationally linked to the orthosteric binding site” (Neubig et al., 2003). There are
several varieties of allosteric modulators and can be classified into four types: (1) negative allosteric
modulators (NAMs), ligands that conformationally change the receptor to decrease the affinity, potency,
and/or efficacy of orthosteric ligands; (2) positive allosteric modulators (PAMs), ligands that
conformationally change the receptor to increase the affinity, potency, and/or efficacy of orthosteric
ligands; (3) positive (ago-PAMs) or negative (ago-NAMs) allosteric agonists, allosteric compounds that
modulate the receptor in the absence of the orthosteric ligand; and (4) neutral allosteric ligands (NALs),
ligands that bind the allosteric site but do not modulate receptor function (Gentry et al., 2015).
1.5.2.

Identifying and quantifying allosteric modulators
The detection and quantification of allostery can be performed through several means.

Determining a high-resolution structure with bound allosteric modulators in the presence and absence of
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orthosteric ligands is the most direct approach (Christopoulos et al., 2014). Other approaches use more
indirect pharmacological approaches to infer whether a ligand is an allosteric compound. Equilibrium
ligand binding is commonly used by testing the effect(s) of potential allosteric modulators on a known,
labeled orthosteric ligand (i.e., by using a fluorophore or radioactive labeled ligand). This assay identifies
two important parameters for allostery: (1) KB, the equilibrium dissociation constant which measures the
affinity of the allosteric modulator for its receptor; and (2) α, the cooperativity factor, which defines the
magnitude and direction the allosteric modulator has on the orthosteric ligand when both are bound to the
receptor. The two parameters are calculated based on the allosteric cubic ternary complex model (Weiss
et al., 1996), using the following equation:
𝑌=

[𝐴]
[𝐵]
)
𝐾𝐵
[𝐴] + 𝐾𝐴
𝛼[𝐵]
(1 +
)
𝐾𝐵
(1 +

where Y represents the fractional specific binding; KA and KB are the equilibrium dissociation constants
for the orthosteric and allosteric ligands, respectively; [A] and [B] are the concentrations of the orthosteric
and allosteric ligands, respectively; and α represents the cooperativity factor. An α > 1 indicates a ligand
is a PAM, an α < 1 indicates a ligand is a NAM, and an α = 1 indicates no allosteric modulation or a
potential NAL (Christopoulos and Kenakin, 2002; Price et al., 2005). Notably, equilibrium ligand binding
assays only detect the modulation of affinity of the labeled orthosteric ligand being used and so a
limitation of this assay is identifying NALs because the allosteric modulator may elicit efficacy in
functional assays, but still have no effect in the binding assay. Ligand binding kinetic assays on the other
hand are used to assess whether the allosteric modulator alters the affinity when increasing concentrations
of a radiolabeled orthosteric ligand are used to assess the association or dissociation rate constants. If, for
example, the dissociation rate constant of the orthosteric ligand is decreased in the presence of an
allosteric modulator, it would be classified as a PAM. NAMs would increase the dissociation rate
constant, whereas NALs would have a lack of a net effect. To discern the impact of allosteric modulators
on the efficacy of orthosteric ligands, functional assays are readily used where the operational model of
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allosterism quantifies allosteric effects on both affinity and efficacy (Price et al., 2005; May et al., 2007).
The operational model also calculates the β parameter as a measure of allosteric impact on efficacy
relating to the functional assay being used. Furthermore, two additional parameters τA and τB, represent
the intrinsic efficacy of the orthosteric and allosteric ligand, respectively, independent of the other ligand.
The following equation relates these parameters described in the operational model of allosterism
(Gregory et al., 2010):
𝐸=

𝐸𝑚 (𝜏𝐴 [𝐴](𝐾𝐵 + 𝛼𝛽[𝐵] + 𝜏𝐵 [𝐵]𝐾𝐴 )𝑛
([𝐴]𝐾𝐵 + 𝐾𝐴 𝐾𝐵 + 𝐾𝐴 [𝐵] + 𝛼[𝐴][𝐵])𝑛 + (𝜏𝐴 [𝐴](𝐾𝐵 + 𝛼𝛽[𝐵]) + 𝜏𝐵 [𝐵]𝐾𝐴 )𝑛

where E and Em represents the effect and maximum possible effect, respectively, and n represents the
slope factor governing the shape of the stimulus-response function. The use of functional assays has the
clear advantage of detecting all four types of allosteric modulators, particularly allosteric agonists.
However, while functional assays are suited to detect allosteric ligands, equilibrium binding and kinetic
assays are suited to classify the mechanism of which the allosteric ligand modulate the receptor
(Christopoulos et al., 2014). An important note when classifying allosteric ligands is that is highly
dependent on the assay that is being used to describe it. An allosteric ligand can act as a PAM by
enhancing the affinity of an orthosteric ligand, but act as a NAM for a specific downstream signaling
pathway or as an ago-PAM on another downstream signaling pathway by activating it in the absence of
an orthosteric ligand. Thus, allosteric ligands may act as multiple types of modulators when considering
binding and functional assays in general. In sum, multiple tools are used to characterize allosteric
modulators and the next section will discuss potential therapeutic advantages.
1.5.3.

Therapeutic potential of allosteric modulators
There are several potential therapeutic advantages of allosteric modulators over their orthosteric

counterparts. First, allosteric ligands can exhibit enhanced specificity to the target receptor subtype (e.g.,
more specifically target the CB1 receptor over the CB2 receptor) because higher levels of sequence
variability in the allosteric sites since most allosteric sites are not constrained by high evolutionary
pressure to maintain endogenous ligand binding (Conn et al., 2009). Second, is the selectivity of the
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target downstream signaling pathways. Endogenous orthosteric ligands affect multiple downstream
signaling pathways throughout the entire body, whereas allosteric modulation can control the receptor
response only in the tissue where the endogenous orthosteric ligand is present and more importantly in
specific tissues affected within a pathological state (Gao and Jacobson, 2013) where altered levels of the
endogenous orthosteric ligand is common. Third, allosteric modulators often exhibit a saturable effect or
ceiling effect, where no additional modulation is observed beyond a certain concentration of the allosteric
ligand which mitigates potential adverse effect profiles (Wild et al., 2014). Lastly, allosteric modulators
can elicit probe dependence, where the same allosteric ligand may have different effects on different
orthosteric ligands related to binding and downstream signaling pathways (Baillie et al., 2013).
1.5.4.

CB1 receptor NAMs and PAMs
The first report of three allosteric modulators for the CB1 was in 2005 where Org27569,

Org27759, and Org29647 were characterized (Price et al., 2005). Org27569 has been extensively studied
where it is generally recognized as a PAM with respect orthosteric binding assays where it increases the
binding of CP55,940, and decreases binding of rimonabant (Price et al., 2005; Ahn et al., 2012; Khajehali
et al., 2015). Conversely, with respect to signaling it is generally regarded as a NAM because it
diminishes the efficacy of CP55,940 inhibition of cAMP accumulation and β-arrestin2 recruitment (Ahn
et al., 2012; Khajehali et al., 2015). In 2019, the crystal structure of the CB1 receptor was resolved with
Org27569 and CP55,940 (Shao et al., 2019) demonstrating the first direct mechanism of a CB1 receptor
allosteric modulator in combination with an orthosteric ligand. The structure revealed that Org27569
bound to an extrahelical site within the inner leaflet of the membrane, while CP55,940 was shown to bind
to the orthosteric site within the transmembrane domains of CB1 receptors. Other well studied CB1
receptor NAMs include PSNCBAM-1 (Khurana et al., 2017) and the endogenous ligand pepcan-12
(Bauer et al., 2012) considering they both diminish G-protein coupling of CP55,940 and 2-AG,
respectively.
The most studied CB1 receptor PAMs, ZCZ011 and GAT211, have been shown to enhance
binding of CP55,940 and WIN55,212-2 (see table 1), enhance downstream signaling pathways of 2-AG,
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AEA and CP55,940, and activate these pathways in the absence of an orthosteric ligand (see table 2)
suggesting they act as ago-PAMs at certain concentrations (Ignatowska-Jankowska, Baillie, et al., 2015;
Laprairie et al., 2017). Additionally, the stereoisomers of GAT211 were resolved and revealed that
GAT228 acts as an allosteric agonist (ago-PAM) whereas GAT229 exhibits PAM activity (Laprairie et
al., 2017). Other CB1 receptor PAMs include ABD1236 (Tseng et al., 2019) and the endogenous ligand,
lipoxin A4 (Pamplona et al., 2012). The characterization of CB1 recptor PAMs in binding and functional
assays are summarized in tables 1 and 2. Considering the focus of this dissertation is on CB1 receptor
PAMs, the effects of these compounds in rodent models are discussed next.
1.5.5.

Pre-clinical effects of CB1 receptor PAMs
CB1 receptor PAMs are hypothesized to enhance antinociceptive effects and other therapeutic

effects (outlined in section 1.4.) of endogenously released cannabinoids with limited cannabimimetic side
effects (Price et al., 2005). Recent evidence of the synthetic CB1 receptor PAMs, ZCZ011 and GAT211,
demonstrate antinociceptive effects in inflammatory, neuropathic, and ocular pain models without
producing tolerance or dependence upon repeated administration or acute cannabimimetic side effects as
measured in the tetrad assay (Ignatowska-Jankowska, Baillie, et al., 2015; Slivicki et al., 2017, 2020;
Thapa et al., 2020). Additionally, the CB1 receptor PAM, ZCZ011, did not substitute for CP55,940 in the
drug discrimination paradigm or suppress response rates (Ignatowska-Jankowska, Baillie, et al., 2015)
and did not produce a conditioned place preference (CPP) or aversion (CPA) (Trexler et al., 2019). This
indicates that ZCZ011 may not display a potential for abuse liability which contrast studies examining
direct CB1 receptor agonists (e.g., THC and CP55,940) or selective MAGL (e.g., MJN110) and dual
MAGL/FAAH inhibitors (e.g., SA-57). ZCZ011 also did not alter levels of the endocannabinoids, 2-AG
or AEA, in the whole brain (Ignatowska-Jankowska, Baillie, et al., 2015). Lastly, ZCZ011 attenuated
rimonabant-precipitated withdrawal signs in THC-dependent mice and produced additive gastroprotective
effects with JZL184 on diclofenac-induced ulcers (Trexler et al., 2019). With respect to GAT211, it
produces synergistic antinociceptive effects with JZL184 and URB597 (Slivicki et al., 2017) as well as
morphine (Slivicki et al., 2020) in the paclitaxel-induced neuropathic pain model without producing any
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CPP or CPA (Slivicki et al., 2017). This demonstrates that CB1 receptor PAMs directly interact with the
opioid system to produce therapeutic effects and supports the notion that the endocannabinoid and opioid
system heavily interact with each other to elicit potential therapeutic effects, particularly pain modulation
(Mohammadkhani and Borgland, 2020; Ozdemir, 2020) Moreover, a subthreshold dose of GAT211
prevented the development of tolerance to the antinociceptive effects of morphine in the paclitaxelinduced neuropathic pain model, but did not alter morphine CPP (Slivicki et al., 2020). An analog of
ZCZ011, ABD1236 (exhibits enhanced potency and metabolic stability), also demonstrated
antinociceptive effects in the chronic constriction injury model of neuropathic pain without producing any
tetrad effects (Tseng et al., 2019). Furthermore, an endogenous anti-inflammatory lipid, lipoxin A4, was
discovered as the first naturally-occurring CB1 receptor PAM and produces protective effects against βamyloid-induced spatial memory impairment in mice using the Morris water maze, but does in fact
produce tetrad effects when given through intracerebroventricular injections whereby hypo-locomotion,
catalepsy, antinociception (hot plate), and hypothermia were observed even though is does not alter AEA
or 2-AG levels (Pamplona et al., 2012; Pertwee, 2012). In fact, the hypo-locomotion, catalepsy, and
hypothermic effects were confirmed to be CB1-mediated through the use of rimonabant and the cataleptic
effect was absent in CB1 (-/-) mice (Pamplona et al., 2012). Although several studies demonstrate the
attenuation of withdrawal signs in opioid-dependent mice by activating the CB1 receptor through the
orthosteric site or by elevating endocannabinoids through the inhibition of MAGL and/or FAAH, these
approaches elicit profound side effects in animal models (summarized in table 3). Therefore, we sought to
investigate whether the CB1 receptor PAM, ZCZ011, reduces withdrawal signs in opioid-dependent mice
as a potentially favorable strategy due to its diminished side effect profile.
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Table 1. In vitro effects of CB1 receptor positive allosteric modulators in radioligand binding assays
Radioligand binding assays
CB1 receptor
PAMs
(Structures)
ZCZ011

KB,
dissociation
constant
ND

[3H]CP55,940
and/or
[3H]WIN55,212-2
Enhances affinity
of CP55 and
WIN55 equally

GAT211

ND

Enhances affinity
of CP55 (90%)

Decreases
affinity (90%)

Slows down
CP55
displacement

(Laprairie et
al., 2017)

GAT228 (R
enantiomer of
GAT211)

ND

Modestly enhances
affinity or CP55
(30%)

ND

ND

(Laprairie et
al., 2017)

GAT229 (S
enantiomer of
GAT211)

ND

Enhances affinity
of CP55 (130%)

ND

ND

(Laprairie et
al., 2017)

ABD1236

ND

Enhances affinity
of CP55

ND

ND

(Tseng et
al., 2019)

Lipoxin A4

ND

Enhances affinity
of CP55 more than
WIN55

Decreases
affinity

[3H]SR141716A
(Rimonabant)
Decreases
affinity

ND = not determined; CP55 = CP55,940; WIN55 = WIN55,212-2
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Orthosteric
Ligand Binding
Kinetics
Enhances CP55
saturation
binding

References

(Ignatowska
-Jankowska,
Baillie, et
al., 2015)

Slows down
(Pamplona
WIN55
et al., 2012)
displacement of
CP55

Table 2. In vitro effects of CB1 receptor positive allosteric modulators in functional assays

CB1 receptor
PAMs
(Structures)
ZCZ011

GAT211
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[ S]GTPγS Binding
CB1
CB1 agonist
PAM
combination
Alone
AEA, CP55:
No
enhanced
effect
efficacy
CP55:
enhanced
potency
ND
ND

Functional Assays
β-arrestin Recruitment
cAMP inhibition

ERK Phosphorylation
References

CB1 agonist
combination

CB1 PAM
Alone

CB1 agonist
combination

CB1 PAM
Alone

CB1 agonist
combination

CB1 PAM
Alone

AEA:
enhanced
efficacy and
potency

Partial
activation
(30%)

AEA,
CP55:
enhanced
efficacy

Partial
activation
(40%)

Moderate
activation
(70%)

AEA, 2AG, CP55:
enhanced
efficacy and
potency

Full
activation

CP55:
enhanced
potency

Full
activation

AEA:
enhanced
potency
CP55:
enhanced
potency
AEA, 2-AG,
CP55:
enhanced
efficacy and
potency

Partial
activation

(Ignatowska
-Jankowska,
Baillie, et
al., 2015;
Tseng et al.,
2019)
(Laprairie et
al., 2017)

GAT228 (R
enantiomer of
GAT211)

ND

ND

AEA, 2AG, CP55:
no effect

Full
activation

CP55: no
effect to
efficacy or
potency

Weak
activation
versus
arrestin

AEA, 2-AG,
CP55: no
effect

Partial
activation

(Laprairie et
al., 2017)

GAT229 (S
enantiomer of
GAT211)

ND

ND

AEA, 2AG, CP55:
enhanced
efficacy and
potency

No effect

CP55:
enhanced
efficacy and
potency

Full
activation
versus
arrestin

AEA, 2-AG,
CP55:
enhanced
efficacy and
potency

No effect

(Laprairie et
al., 2017)
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ABD1236

ND

ND

CP55:
enhanced
efficacy and
potency

Partial
activation

CP55:
enhanced
efficacy

Partial
activation

ND

ND

(Tseng et
al., 2019)

Lipoxin A4

AEA:
Modestly
reduced GTP
activation

No
effect

ND

ND

AEA:
enhanced
potency
2-AG:
reduced
efficacy

No effect

ND

ND

(Pamplona
et al., 2012)

ND = not determined; CP55 = CP55,940
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1.6. Natural opiates and opioid receptors
While morphine is the prototypical opioid analgesic obtained from the poppy plant Papaver
somniferum, oxycodone, which is derived from the natural opiate thebaine, is highly addictive and is one
of the most abused prescription opiates on the market today (Substance Abuse and Mental Health
Services Administration, 2020). Natural, semi-synthetic, and synthetic opioids act upon the endogenous
opioid system which consists of several families of related neuropeptides and three primary opioid
receptor subtypes: mu, delta, and kappa (Akil et al., 1984; Thompson et al., 1993; Mansour et al., 1995).
The existence of opioid receptors was first identified in 1973 through stereospecific opiate binding in the
central nervous system (Pert and Snyder, 1973; Simon et al., 1973; Terenius, 1973) and subsequent
studies classified them into mu (MOR), delta (DOR), and kappa (KOR) opioid receptors using several
opiates (morphine, ketocyclazocine, and SKF-10,047) in neurophysiological and behavioral assays
(Martin, 1976; Lord et al., 1977). Additional pharmacological characterization has revealed that mu
opioid receptors mediate much of the clinical effects of commonly used opioids, such as oxycodone and
heroin. Moreover, genetically altered (transgenic) mice lacking each respective subtype confirmed that
MORs mediate acute clinical effects such as analgesia, respiratory depression, locomotor stimulation and
reinforcement, as well as chronic effects such as physiological withdrawal signs (Matthes et al., 1996;
Sora et al., 1997; Loh et al., 1998; Becker et al., 2000). MORs are members of the class A (rhodopsin)
family of receptors that couple to the pertussis toxin sensitive, heterotrimeric Gi/o proteins (Jordan and
Devi, 1998) where upon stimulation they inhibit adenylyl cyclase (Sharma et al., 1975), inhibit N and P/Q
type Ca2+ channels, and activate inwardly rectifying K+ channels (Darlison et al., 1997).
With respect to the enteric nervous system, MORs are readily expressed in the submucosal and
myenteric plexuses and longitudinal muscle of the ileum and colon in several species including rat,
mouse, guinea pig, pig, and human (DeHaven-Hudkins et al., 2008) and can be found on both excitatory
and inhibitory myenteric neurons that control smooth muscle tone (DiCello et al., 2020). DORs are also
expressed in the myenteric and submucosal plexuses and more specifically in excitatory motor neurons
and interneurons that express substance P (SP; excitatory), acetylcholine (ACh; excitatory) and nitric
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oxide (NO: inhibitory). Moreover, DORs are expressed in neuropeptide Y-positive secretomotor and
vasodilator neurons in the submucosal plexus (Poole et al., 2011). MORs and DORs readily co-localize
throughout the myenteric plexus of the ileum and colon (DiCello et al., 2020). KORs have also been
localized to myenteric and submucosal neurons, but with higher abundance in myenteric over submucosal
neurons (Bagnol et al., 1997). The major effects of opioid receptor agonists are inhibition of tonic and
peristaltic contractions throughout the small and large intestine by inhibiting ACh and SP release, as well
as decrease GI secretion by inhibiting ACh- and vasoactive intestinal peptide-containing neurons (De
Luca and Coupar, 1996).
In general, opioids have a wide array of clinical uses including analgesia and gastrointestinal
effects; however, continued use of opioids increases the risk of an individual to misuse it and potentially
develop opioid use disorder.
1.7. Opioid use disorder
Opioids are used clinically for their efficacious analgesic, antitussive, and antidiarrheal effects.
Although they are the primary medication used to treat chronic pain, opioids can induce a paradoxical
hyperalgesia, drowsiness, nausea, and constipation following chronic treatment, and individuals can
develop an abuse and dependence liability that limits their therapeutic use (Benyamin et al., 2008). The
DSM-5 reevaluated opioid addiction and has replaced the term with opioid use disorder (OUD) where the
problematic pattern of opioid misuse that leads to problems or distress is classified on a spectrum of 2-3
(mild), 4-5 (moderate), or 6-11 (severe) symptoms that occur in a 12-month period. These include: (1)
taking opioids in larger amounts or over a longer period of time than intended for; (2) a persistent desire
or unsuccessful effort to cut down or control opioid use; (3) a great deal of time is devoted to obtaining
the opioid, using the opioid, and/or recovering from its effects; (4) craving, or having a strong desire to
use opioids; (5) recurrent opioid use resulting in failure to fulfill major role obligations at work, school, or
home; (6) continued opioid use despite having persistent or recurrent social or interpersonal problems
caused or exacerbated by the effects of the opioid; (7) important social, occupational, or recreational
activities are given up or reduced because of opioid use; (8) recurrent opioid use in situations in which it
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is physically hazardous; (9) continued use despite knowledge of having a persistent or recurrent physical
or psychological problem that is likely to have been caused or exacerbated by opioids; (10) tolerance; and
(11) withdrawal. Tolerance is defined as either having a need for markedly increased amounts of opioids
to achieve intoxication or the desired effect, or a markedly diminished effect with continued use of the
same amount of an opioid. Withdrawal manifests from chronic opioid use where cessation of opioid
treatment results in individuals experiencing a withdrawal syndrome characterized by behavioral,
physiological, and psychological symptoms. These include physical symptoms such as diarrhea,
gastrointestinal cramps, emesis, dehydration, hypertension, hyperthermia, tachycardia, and body aches as
well as psychological symptoms such as anxiety, dysphoria, and panic attacks (Jasinski, 1981; Gossop,
1988; Farrell, 1994; Wesson and Ling, 2003; Stolbach and Hoffman, 2020). Tolerance and withdrawal are
two well-studied phenomena in pre-clinical animal research and are a major focus of this current research.
In the United States, misuse of opioids and the prevalence of individuals with OUD remains a
significant public health problem since the late 1990’s when the opioid pandemic began. In 2019,
estimates illustrate that 9.7 million individuals aged 12 or older misused opioids and 1.4 million
individuals developed OUD (Substance Abuse and Mental Health Services Administration, 2020).
Furthermore, emergency departments (ED) provide insightful data and critical information on opioidrelated OUD treatments, detoxification of individuals undergoing opioid withdrawal, and management of
opioid adverse effects (Jackson et al., 2020). Opioid-involved ED visits represent both men (57.8%) and
women (42.2%) with individuals predominantly aged between 24-54 years old (Jackson et al., 2020). In
relevance to the current COVID-19 pandemic, 25 EDs across six US health care systems were
retrospectively studied and found ED visits related to opioid overdoses increased by 28.5% in 2020 (0.32
per 100 adults) compared to 2018 and 2019 (0.25 per 100 adults) and suggest a widespread increase in
opioid-related complications during the pandemic (Soares et al., 2021). It is imperative to find newer and
better treatment options for OUD patients.
1.8. Opioid tolerance and withdrawal in humans
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Tolerance and withdrawal are two phenomena that are readily observed in the clinic where both
develop from prolonged administration of an opioid agonist. In contrast, the measurement of tolerance
and withdrawal are distinct and separate phenomena whereby changes to behavior, physiology, as well as
cellular and molecular responses underlie important differences between each. Opioid tolerance is highly
contextual and depends on the response. For example, individuals often undergo tolerance to the analgesic
effects (Mercadante et al., 2019) whereas constipation is resistant to tolerance signifying a major clinical
problem that limits their use (Kumar et al., 2014). Opioid withdrawal is another major issue in the clinic
because it often becomes a primary driver and acts as a negative reinforcer, which results in perpetuating
ongoing drug use (Bart, 2012; Koob, 2019).
1.8.1.

Opioid withdrawal symptoms in humans
Human opioid withdrawal symptoms are characterized as acute (occur within the first 1-2 weeks)

and protracted (occur after 1-2 weeks and can last for months) withdrawal. Acute withdrawal consists of
many physiological responses such as muscle aches and pains, joint aches, lacrimation, nausea, vomiting,
diarrhea, and so on whereas protracted withdrawal consists of psychological disturbances such as
cravings, insomnia, anxiety, and depression (Dunn et al., 2019). Although the specific duration,
magnitude, and variety of withdrawal symptoms vary across individuals, acute withdrawal symptoms
from short-acting opioids, such as oxycodone and fentanyl, can begin as early as 4-6 hours, peak within 23 days and diminish within 5-7 days. Long-acting opioids, such as methadone, can elicit acute withdrawal
as early as 24-36 hours, peak within 3-7 days, and end within 7-14 days. In addition, certain symptoms
may arise at different times, but the progression of these symptoms often develops as listed above.
Protracted withdrawal extends for additional weeks following acute withdrawal and typically progresses
by starting with cravings and ending with severe anxiety and depression (Dunn et al., 2019).
1.8.2.

Treatments for opioid withdrawal symptoms
Currently, there are a handful of FDA-approved medications to treat acute opioid withdrawal.

Opioid-based medications such as methadone and buprenorphine are the primary treatments used to
reduce acute opioid withdrawal symptoms whereas naltrexone is more commonly used as maintenance
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therapy during the transition of acute to protracted withdrawal. While methadone and buprenorphine do
ameliorate most if not all withdrawal symptoms (Stolbach and Hoffman, 2020), their clinical use is
limited because methadone and buprenorphine are also highly abused in the United States (Cicero and
Inciardi, 2005) and they can trigger a withdrawal syndrome that, albeit less severe, lasts far longer than
heroin or oxycodone (Kuhlman et al., 1998; Dyer et al., 1999). In 2018, the FDA approved lofexidine, an
analog of clonidine, as the first non-opioid based medication which acts as a direct agonist of the α2adrenergic receptor. Adrenergic receptors have been a mechanistic target for opioid withdrawal since
studies demonstrate clonidine and lofexidine attenuate the increased sympathetic activity that occurs in
the locus coeruleus, a brain region highly associated with opioid withdrawal (Koob and Bloom, 1988;
Koob et al., 1992; Maldonado and Koob, 1993; Koob, 2019). Lofexidine and clonidine are used in the
emergency room setting (Stolbach and Hoffman, 2020), but they can produce postural hypotension,
sedation, cognitive impairment, and are not fully effective in attenuating withdrawal symptoms in humans
(Gossop, 1988; Lobmaier et al., 2010). Moreover, clinicians often use over the counter (OTC)
medications to mitigate other withdrawal symptoms such as promethazine for nausea and vomiting,
acetaminophen and ibuprofen for pain and myalgia, baclofen for muscle cramping, and loperamide for
diarrhea and stomach cramps (Stolbach and Hoffman, 2020). Notably, loperamide, often at exceptionally
high doses, has seen increasingly more reports of toxicity since 2005 (Daniulaityte et al., 2013). Data
from the National Poison Data System showed a 91% increase in loperamide exposures between 2010
and 2015 (Vakkalanka et al., 2017). In addition, published loperamide cardiotoxicity case studies
involved people ingesting between 100 to 800 mg per day when the recommended dose to treat diarrhea
is 4 mg (Stolbach and Hoffman, 2020), which limits the clinical utility of using it to treat withdrawalinduced diarrhea and stomach cramps (Miller et al., 2017; Wu and Juurlink, 2017).
Two double-blind, placebo-controlled clinical trials were conducted to determine whether
dronabinol reduces subjective- and observer-rated acute withdrawal scores in opioid dependent
individuals (Bisaga et al., 2015; Lofwall et al., 2016) and whether it enhances retention rates of patients
to transition onto extended release naltrexone (Bisaga et al., 2015). Bisaga et al. (2015) aimed to compare
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the severity of opioid withdrawal across an eight-day inpatient phase where dronabinol was administered
twice a day and an eight-week outpatient phase where 20 to 30 mg of dronabinol was given once a day.
The Subjective Opiate Withdrawal Scale (SOWS) was used to assess the inpatient phase and the
Hamilton Rating Scale of Depression (HAM-D) for the outpatient phase. The primary result was
dronabinol reduced SOWS from days 2-4 during the inpatient phase, but no differences were observed
between placebo thereafter; however, importantly, patients began naltrexone treatment on day 5 and can
likely explain the lack of differences between groups since naltrexone can also reduce withdrawal scores.
The authors describe that escalating doses of naltrexone were given at day five since it too can precipitate
withdrawal, but it provided a tolerable ramping dose procedure before receiving an administration of
extended-release naltrexone on week one of the 8-week outpatient phase. No differences were observed in
the outpatient phase between dronabinol and placebo groups regarding retention rates on extended-release
naltrexone. In sum, dronabinol elicited reduced opioid withdrawal symptoms during the acute inpatient
phase, but did not affect retention rates when transitioning to naltrexone therapy. Lofwall et al. (2016)
recruited oxycodone-dependent participants that were stabilized on 30 mg of oxycodone before
undergoing acute withdrawal testing. Multiple doses of dronabinol (5, 10, 20, 30 mg) as well as multiple
doses of oxycodone (30 and 60 mg) were used across several withdrawal sessions. Importantly, 40 mg
dronabinol was not used because they reported sinus tachycardia as well as anxiety and panic at this dose
(Jicha et al., 2015). The primary finding was that participants exhibited reduced objective opiate
withdrawal scores with 30 mg of dronabinol relative to placebo, although the suppression was for a
limited duration of time and generally incomplete. With respect to specific withdrawal signs, 30 mg of
dronabinol reduced backaches, feeling sick, lacrimation, rhinorrhea, yawning, and muscular tension.
Importantly, authors discussed how 30 mg of dronabinol elicited tachycardia, psychoactive effects and
slower reaction times in participants suggesting that while a cannabinoid agonist may reduce opioid
withdrawal, there are unwarranted side effects. In fact, they did not recommend using dronabinol as a
monotherapy and combination with other medications (e.g., clonidine/lofexidine) may be needed to
mitigate adverse effects on heart rate. Therefore, alternative and adjunct treatments are needed to combat
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the myriad of side effects associated with FDA-approved and OTC medications to alleviate opioid
withdrawal.
1.9. Neuroadaptive changes of opioid tolerance and withdrawal in rodent models
Complex neuroadaptive changes underlie opioid tolerance and dependence. Tolerance in rodents
is often studied as observing a loss of an effect following repeated administration of the opioid (Bailey
and Connor, 2005). Persistent activation of MORs, desensitization of MORs occurs through G-protein
receptor kinases (GRKs) that phosphorylate the C terminus which subsequently leads to the recruitment
of β-arrestin2 (Williams et al., 2013) and continues to be an underlying mechanism of tolerance.
Moreover, protein kinase C (PKC) is also implicated in opioid tolerance where the Gβγ subunits activate
PKC and can subsequently recruit β-arrestin2 (Bailey and Connor, 2005; Williams et al., 2013).
Thereafter, clathrin-mediated binding to β-arrestin2 can lead to internalization and then
degradation/downregulation or recycling of MORs back to the cell membrane (Ferguson, 2001; Van
Bockstaele and Commons, 2001; Bailey and Connor, 2005). With respect to the enteric nervous system,
tolerance develops to the inhibition of small intestinal transit by chronic morphine treatment using the
charcoal transit model, but not in the colon as measured by the length of time for a bead to be expelled
(Ross et al., 2008). Furthermore, tolerance developed to morphine’s inhibition on electrically-evoked
contractions in the ileum, but not the colon (Ross et al., 2008; Kang et al., 2012). Interestingly, βarrestin2 (-/-) mice did develop tolerance to morphine’s inhibition of electrically-evoked contractions in
the colon, but tolerance continued to be observed in the ileum suggesting that β-arrestin2 is differentially
implicated in the resistance of tolerance in the colon whereas the tolerance observed in the ileum is likely
due to a different cellular signaling pathway (Kang et al., 2012).
While opioid tolerance is often associated with internalization/downregulation of MORs, opioid
dependence involves compensatory changes through downstream effectors, particularly the cyclic
adenosine monophosphate (cAMP) pathway. Of note, the mitogen activated protein kinase (MAPK)
pathway and Ca2+ signaling are also implicated during opioid dependence. Following acute activation of
MORs, Gi/o proteins produce the following actions occur: (1) inhibition of adenylyl cyclase which results
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in decreased levels of cAMP and subsequently reduces the activation of protein kinase A (PKA) activity
and phosphorylation of cAMP response element binding protein (CREB) (Childers et al., 1992); (2)
inhibition of Ca2+ channels; (3) activation of inwardly rectifying K+ channels; (4) inhibition of
neurotransmission release; (5) activation of PKC; (6) activation of MAPK (Williams et al., 2001).
Following the cessation of the opioid agonist (spontaneous withdrawal) or the administration of an opioid
antagonist such as naloxone (precipitated withdrawal), the overactivation of adenylyl cyclase and
subsequent overproduction of cAMP occurs which leads to the overactivation of PKA and CREB (Nestler
and Tallman, 1987; Guitart et al., 1992). More specifically, Lane-Ladd et al. (1997) discovered that the
locus coeruleus (LC) upregulates certain subtypes of adenylyl cyclase (types I and VIII) as well as the
catalytic and type II regulatory subunits of PKA. Direct infusion of a CREB antisense oligonucleotide
completely blocks the upregulation of type VIII adenylyl cyclase and prevented morphine-induced
increases in spontaneous neural firing rates, providing direct evidence that CREB is highly implicated in
regulating physical opiate dependence. CREB is also a downstream target of MAPK and Ca2+ in various
brain regions such as the anterior cingulate, somatosensory and association cortices, LC, and amygdala
(Eitan et al., 2003). The ventral tegmental area (VTA), which contains dopaminergic neurons and is a
component of the mesolimbic reward pathway, is also a brain region associated with gene expression
alterations during morphine withdrawal in rats and mice. While gene expression alterations vary between
brain regions, prodynorphin, the precursor protein to producing endorphins, and FK506 binding protein 5
showed high regulatory responses in both the VTA and the LC and that inhibition of either protein
profoundly affects withdrawal responses, demonstrating that these genes have important functional roles
in mediating physical opiate dependence (McClung et al., 2005).
Much of the neurobiological regions associated with withdrawal-induced jumping, paw flutters,
and head shakes are known. For instance, direct infusion of methylnaltrexone in the LC and PAG of
morphine-dependent mice precipitates withdrawal-induced jumping, paw flutters, and head shakes (Koob
et al., 1992) and electrode-induced lesions to the LC prevents these withdrawal signs (Maldonado and
Koob, 1993). On the contrary, less is known about the neurobiological mechanisms of withdrawal32

induced diarrhea and weight loss. Initial studies assumed that the basis of withdrawal-induced diarrhea
was solely due to increased intestinal motility (Kaymakcalan and Temelli, 1964; Schulz and Herz, 1976;
Gintzler, 1979; Huidoro-Toro and Way, 1981); however, it was established that diarrhea is a consequence
of both increased motility (Brown et al., 1988) and a decreased ability for the small intestinal mucosa to
absorb fluid (Beubler and Juan, 1979; Chang et al., 1984). Naloxone-precipitated motility is readily
modeled using guinea pig, mouse, and rat ileal tissue where prolonged exposure to opioids (commonly
morphine) followed by naloxone leads to profound tissue contractions (Johnson et al., 1988; Capasso and
Sorrentino, 1997; Capasso, 2000; Aricioglu et al., 2003; Ramesh et al., 2011; Singh et al., 2015). Several
non-opioid treatments have been shown to attenuate naloxone-precipitated contractions such as insulin
(Singh et al., 2015), adenosine receptor agonists (Capasso, 2000), and metabolites of arachidonic acid
(Capasso and Sorrentino, 1997). However, the endocannabinoid system has also been implicated in
reducing naloxone-precipitated motility and hypersecretion.
A naloxone-precipitated contraction model in mice was established by exposing isolated ileal
tissue to morphine followed by naloxone to elicit profound contractions. The respective MAGL and
FAAH inhibitors, JZL184 and PF-3845, have been shown to attenuate naloxone-precipitated contractions
in morphine-dependent ileal tissue (Ramesh et al., 2011). Moreover, naloxone-precipitated hypersecretion
can be modeled using segments of ileal tissue in Ussing chambers where the short-circuit (Isc) current is
measured as an indicator of net ion transport across the mucosal layer (Ramesh et al., 2013). Morphine
treatment induced a mild decrease in the Isc current whereas the application of naloxone produced a
profound increase in Isc current, signifying a naloxone-precipitated hypersecretion response. Both MAGL
and FAAH inhibitors attenuated this naloxone-precipitated hypersecretion (Ramesh et al., 2013). While
the cellular hallmark of opioid withdrawal in the brain is the overactivation of the cAMP pathway as
described above, very little is known about the cellular mechanism of naloxone-precipitated motility or
hypersecretion in the ileum. However, inferences from two studies that investigated and established a
naloxone-precipitated withdrawal response in isolated neurons of the ileum and colon of mice may
provide insight (Smith et al., 2012, 2014). Myenteric neurons were isolated and patch-clamped to identify
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afterhyperpolarization (AHP)-positive neurons and voltage-clamped to demonstrate a greater current
density-voltage relationship of Na+ and K+ channels in AHP-positive neurons. Ileal neurons from mice
implanted with 75 mg morphine pellets or incubated with morphine overnight demonstrated a naloxoneprecipitated withdrawal in AHP-positive neurons whereas colonic neurons did not display a naloxoneprecipitated phenotype. Conversely, precipitation of withdrawal did occur in colonic neurons in βarrestin2 (-/-) mice (Smith et al., 2014). These results suggest that the development of naloxoneprecipitated withdrawal in the colon is only revealed when β-arrestin2 is no longer present whereas the
cellular mechanism of withdrawal in the ileum remains to be determined. One can speculate that the
cellular mechanism involved in the development of tolerance (Ross et al., 2008; Kang et al., 2012) and
dependence (Smith et al., 2014) in the ileum could also be a dysregulation of the cAMP pathway
similarly to the brain.
1.10.

Opioid withdrawal signs in rodent models
Pre-clinical research has well characterized withdrawal responses in opioid-dependent rodents.

Both precipitated and spontaneous withdrawal models are used to study opioid withdrawal signs. Rodents
are commonly rendered opioid dependent following repeated injections of opioids over several days or by
implantation of a pellet or mini-pumps that release opioids continually. The administration of an opioid
antagonist (commonly naloxone) is used to precipitate withdrawal signs in opioid dependent rodents or
cessation of injections/removal of pellets or mini-pumps leads to spontaneous withdrawal (Leong Way et
al., 1969; Ramesh et al., 2011, 2013). Rodents display a number of commonly withdrawal signs including
jumping, paw fluttering, head/body shaking, ptosis, teeth chattering, weight loss, and diarrhea (Leong
Way et al., 1969). The precipitated withdrawal model enables researchers to produce high throughput
data and a reliable model to screen novel compounds to assess their anti-withdrawal effects. While
morphine is readily used as the opioid of choice in rodent withdrawal models, over 3 million individuals
misuse oxycodone for pain relief whereas approximately 490,000 individuals misused morphine in 2019
and 2020 (Substance Abuse and Mental Health Services Administration, 2020). Thus, more research is
needed on the use of oxycodone in rodent withdrawal models.
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1.11.

Targeting the endocannabinoid system to ameliorate opioid withdrawal signs in rodents
Several studies have been conducted that demonstrate the efficacy of targeting the

endocannabinoid system to attenuate withdrawal signs in rodent models (see table 3). In the 1970s, THC
was shown to attenuate naloxone-precipitated morphine withdrawal signs (i.e., diarrhea, fecal boli,
defecation, jumping, and wet dog shakes) in male rats and mice (Hine, Friedman, et al., 1975; Bhargava,
1976b). In male mice implanted with a 75 mg morphine pellet, intravenous THC (10 mg/kg) reduced
naloxone-precipitated jumping and weight loss (Vela et al., 1995). Moreover, the same study found that
an intravenous injection of AEA (5 mg/kg) reduced naloxone-precipitated jumping and weight loss in two
different procedures to induce morphine dependence: (1) the sue of 75 mg morphine pellets; and (2) an
escalating dose procedure of morphine (Vela et al., 1995). The endocannabinoid, 2-AG, (10 μg i.c.v.)
reduced naloxone precipitated withdrawal signs in mice following five days of escalating morphine
injections (8-45 mg/kg s.c. twice daily) (Yamaguchi et al., 2001) although CB1 receptor involvement was
not tested in either of the Vela et al. nor Yamaguchi et al. studies. MAGL and FAAH inhibition are also
alternative approaches to targeting the endocannabinoid system to ameliorate opioid withdrawal signs.
Inhibition of the endocannabinoid degradative enzymes reduce withdrawal signs through a CB1
receptor dependent mechanism, supporting this approach as an alternative means to alleviate opioid
withdrawal (Ramesh et al., 2011). Male mice implanted with a 75 mg morphine pellet were administered
the MAGL inhibitor, JZL184, or the FAAH inhibitor, PF-3845 2 h prior to naloxone administration. 4,
16, and 40 mg/kg i.p. of JZL184 reduced the number of jumps while 16 and 40 mg/kg i.p. of JZL184
reduced paw flutters, weight loss, and diarrhea. The anti-withdrawal effects of JZL184 were all blocked
by the selective CB1 receptor antagonist, rimonabant (3 mg/kg), but not the selective CB2 receptor
antagonist, SR144528 (3 mg/kg). In contrast, the FAAH inhibitor, PF-3845 (10 mg/kg i.p.) reduced
jumping and paw flutters, which was reversed by rimonabant, but no anti-withdrawal effects were
observed on weight loss or the presence of diarrhea. These data suggest that selective MAGL inhibition
attenuates several withdrawal signs (i.e., diarrhea, weight loss, jumps, paw flutters, and head shakes),
whereas inhibition of FAAH reduces a subset of withdrawal signs (i.e., jumping and paw flutters). A
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follow-up study examined the combination of a low-dose of the MAGL inhibitor, JZL184 (4 mg/kg i.p.),
that is known to not produce antinociceptive tolerance or cannabinoid dependence (Kinsey et al., 2013)
with a high-dose of the FAAH inhibitor, PF-3845 (10 mg/kg i.p.), that only reduced a subset of
withdrawal signs to determine whether concomitant increase of 2-AG and AEA levels would reduce
naloxone-precipitated and spontaneous withdrawal signs in morphine-dependent mice (Ramesh et al.,
2013). Moreover, the dual MAGL/FAAH inhibitor, SA-57, was also assessed. The results indicated that
the combination of JZL184 and PF-3845 reduced naloxone-precipitated and spontaneous withdrawalinduced jumps, paw flutters, weight loss, and diarrhea to a greater extent than either alone, with
rimonabant blocking these anti-withdrawal effects suggesting a CB1 receptor dependent mechanism.
Furthermore, SA-57 also reduced the number of jumps, paw flutters, head shakes, weight loss, and the
presence of diarrhea in morphine-dependent mice undergoing spontaneous withdrawal (Ramesh et al.,
2013). Because FAAH inhibition only reduces a subset of withdrawal signs and selective MAGL
inhibition and dual MAGL/FAAH inhibition elicits a discriminative stimulus in mice (Owens et al., 2017)
the approach of targeting endocannabinoid degradative enzymes is diminished and a more selective
approach in targeting the CB1 receptor without untoward side effects are suggested.
The CB1 receptor PAM, GAT211, was examined in a naloxone-precipitated withdrawal model of
morphine-dependent mice and did not reduce the number of jumps or paw flutters in mice implanted with
a 75 mg morphine pellet challenged with naloxone (Slivicki et al., 2020). In contrast, we tested the CB1
receptor PAM, ZCZ011, before the Slivicki et al. (2020) manuscript was published in a recently
established model of naloxone-precipitated withdrawal in oxycodone-dependent mice (Enga et al., 2016;
Carper et al., 2021) whereby mice receive escalating doses of oxycodone over eight days and on day nine,
mice undergo naloxone-precipitated withdrawal. The results indicated that ZCZ011 reduced naloxoneprecipitated diarrhea and weight loss through a CB1 receptor, not a CB2 receptor, dependent mechanism.
The discrepancies between these studies are likely due to, (1) the opioid used (i.e., morphine versus
oxycodone), and (2) the pre-treatment time (75 min for ZCZ011 and 30 min for GAT211) used. Further
studies are needed to test multiple CB1 receptor PAMs in multiple models of opioid dependence. The
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effects of targeting the CB1 receptor on naloxone-precipitated withdrawal in opioid-dependent animals is
summarized in table 3.
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Table 3. Effects of cannabinoids targeting the CB1 receptor on precipitated-withdrawal in opioid-dependent animals
Cannabinoid Target
and in vivo
Side effects
CB1 Receptor
Agonists through the
Orthosteric Site
Side Effects
• HypoLocomotion
• Catalepsy
• Hypothermia
• Discriminative
stimulus
produced
• CB dependence
• Anti-nociceptive
tolerance

Cannabinoid
compound

Sex and
Species

Dependence
Induction

∆9-THC (1, 2, 5,
10 mg/kg i.p.)

Male rats

75 mg morphine
pellet (72 h) s.c.

Naloxone (4
mg/kg, i.p.)

∆9-THC (2.5, 5,
10 mg/kg i.p.)

Male mice

75 mg morphine
pellet (72 h) s.c.

∆9-THC (2
mg/kg p.o.)

Female
guinea
pigs

∆9-THC (10
mg/kg i.v.)

Male mice

AEA (1, 5
mg/kg, i.v.)

Male mice

AEA (0.1, 1, 5
mg/kg, i.v.)

Male mice

∆9-THC (0.1,
0.3, 1, 3, 10
mg/kg p.o.)
HU-210 (0.01,
0.1 mg/kg i.p.)

Male mice

Slow-release
suspension of
morphine (300
mg/kg) (48 h)
75 mg
morphine pellet
(72 h) s.c.
75 mg
morphine pellet
(72 h) s.c.
Morphine b.i.d.,
8-45 mg/kg (5
days) s.c.
75 mg morphine
pellet (72 h) s.c.

Naloxone, i.p.
(specific doses
not reported)
Naloxone (0.1
mg/kg, s.c.)

2-AG (1, 10
μg/kg i.c.v.)

Male
Mice

Male
Mice

Morphine b.i.d.,
8-45 mg/kg (5
days) s.c.
Morphine b.i.d.,
8-45 mg/kg (5
days) s.c.
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Withdrawal
Type

Outcome on Precipitated
Withdrawal Signs

Reference

(Hine,
Friedman, et
al., 1975)
(Bhargava,
1976b)

Naloxone (1
mg/kg, i.p.)

5 and 10 mg/kg reduced wet
shakes, fecal boli, and diarrhea
(only 5 mg/kg)
All doses reduced jumping,
defecation, and rearing; shifted
naloxone ED50
2 mg/kg reduced total
withdrawal score (jumping, wet
shakes, digging, yawning, ptosis,
diarrhea)
10 mg/kg reduced jumping and
weight loss

Naloxone (1
mg/kg, i.p.)

5 mg/kg reduced jumping and
weight loss

(Vela et al.,
1995)

Naloxone (5
mg/kg, s.c.)

5 mg/kg reduced jumping and
weight loss

(Vela et al.,
1995)

Naloxone (1
mg/kg, s.c.)

(Lichtman et
al., 2001)

Naloxone (3.2
mg/kg, i.p.)

0.3-10 mg/kg reduced paw
flutters and head shakes, but no
effect on diarrhea or jumping
0.1 mg/kg reduced jumping and
paw flutters

Naloxone (3.2
mg/kg, i.p.)

10 mg/kg reduced jumping and
paw flutters

(Yamaguchi
et al., 2001)

(Frederickso
n et al.,
1976)
(Vela et al.,
1995)

(Yamaguchi
et al., 2001)

Inhibitors of eCB
degradative enzymes
Side effects
• HypoLocomotion
• Discriminative
stimulus
produced
• CB dependence
• Anti-nociceptive
tolerance

AM404 (2, 10
mg/kg i.p.)

Mice (no
sex
specified)

Morphine b.i.d.,
20-100 mg/kg (5
days) i.p.

Naloxone (1
mg/kg, i.p.) on
day 6

∆9-THC (1, 20,
50 mg/kg p.o.)

Male mice

Naloxone (1
mg/kg, s.c.)

∆9-THC (1, 3,
10 mg/kg
i.p.)

Male mice

Morphine b.i.d.,
200-300 mg/kg
(7 days), p.o.
75 mg
morphine pellet
(72 h) s.c.

∆9-THC (1, 3,
10 mg/kg
i.p.)

Male mice

75 mg
morphine pellet
(48 h) s.c.

Naloxone
(0.056 mg/kg,
s.c.)

URB597
(FAAH
inhibitor) (0.03,
0.1, 0.3, 0.5, 1
mg/kg i.p.)
JZL184 (MAGL
inhibitor) (4, 16,
40 mg/kg, i.p.)

Male rats

Morphine q.d. 666 mg/kg (7
days) s.c.

Male mice

75 mg
morphine pellet
(72 h) s.c.

Naloxone (3
mg/kg, s.c.) 24
h after last
morphine
injection
Naloxone (1
mg/kg, s.c.)

PF-3845 (FAAH
inhibitor) (10
mg/kg, i.p.)
JZL184 (4
mg/kg i.p.) +
PF-3845 (10
mg/kg i.p.)

Male mice

75 mg
morphine pellet
(72 h) s.c.
75 mg
morphine pellet
(72 h), s.c.

Male mice
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Naloxone (1
mg/kg, s.c.)

Naloxone (1
mg/kg, s.c.)
Naloxone (1
mg/kg, s.c.)

AM404 did not reduce
precipitated jumping, wet dog
shakes, abdominal constrictions,
weight loss, swallowing
movement, or piloerection
All doses reduced jumping, but
no reduction in diarrhea
All doses reduced paw flutters
and weight loss #; 3 and 10
mg/kg THC reduced jumping
and diarrhea
10 mg/kg THC reduced jumping

0.3-1 mg/kg URB597 reduced
jumping, teeth chattering, wet
dog shakes, weight loss,
standing, sniffing, face
grooming, penis licking
All doses reduced jumping #; 16
and 40 mg/kg JZL184 reduced
paw flutters, weight loss, and
diarrhea #
PF-3845 reduced jumping and
paw flutters #, but not weight
loss or diarrhea
Combination of JZL184+PF3845 reduced jumping, paw
flutters, weight loss, diarrhea

(Del Arco et
al., 2002)

(Cichewicz
and Welch,
2003)
(Ramesh et
al., 2011)

(Gamage et
al., 2015)

(Shahidi and
Hasanein,
2011)

(Ramesh et
al., 2011)

(Ramesh et
al., 2011)
(Ramesh et
al., 2013)

CB1 Receptor
Positive Allosteric
Modulators through
an Allosteric Site
Side effects
• No known side
effects in animals

JZL184 (4 and
40 mg/kg i.p.)

Male mice

PF-3845 (1, 3,
10 mg/kg i.p.)

Male mice

SA-57 (dual
MAGL + FAAH
inhibitor) (1.25,
5, 12.5 mg/kg
i.p.)

Male mice

GAT211 (20
mg/kg i.p.)

Male mice

ZCZ011 (5, 10,
20 ,40 mg/kg
i.p.)

Male and
female
mice

75 mg
morphine pellet
(48 h) s.c.
75 mg
morphine pellet
(48 h) s.c.
75 mg
morphine pellet
(48 h) s.c.

Naloxone
(0.056 mg/kg,
s.c.)
Naloxone
(0.056 mg/kg,
s.c.)
Naloxone
(0.056 mg/kg,
s.c.)

40 mg/kg JZL184 reduced
jumping

(Gamage et
al., 2015)

No dose reduced jumping

(Gamage et
al., 2015)

5 and 12.5 mg/kg SA-57 reduced
jumping

(Gamage et
al., 2015)

75 mg
morphine pellet
(72 h), s.c.
Oxycodone b.i.d.
9-33 mg/kg (8
days) s.c. + 33
mg/kg on day 9

Naloxone (1
mg/kg, i.p.)

Did not reduce jumping or paw
flutters

(Slivicki et
al., 2020)

40 mg/kg ZCZ011 fully reduced (Dodu et al.,
diarrhea and weight loss #. 20
2021)
and 40 mg/kg partially reduced
paw flutters and head shakes.
ZCZ011 did not reduce jumping.
# indicates CB1-mediated effects. B.i.d. indicates “bis in die” meaning twice a day. Q.d. indicates “quaque die” meaning once a day.
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Naloxone (1
mg/kg, s.c.) 2
h after last
injection

1.12.

Hypothesis and Rationale

1.12.1. Overall Hypothesis
The CB1 receptor positive allosteric modulator, ZCZ011, attenuates naloxone-precipitated
withdrawal signs in oxycodone-dependent male and female mice through the activation of CB1 receptors.
1.12.2. Objectives
Our aims for these studies were to (1) assess the efficacy of the CB1 receptor PAM, ZCZ011, in
oxycodone-dependent mice undergoing naloxone-precipitated withdrawal and determine which
cannabinoid receptors mediate the anti-withdrawal effects of ZCZ011; and (2) determine cannabinoid
receptor involvement of how ZCZ011 inhibits small intestinal transit in mice and whether these effects
undergo tolerance.
1.12.3. Rationale
Although several pre-clinical studies targeting the CB1 orthosteric receptor have shown
reductions of withdrawal signs in opioid-dependent laboratory animals (Hine, Friedman, et al., 1975;
Hine, Torrelio, et al., 1975; Bhargava, 1976b; a; Vela et al., 1995; Lichtman et al., 2001; Cichewicz and
Welch, 2003; Ramesh et al., 2011; Gamage et al., 2015), this pharmacological approach also elicits acute
cannabimimetic side effects and results in tolerance and physical dependence following repeated
administration (Wiley and Martin, 2003; Grim, Samano, et al., 2016; Trexler et al., 2018, 2019).
Moreover, while inhibitors of MAGL and FAAH (both selective inhibition or non-selective dual
inhibition) attenuate naloxone-precipitated and spontaneous withdrawal signs in opioid-dependent mice
with reduced cannabimimetic side effects (Ramesh et al., 2011, 2013; Gamage et al., 2015; Wills et al.,
2016), MAGL inhibitors can also elicit CB1 receptor downregulation and desensitization, and physical
dependence following repeated administration and FAAH inhibitors only reduce a subset of withdrawal
signs (Schlosburg et al., 2010, 2014; Ramesh et al., 2011) thereby limiting this indirect approach of
activating CB1 receptors to alleviate withdrawal signs.
On the contrary, CB1 receptor PAMs can offer therapeutic potential to treat opioid dependence
without eliciting side effects associated with activating CB1 receptors through the orthosteric site. The
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rationale to select the CB1 receptor PAM, ZCZ011, are due to multiple reasons based two studies. First,
ZCZ011 did not substitute for CP55,940 in C57BL/6J mice or AEA in FAAH (-/-) mice demonstrating a
lack of potential abuse liability (Ignatowska-Jankowska, Baillie, et al., 2015), whereas other CB1 receptor
PAMs have yet to be tested in the drug discrimination paradigm. And second, a previous study
demonstrated that ZCZ011 does in fact readily cross the blood-brain barrier (Poklis et al., 2015) at times
that correlate with the pre-treatment time of 75 min used in inflammatory and neuropathic pain models,
whereas no other CB1 receptor PAM published has been measured in the brain directly.
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Chapter 2: The CB1 Receptor Positive Allosteric Modulator, ZCZ011, Attenuates NaloxonePrecipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice1
2.1. Introduction
Misuse of opioids and the prevalence of individuals with opioid use disorder (OUD) remains a
significant public health problem in the United States. Recent 2019 estimates are that 9.7 and 1.4 million
individuals aged 12 or older misused opioids and developed OUD, respectively (Substance Abuse and
Mental Health Services Administration, 2020). Although current medications used to treat opioid
dependence attenuate withdrawal symptoms such as diarrhea, emesis, hand tremors, and anxiety (Farrell,
1994; Wesson and Ling, 2003), they also possess abuse liability (e.g., methadone and buprenorphine)
(Cicero and Inciardi, 2005) and are not fully effective for all patients (e.g., lofexidine/clonidine)
(Kuhlman et al., 1998; Stolbach and Hoffman, 2020). Thus, a great need exists to develop new
efficacious pharmacotherapies, which lack abuse potential, to alleviate opioid withdrawal.
A case report from the 19th century describing an opium-dependent patient treated with cannabis
extract (Birch, 1889) suggested that cannabinoid-based medications may effectively treat opioid
dependence. A clinical trial conducted more than a century later demonstrated that the primary active
constituent of cannabis, ∆9-tetrahydrocannabinol (THC), alleviates withdrawal symptoms in opioiddependent patients (Bisaga et al., 2015; Lofwall et al., 2016). Nevertheless, unwanted side effects of
THC, including tachycardia, somnolence, and intoxication (Jicha et al., 2015; Lofwall et al., 2016),
hinders its application to treat opioid use disorder. THC produces most of its pharmacological effects
through the activation of two G-protein coupled receptors, cannabinoid receptor type 1 (CB1; Matsuda et
al., 1990) and type 2 (CB2; Munro et al., 1993). THC and other CB1 receptor agonists effectively
attenuate withdrawal signs in opioid-dependent rodents (Hine, Friedman, et al., 1975; Hine, Torrelio, et
al., 1975; Bhargava, 1976a,b; Vela et al., 1995; Lichtman et al., 2001; Cichewicz and Welch, 2003;
Ramesh et al., 2011; Gamage et al., 2015), though this pharmacological approach elicits acute

1

This chapter reflects the article that was recently published in the Journal of Pharmacology and Experimental
Therapeutics (Dodu et al., 2021).
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cannabimimetic side effects and results in tolerance and physical dependence after repeated
administration (Wiley and Martin, 2003; Grim, Samano, et al., 2016; Trexler et al., 2018, 2019).
Alternatively, inhibitors of monoacylglycerol lipase (MAGL; Dinh et al., 2002) and fatty acid amide
hydrolase (FAAH; Cravatt et al., 1996), which hydrolyze the respective endogenous cannabinoids, 2arachidonoylglycerol (2-AG; Mechoulam et al., 1995; Sugiura et al., 1995) and anandamide (AEA;
Devane et al., 1992), attenuate naloxone-precipitated and spontaneous withdrawal signs in morphinedependent mice with reduced cannabimimetic side effects (Ramesh et al., 2011, 2013; Gamage et al.,
2015; Wills et al., 2016). However, CB1 receptor downregulation and desensitization, and physical
dependence following repeated administration of high doses of MAGL inhibitors (Schlosburg et al.,
2010, 2014; Ramesh et al., 2011) represents a challenge for this approach.
CB1 receptor positive allosteric modulators (PAMs) offer therapeutic potential to treat opioid
dependence and other conditions, without eliciting side effects associated with THC. Indeed, the CB1
receptor PAMs ZCZ011 and GAT211 lack overt behavioral cannabimimetic effects, but produce
antinociceptive effects in multiple rodent models of pain (Ignatowska-Jankowska, Baillie, et al., 2015;
Slivicki et al., 2017, 2020; Thapa et al., 2020) as well as reduce withdrawal signs in cannabinoiddependent mice (Trexler et al., 2019). These molecules are believed to bind at allosteric site(s) on the CB1
receptor that results in a conformational change of the orthosteric site to enhance the binding and efficacy
of endogenous cannabinoids and/or elicit allosteric agonist effects on their own (Dopart et al., 2018;
Tseng et al., 2019), and may also be classified as a positive allosteric agonist (ago-PAMs) (Kenakin,
2013).
Here we tested whether the CB1 receptor PAM, ZCZ011, attenuates naloxone-precipitated
withdrawal signs using an established mouse model of oxycodone-dependence (Enga et al., 2016; Carper
et al., 2021). Oxycodone represents a widely used prescription opioid misused by 3.2 million people aged
12 or older in the United States (Substance Abuse and Mental Health Services Administration, 2020).
Oxycodone-dependent male and female mice were challenged with naloxone to precipitate multiple
withdrawal signs including, diarrhea, body weight loss, jumps, paw flutters, and head shakes. We
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compared the actions of ZCZ011 on naloxone-precipitated withdrawal signs to those of oxycodone, which
served as a positive control. Lastly, we employed the CB1 receptor inverse agonist/antagonist, rimonabant,
the CB2 receptor antagonist, SR144528, and constitutive CB1 (-/-) mice (Zimmer et al., 1999) to assess
cannabinoid receptor involvement of the anti-withdrawal effects of ZCZ011.
2.2. Methods
2.2.1.

Animals
Male and female ICR mice (minimum 8 weeks of age; Envigo, Indianapolis, IN, USA) with

respective body weights of 35-45 g and 30-40 g served as subjects. ICR mice were delivered at 7 weeks
followed by one week of habituation in VCU’s vivarium before testing began. Age-matched male and
female CB1 (+/+) and CB1 (-/-) mice, derived from CB1 (+/-) breeding pairs bred within the Mutant
Mouse Core at Virginia Commonwealth University, also served as subjects. These transgenic mice were
created by Zimmer and colleagues (1999) and have been backcrossed onto a C57BL/6J background for at
least 15 generations. The subjects were housed up to four mice per cage, in a light- (12 h light/dark cycle;
lights on at 0600), temperature- (20–22°C) and humidity-controlled (55% ± 10%) AAALAC–approved
facility at Virginia Commonwealth University. Mice received water and standard rodent chow ad libitum.
Animal protocols were approved by the Institutional Animal Care and Use Committee at Virginia
Commonwealth University and were in accordance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals.
2.2.2.

Drugs
Oxycodone hydrochloride [(5α)-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one],

naloxone hydrochloride [(1S,5R,13R,17S)-10,17-dihydroxy-4-(prop-2-en-1-yl)-12-oxa-4azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one], rimonabant, the CB1 receptor
inverse agonist/antagonist [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1Hpyrazole-3-carboxamide HCl], and SR144528, the CB2 receptor antagonist, [N-[(1S)-endo-1,3,3,trimethylbicyclo[2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3carboxamide], were obtained from the National Institute on Drug Abuse Drug Supply Program (Bethesda,
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MD). ZCZ011, the CB1 receptor PAM [6-methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole],
was synthesized based on Ignatowska-Jankowska and colleagues (2015) and improved upon according to
an established protocol in the Lu laboratory (see Supplemental information for revised synthesis).
ZCZ011, rimonabant, and SR144528 were dissolved in a vehicle solution consisting of a mixture of
ethanol, alkamuls-620 (Sanofi-Aventis, Bridgewater, NJ), and saline (0.9% NaCl; sterile) in a 1:1:18
ratio. Oxycodone and naloxone were dissolved in sterile 0.9% saline. All injections were administered in
a volume of 10 ml/kg of body weight. Oxycodone and naloxone were administered via the subcutaneous
(s.c.) route of administration, whereas ZCZ011, rimonabant, and SR144528 were given via intraperitoneal
(i.p.) injection.
2.2.3.

Naloxone-precipitated oxycodone withdrawal model
To induce oxycodone dependence, counter-balanced groups of male and female mice were

administered escalating doses of oxycodone over an eight day period as previously described (Enga et al.,
2016; Carper et al., 2021). In brief, mice were administered s.c. injections of 9.0, 17.8, 23.7, then 33.0
mg/kg oxycodone (or saline) twice a day separated by approximately 7 h on days 1-2, 3-4, 5-6, and 7-8,
respectively. On day nine, mice were administered 33 mg/kg oxycodone (or saline) followed by 1 mg/kg
naloxone 2 h later to precipitate withdrawal (Enga et al., 2016; Carper et al., 2021) and withdrawal signs
were assessed (Fig. 1) as previously described with some modifications (Ramesh et al., 2011).
Plexiglas chambers were used to house mice during withdrawal assessment, with each chamber
constructed of white sides and white bottom panels, a clear perforated top panel (eight ¼ inch diameter
holes for ventilation), a sliding clear front panel (23 cm H), and a sliding mirrored back panel (23 cm H).
The chambers were enclosed in sound-attenuating cabinets that contained an indirect filtered LED light
source and fans for air circulation and white noise. Each cabinet contained a mounted 2.8-12.0mm
varifocal lens mini-USB camera (Ailipu Technology Co., Ltd, Guangdong, China) that recorded mice
through the clear front panel and were saved using ANY-maze video tracking software (Stoelting Co.,
Wood Dale, IL). All recorded videos were randomized and scored by one primary trained observer who
was blinded to treatment condition or genotype using ANY-maze software and ODLog (v2.7.2 for
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Windows; Macropod), respectively. A subset of sixteen videos of oxycodone-dependent mice were
scored by a second trained observer to ensure inter-rater reliability (Fig. 2).
On the morning of day 9 (i.e., 0900 h), mice were administered 33 mg/kg oxycodone and were
placed in their respective Plexiglas chambers after 90 min for a 30-min acclimation period. At 120 min,
the mice were removed from the chambers, weighed, administered naloxone (1 mg/kg s.c.), and returned
to the chambers for a 30-min test session after the chambers were cleaned using a paper towel moistened
with water. The mice were weighed again immediately after the test session. Chambers were changed
between tests and cleaned with 10% ethanol to mitigate accumulation of residual odor between cohorts of
mice.
Naloxone-precipitated withdrawal signs (i.e., diarrhea, body weight loss, jumps, single and
double paw flutters, and head shakes) were assessed as previously described (Ramesh et al., 2011;
Gamage et al., 2015) in a recently established model of oxycodone dependence in mice (Enga et al.,
2016; Carper et al., 2021). A primary observer (Julien Dodu) and secondary observer (Rebecca Moncayo)
scored a subset of 16 videos of oxycodone-dependent mice to establish inter-rater reliability. The primary
observer scored withdrawal signs for all experiments. Jumps were recorded as every incident when the
mouse presented a swift jumping behavior from its hind legs or all four legs. Paw flutters were recorded
as single or double flutters separated by at least 1 s or interrupted by any other behavior, e.g., jumps, head
shakes, or grooming. Head shakes were recorded as every incident when the mouse quickly rotated the
head clockwise and counter-clockwise. The occurrence of diarrhea was assessed by the presence of
increased fluid content in the fecal pellets, discoloration of the pellet (e.g., dark brown to light brown), or
fragmentation/smearing of fecal pellets. Body weight loss (%) was calculated using the following
formula:
𝐵𝑊𝐿(%) = (1 − (

𝑝𝑜𝑠𝑡𝑇
)) ∗ 100%
𝑝𝑟𝑒𝑇

Where postT represents the body weight of mice after the 30-min test period and preT represents body
weight of mice before the 30-min test period.
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2.2.4.

Treatment schedule for experiments
To reduce the number of mice (Kirk, 2013) used for these studies, Fig. 3 demonstrated that a

sample size of 12 and 16 mice per group was required to achieve sufficient power in experiments testing
acute oxycodone (Fig. 4) and ZCZ011 (Fig. 5) dose-response experiments. In the experiment testing
whether 40 mg/kg ZCZ011 attenuates naloxone-precipitated withdrawal signs (Fig. 3), counter-balanced
groups of male and female ICR mice repeatedly administered saline or escalating doses of oxycodone
received an injection of vehicle or ZCZ011 (40 mg/kg i.p.) 75 min before naloxone administration. The
pretreatment time and dose of ZCZ011 were based upon previous literature coinciding with its peak
antinociceptive effects (Ignatowska-Jankowska, Baillie, et al., 2015). In the dose-response experiment
testing whether acute oxycodone administration will attenuate withdrawal responses (Fig. 4), counterbalanced groups of male and female oxycodone-dependent ICR mice received an acute oxycodone
injection (17, 33, or 75 mg/kg s.c.) or saline 30 min before naloxone administration with doses based on
experiments conducted in C57BL/6J male mice (Carper et al., 2021). Male and female ICR mice injected
repeatedly with saline received an acute saline injection 30 min before naloxone to serve as a negative
control. The two experimental factors of repeated oxycodone and acute oxycodone were treated as a
single statistical factor and were analyzed as a 2-way ANOVA of oxycodone treatment by sex. In the
experiment evaluating the dose-response relationship of ZCZ011 (Fig. 5), counter-balanced groups of
male and female oxycodone-dependent ICR mice received ZCZ011 (5, 10, 20, or 40 mg/kg i.p.) or
vehicle 75 min before naloxone. An additional group of male and female oxycodone-dependent ICR mice
were administered oxycodone (75 mg/kg s.c.) 30 min before naloxone to serve as a positive control. Male
and female ICR mice repeatedly administered saline received vehicle 75 min before naloxone
administration to serve as a negative control. The two experimental drug factors of oxycodone treatment
and ZCZ011 treatment were also collapsed and treated as a single statistical factor.
We employed pharmacological and genetic approaches to determine the involvement of
cannabinoid receptors of the anti-withdrawal effects of ZCZ011 (Fig. 6 and 7). Employing
pharmacological and genetic approaches mitigates associated pitfalls when investigating cannabinoid
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receptor involvement for CB1 receptor PAMs in vivo; ZCZ011 decreases equilibrium binding of
rimonabant, the CB1 receptor inverse agonist/antagonist, in vitro (Ignatowska-Jankowska, Baillie, et al.,
2015) and constitutive CB1 (-/-) mice exhibit a lower frequency of opioid withdrawal signs in vivo
(Ledent et al., 1999; Lichtman et al., 2001), which provides potential alternative explanations for
cannabinoid receptor involvement when examining CB1 receptor PAMs in animal models of opioid
dependence. In the rimonabant experiment, counter-balanced groups of male and female oxycodonedependent ICR mice received two i.p. injections before naloxone administration. The first injection
consisted of an i.p. injection of vehicle, rimonabant (3 mg/kg), or SR144528 (3 mg/kg), the CB2 receptor
antagonist, and the second injection consisted of vehicle or ZCZ011 (40 mg/kg), with the respective
injections given 85 and 75 min before naloxone administration. A dose of 3 mg/kg for rimonabant and
SR144528 was chosen based upon previous literature demonstrating reversal of the effects of CB1 and
CB2 receptor agonists in models of inflammatory and neuropathic pain (Kinsey et al., 2009; Kinsey,
Mahadevan, et al., 2011; Ignatowska-Jankowska, Wilkerson, et al., 2015) as well as cannabinoid and
opioid withdrawal (Long, Li, et al., 2009; Schlosburg et al., 2009; Ramesh et al., 2011, 2013). In the
experiment using CB1 (-/-) mice, we used age-matched male and female oxycodone-dependent CB1 (+/+)
and CB1 (-/-) mice that were administered vehicle or ZCZ011 (40 mg/kg i.p.) 75 min before undergoing
naloxone-precipitated withdrawal. Each figure contains schematics outlining the timeline of treatments
for each experiment.
2.2.5.

Statistical analyses
All data are reported as mean ± standard deviation (SD). The number of jumps, paw flutters, and

head shakes are presented as counted observations. The occurrence of diarrhea was scored as a quantal
measure following the 30-min test period. A power analysis (G*Power 3.1) of Fig. 3 indicated that a
sample size of 16 mice per group was required to detect significant effects of ZCZ011 in withdrawalinduced body weight loss, a highly objective withdrawal measure. Furthermore, because 7-8 male and
female mice were tested in subsequent experiments, sex was included as a variable for subsequent
analysis. The Fisher exact test was used to analyze occurrence of diarrhea. Data were analyzed using two49

and three-way between-measures analysis of variance (ANOVA) and Student’s t-test (for planned
comparisons if no relevant interaction was present and main effects were observed) were used to analyze
body weight loss, jumps, paw flutters, and head shakes. Dunnett’s post-hoc test was used to compare drug
treatments to oxycodone-dependent saline-treated or vehicle-treated mice and Tukey’s post-hoc test was
used to compare between various treatments. To determine the strength of the inter-rater reliability, a
Pearson correlation was used with a minimum of r = 0.9 to ensure reliable scoring was conducted. The
criterion of significance for all statistical tests was p < 0.05.
2.3. Results
2.3.1.

Naloxone precipitates withdrawal signs in oxycodone-dependent male and female mice
To establish the naloxone-precipitated oxycodone withdrawal model in our laboratory, mice were

repeatedly administered saline or escalating doses of oxycodone (9.0, 17.8, 23.7, and 33.0 mg/kg s.c.) for
eight days. Student’s t-test was used to determine the effect of naloxone-precipitated withdrawal signs. A
schematic of treatment conditions for this experiment is shown in figure 1A. On day 9, 2 h following the
last injection of saline or oxycodone (33 mg/kg s.c.), naloxone precipitated several withdrawal signs,
including diarrhea (p = 0.015), body weight loss (p = 0.00010), jumps (p = 0.00014), paw flutters (p <
0.0001), and head shakes (p = 0.00057).
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Figure 1. Naloxone (1 mg/kg s.c.) precipitates withdrawal signs in oxycodone-dependent male and
female mice. Panel A illustrates the timeline of treatments mice received prior to naloxone-precipitated
withdrawal. The withdrawal signs measured include the occurrence of diarrhea (B), body weight loss (C),
number of jumps (D), number of paw flutters (E), and number of head shakes (F). Data are expressed as
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percentage scores for panel B and mean ± SD for panels C-F. Numbers at the bottom of bar graphs in
panel B indicate number of mice that presented with diarrhea. Fisher exact test was used to analyze the
occurrence of diarrhea (B). Student’s unpaired t-test was used to analyze all other withdrawal signs (C, D,
E, and F). *, p < 0.05; ***, p < 0.001; ****, p < 0.0001 versus saline. Sample size was n = 6 mice/group
(n = 3 male and n = 3 female mice/group).
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2.3.2.

Withdrawal scoring between observers
Two blinded observers scored the experiment testing 40 mg/kg ZCZ011 in saline-treated and

oxycodone-dependent mice undergoing naloxone-precipitated withdrawal (Fig 3). Both observers scored
the sixteen videos of oxycodone-dependent mice and demonstrated strong Pearson correlations for
naloxone-precipitated jumps (r = 0.9995; p < 0.0001; Fig. 2A), paw flutters (r = 0.9953; p < 0.0001; Fig.
2B), and head shakes (r = 0.9180; p < 0.0001; Fig. 2C).
2.3.3.

The CB1 receptor PAM, ZCZ011, attenuates naloxone-precipitated withdrawal signs in
oxycodone-dependent male and female mice without affecting saline-treated mice
In this experiment, ZCZ011 (40 mg/kg i.p.) was tested to determine whether it attenuates

naloxone-precipitated withdrawal signs in oxycodone-dependent male and female ICR mice. Table 4
summarizes Fisher exact test results for naloxone-precipitated diarrhea and two-way ANOVAs
(oxycodone treatment x ZCZ011 treatment) for each of the other withdrawal signs. We did not
incorporate sex as a statistical factor since 4 mice per sex per group were used. A schematic of treatment
conditions for this experiment is shown in Fig. 3A. In Fig. 3B, 40 mg/kg ZCZ011 elicited a lower
incidence of naloxone-precipitated diarrhea (3 of 8 mice) than oxycodone-dependent vehicle mice (8 of 8
mice). In Fig. 3C, no two-way interaction for naloxone-precipitated weight loss was observed, however,
main effects for both oxycodone and ZCZ011 treatment were found. A post-hoc power analysis revealed
that we were underpowered to observe a significant two-way interaction for weight loss; therefore,
subsequent studies increased sample sizes to 16 mice (8 male and 8 female mice). Furthermore, Fig. 3D
illustrates that 40 mg/kg ZCZ011-treated mice elicited a lower frequency of naloxone-precipitated
jumping behavior than oxycodone-dependent vehicle-treated mice. Fig. 3E also demonstrates that 40
mg/kg ZCZ011-treated mice lowered the frequency of naloxone-precipitated paw flutters than
oxycodone-dependent vehicle-treated mice. Lastly, 40 mg/kg ZCZ011 elicited a lower frequency of
naloxone-precipitated head shaking behavior than oxycodone-dependent vehicle-treated mice. No
differences were observed in mice receiving ZCZ011 and repeatedly administered saline in any
withdrawal sign measured.
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Figure 2. Two observers blinded to treatment conditions produced high inter-rater reliability for jumps,
paw flutters, and head shakes. Videos from oxycodone-dependent mice in figure 3 were used to determine
inter-rater reliability. Withdrawal signs include jumps (A), paw flutters (B), and head shakes (C). Pearson
correlations were used to determine the correlation between each observer and the dotted line represents
the line of best fit.
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Figure 3. The CB1 receptor PAM, ZCZ011 (40 mg/kg i.p.), attenuates naloxone-precipitated withdrawal
signs in oxycodone-dependent male and female mice. The withdrawal signs measured include the
occurrence of diarrhea (B), body weight loss (C), number of jumps (D), number of paw flutters (E), and
number of head shakes (F). Data are expressed as percentage scores for panel B and individual data points
with mean ± SD for panels C-F. Numbers at the bottom of bar graphs in panel B indicate the number of
mice that presented with diarrhea. Fisher exact test was used to analyze the occurrence of diarrhea (B).
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Two-way ANOVAs and Tukey’s post hoc comparisons were used to analyze all other withdrawal signs
(C, D, E, and F). *, p < 0.05; **, p < 0.01; ***, p < 0.001 versus oxycodone-vehicle mice. n = 8
mice/group (n = 4 male and n = 4 female mice/group).
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Table 4
Summary of statistical results from Fisher exact tests and two-way ANOVA analyses for Figure 3
Withdrawal Signs
Diarrhea
Sal-Veh vs Sal-ZCZ
Sal-Veh vs Oxy-Veh
Oxy-Veh vs Oxy-ZCZ
Body Weight Loss
2-way interaction: Oxy x
ZCZ tx
Main effect: Oxy tx
Main effect: ZCZ tx
Jumps
2-way interaction: Oxy x
ZCZ tx
Planned Comparisons:
Sal-Veh vs Sal-ZCZ
Sal-Veh vs Oxy-Veh
Oxy-Veh vs Oxy-ZCZ
Main effect: Oxy tx
Main effect: ZCZ tx
Paw Flutters
2-way interaction: Oxy x
ZCZ tx
Planned Comparisons:
Sal-Veh vs Sal-ZCZ
Sal-Veh vs Oxy-Veh
Oxy-Veh vs Oxy-ZCZ
Main effect: Oxy tx
Main effect: ZCZ tx
Head Shakes
2-way interaction: Oxy x
ZCZ tx
Planned Comparisons:
Sal-Veh vs Sal-ZCZ
Sal-Veh vs Oxy-Veh
Oxy-Veh vs Oxy-ZCZ
Main effect: Oxy tx
Main effect: ZCZ tx

F Statistic, P value

Tukey’s

Fisher

—
—
—

—
—
—

P > 0.99
P = 0.0002***
P = 0.026*

F (1,28) = 2.92, p = 0.099

—

—

F (1,28) = 32.5, p < 0.0001****
F (1,28) = 7.36, p = 0.011*

—
—

—
—

F (1,28) = 6.54, p = 0.016*

—

—

—
—
—
F (1, 28) = 15.1, p = 0.0006**
F (1, 28) = 6.54, p = 0.016*

P > 0.99
P = 0.0005***
P = 0.0060**
—
—

—
—
—
—
—

F (1,28) = 11.2, p = 0.0024**

—

—

—
—
—
F (1, 28) = 29.3, p < 0.0001****
F (1, 28) = 11.8, p = 0.0018**

P = 0.99
P < 0.0001****
P = 0.0003***
—
—

—
—
—
—
—

F (1,28) = 7.84, p = 0.0091**

—

—

—

P = 0.99
P = 0.0010**
P = 0.0016**
—
—

—

—
—
F (1, 28) = 10.7, p = 0.0029**
F (1, 28) = 9.21, p = 0.0052**
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—
—
—
—

2.3.4.

Acute oxycodone administration dose-dependently attenuates naloxone-precipitated
withdrawal signs in oxycodone-dependent male and female mice
In this experiment we tested whether acute oxycodone (17, 33, and 75 mg/kg s.c.), attenuates

naloxone-precipitated diarrhea, weight loss, jumps, paw flutters, or head shakes to serve as a positive
control. Table 5 summarizes Fisher exact test results for naloxone-precipitated diarrhea and two-way
ANOVAs (Sex x Oxycodone treatment) for each of the other withdrawal signs. A schematic of treatment
conditions for this experiment is shown in Fig. 4A. As illustrated in Fig. 4B, 33 mg/kg oxycodone (3 of
12 mice) and 75 mg/kg oxycodone (0 of 12 mice) elicited a lower incidence of naloxone-precipitated
diarrhea than oxycodone-dependent saline-treated (12 of 12) mice. Moreover, mice repeatedly
administered saline (3 of 12) elicited a lower incidence of naloxone-precipitated diarrhea than oxycodonedependent saline-treated (12 of 12) mice. Furthermore, 75 mg/kg oxycodone completely blocked
naloxone-precipitated body weight loss, while 33 mg/kg oxycodone blocked half the amount of body
weight loss compared to oxycodone-dependent saline-treated mice (Fig. 4C). Notably, while micturition
was not quantified, weight loss often occurred in mice whose withdrawal chamber was saturated with
substantial volumes of urine following the 30-min test period. In addition, 33 mg/kg and 75 mg/kg
oxycodone completely lowered the frequency of naloxone-precipitated jumps compared to oxycodonedependent saline-treated mice (Fig. 4D). Furthermore, 75 mg/kg oxycodone completely lowered the
frequency of naloxone-precipitated paw flutters, whereas 33 mg/kg oxycodone lowered the frequency by
approximately half compared to oxycodone-dependent saline-treated mice (Fig. 4E). Lastly, 33 mg/kg
and 75 mg/kg oxycodone lowered the frequency of naloxone-precipitated head shakes compared to
oxycodone-dependent saline-treated mice (Fig. 4F). No endpoint showed a significant sex by oxycodone
treatment interaction or main effect of sex. Since no significant interactions between oxycodone and sex
in this experiment or ZCZ011 by sex were observed throughout the subsequent experiments, the variable
of sex was collapsed in all figures.
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2.3.5.

ZCZ011 dose-dependently attenuates naloxone-precipitated withdrawal signs in oxycodonedependent male and female mice
Multiple doses of ZCZ011 (5, 10, 20, 40 mg/kg i.p.) were tested to determine whether a dose-

dependent anti-withdrawal effect was present in oxycodone-dependent male and female mice. Table 6
summarizes Fisher exact test results for naloxone-precipitated diarrhea and two-way ANOVAs (Sex x
Drug treatment) for each of the other withdrawal signs. A schematic of the treatment conditions for this
experiment in which all mice were challenged with 1 mg/kg naloxone before behavioral observations is
shown in Fig. 5A. As illustrated in Fig. 5B, 40 mg/kg ZCZ011 (3 of 16 mice) and 75 mg/kg oxycodone (0
of 16 mice) elicited a lower incidence of naloxone-precipitated diarrhea than oxycodone-dependent
vehicle-treated (15 of 16) mice. Furthermore, naloxone did not elicit diarrhea in control mice that
received repeated injections of saline (0 of 16 mice). In addition, 40 mg/kg ZCZ011 and 75 mg/kg
oxycodone completely blocked naloxone-precipitated body weight loss compared to oxycodonedependent vehicle-treated mice (Fig. 5C). As illustrated in Fig. 5D, 75 mg/kg oxycodone completely
lowered the frequency of naloxone-precipitated jumps compared to oxycodone-dependent vehicle-treated
mice, whereas no dose of ZCZ011 affected jumping behavior. Although a sex by ZCZ011 treatment
interaction failed to achieve significance, a main effect of sex was observed with male mice averaging 61
jumps and female mice averaging 29 jumps. As shown in Fig. 5E, 20 mg/kg and 40 mg/kg ZCZ011
lowered the frequency of naloxone-precipitated paw flutters by about half while 75 mg/kg oxycodone
completely lowered the frequency of paw flutters compared to oxycodone-dependent vehicle-treated
mice. Lastly, 20 mg/kg ZCZ011, 40 mg/kg ZCZ011, and 75 mg/kg oxycodone lowered the frequency of
naloxone-precipitated head shakes compared to oxycodone-dependent vehicle-treated mice (Fig. 5F).
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Figure 4. Acute oxycodone (17-75 mg/kg s.c.) dose-dependently attenuates naloxone-precipitated
withdrawal signs in oxycodone-dependent male and female mice. Panel A illustrates the timeline of
treatments mice received prior to naloxone-precipitated withdrawal. The withdrawal signs measured
include the occurrence of diarrhea (B), body weight loss (C), number of jumps (D), number of paw
flutters (E), and number of head shakes (F). Data are expressed as percentage scores for panel B and
individual data points with mean ± SD for panels C-F. Numbers at the bottom of bar graphs in panel B
indicate the number of mice that presented with diarrhea. Fisher exact test was used to analyze the
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occurrence of diarrhea (B). Between-measures two-way ANOVA and Dunnett’s post hoc test was used to
analyze all other withdrawal signs (C, D, E, and F). **, p < 0.01; ***, p < 0.001; ****, p < 0.0001 versus
oxycodone-saline mice. n = 12 mice/group (n = 6 male and n = 6 female mice/group).
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Table 5
Summary of statistical results from Fisher exact tests and two-way ANOVA analyses for Figure 4
Withdrawal Signs
Diarrhea
Oxy-Sal vs Sal-Sal
Oxy-Sal vs Oxy-Oxy (17)
Oxy-Sal vs Oxy-Oxy (33)
Oxy-Sal vs Oxy-Oxy (75)
Body Weight Loss
2-way interaction: Sex x Oxy
Main effect: Sex
Main effect: Oxy
Planned Comparisons:
Oxy-Sal vs Sal-Sal
Oxy-Sal vs Oxy-Oxy (17)
Oxy-Sal vs Oxy-Oxy (33)
Oxy-Sal vs Oxy-Oxy (75)
Jumps
2-way interaction: Sex x Oxy
Main effect: Sex
Main effect: Oxy
Planned Comparisons:
Oxy-Sal vs Sal-Sal
Oxy-Sal vs Oxy-Oxy (17)
Oxy-Sal vs Oxy-Oxy (33)
Oxy-Sal vs Oxy-Oxy (75)
Paw Flutters
2-way interaction: Sex x Oxy
Main effect: Sex
Main effect: Oxy
Planned Comparisons:
Oxy-Sal vs Sal-Sal
Oxy-Sal vs Oxy-Oxy (17)
Oxy-Sal vs Oxy-Oxy (33)
Oxy-Sal vs Oxy-Oxy (75)
Head Shakes
2-way interaction: Sex x Oxy
Main effect: Sex
Main effect: Oxy
Planned Comparisons:
Oxy-Sal vs Sal-Sal
Oxy-Sal vs Oxy-Oxy (17)
Oxy-Sal vs Oxy-Oxy (33)
Oxy-Sal vs Oxy-Oxy (75)

F Statistic, P value

Dunnett’s

Fisher

—
—
—
—

—
—
—
—

P = 0.0003***
P = 0.48
P = 0.0003***
P < 0.0001****

F (4, 50) = 0.271, p = 0.90
F (1, 50) = 0.169, p = 0.68
F (4, 50) = 21.9, p < 0.0001****

—
—
—

—
—
—

—
—
—
—

P < 0.0001****
P = 0.15
P = 0.0002***
P < 0.0001****

—
—
—
—

F (4, 50) = 0.853, p = 0.50
F (1, 50) = 1.69, p = 0.20
F (4, 50) = 6.38, p = 0.0003***

—
—
—

—
—
—

—
—
—
—

P = 0.0017**
P = 0.53
P = 0.0022**
P = 0.0010**

—
—
—
—

F (4, 50) = 2.52, p = 0.0530
F (1, 50) = 0.0865, p = 0.77
F (4, 50) = 36.5, p < 0.0001****

—
—
—

—
—
—

—
—
—
—

P < 0.0001****
P = 0.99
P < 0.0001****
P < 0.0001****

—
—
—
—

F (4, 50) = 0.507, p = 0.73
F (1, 50) = 0.00, p > 0.99
F (4, 50) = 7.74, p < 0.0001****

—
—
—

—
—
—

—
—
—
—

P = 0.0004***
P = 0.22
P = 0.0004***
P = 0.0002***

—
—
—
—

62

A

B
Saline or
Oxycodone
(9, 17.8, 23.7
33 mg/kg)

Saline or
Oxycodone
(33 mg/kg)

Vehicle or
ZCZ011
(5, 10, 20, 40 mg/kg)

Oxycodone
(75 mg/kg)

Day 1-8

Day 9: 0 min

45 min

90 min

% Mice with Diarrhea

100

Naloxone
(1 mg/kg)

Acclimate

Observation

120 min

150 min

75
50
25

****

****

****
0

15

0

16

14

12

3

Repeated Adminstration

Sal

Oxy

Oxy

Oxy

Oxy

Oxy

Oxy

ZCZ011 (mg/kg)

Veh

Veh

-

5

10

20

40

-

-

75

-

-

-

-

0

Acute oxycodone (mg/kg)

C

D
250

****
3

# of Jumps  SD

% Decrease in
Body Weight  SD

5

****
****

1
0

150

50

***

**

0
-1
Repeated Adminstration

Sal

Oxy

Oxy

Oxy

Oxy

Oxy

Oxy

ZCZ011 (mg/kg)

Veh

Veh

-

5

10

20

40

-

-

75

-

-

-

-

Acute oxycodone (mg/kg)

Repeated Adminstration

Sal

Oxy

Oxy

Oxy

Oxy

Oxy

Oxy

ZCZ011 (mg/kg)

Veh

Veh

-

5

10

20

40

-

-

75

-

-

-

-

Acute oxycodone (mg/kg)

E

F
25

# of Head Shakes  SD

# of Paw Flutters  SD

80
60

***

40
20

****

***

****

0

Repeated Adminstration

Sal

Oxy

Oxy

Oxy

Oxy

Oxy

Oxy

ZCZ011 (mg/kg)

Veh

Veh

-

5

10

20

40

-

-

75

-

-

-

-

Acute oxycodone (mg/kg)

20
15
10
5

****

*

***

****

0

Repeated Adminstration

Sal

Oxy

Oxy

Oxy

Oxy

Oxy

Oxy

ZCZ011 (mg/kg)

Veh

Veh

-

5

10

20

40

-

-

75

-

-

-

-

Acute oxycodone (mg/kg)

Figure 5. ZCZ011 (5-40 mg/kg i.p.) dose-dependently attenuates naloxone-precipitated withdrawal signs
in oxycodone-dependent male and female mice. Panel A illustrates the timeline of treatments mice
received prior to naloxone-precipitated withdrawal. The withdrawal signs measured include the
occurrence of diarrhea (B), body weight loss (C), number of jumps (D), number of paw flutters (E), and
number of head shakes (F). Data are expressed as percentage scores for panel B and individual data points
with mean ± SD for panels C-F. Numbers at the bottom of bar graphs in panel B indicate the number of
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mice that presented with diarrhea. Fisher exact test was used to analyze the occurrence of diarrhea (B).
Between-measures two-way ANOVA and Dunnett’s post hoc test was used to analyze all other
withdrawal signs (C, D, E, and F). *, p < 0.05; ***, p < 0.001; ****, p < 0.0001 versus oxycodonevehicle mice. n = 15-16 mice/group (n = 8 male and n = 7-8 female mice/group due to lost video footage).
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TABLE 6
Summary of statistical results from Fisher exact tests and two-way ANOVA analyses for Figure 5
Withdrawal Signs
Diarrhea
Oxy-Veh vs Sal-Veh
Oxy-Veh vs Oxy-Oxy (75)
Oxy-Veh vs Oxy-ZCZ (5)
Oxy-Veh vs Oxy-ZCZ (10)
Oxy-Veh vs Oxy-ZCZ (20)
Oxy-Veh vs Oxy-ZCZ (40)
Body Weight Loss
2-way interaction: Sex x
Drug tx
Main effect: Sex
Main effect: Drug tx
Planned Comparisons:
Oxy-Veh vs Sal-Veh
Oxy-Veh vs Oxy-Oxy (75)
Oxy-Veh vs Oxy-ZCZ (5)
Oxy-Veh vs Oxy-ZCZ (10)
Oxy-Veh vs Oxy-ZCZ (20)
Oxy-Veh vs Oxy-ZCZ (40)
Jumps
2-way interaction: Sex x
Drug tx
Main effect: Sex
Main effect: Drug tx
Planned Comparisons:
Oxy-Veh vs Sal-Veh
Oxy-Veh vs Oxy-Oxy (75)
Oxy-Veh vs Oxy-ZCZ (5)
Oxy-Veh vs Oxy-ZCZ (10)
Oxy-Veh vs Oxy-ZCZ (20)
Oxy-Veh vs Oxy-ZCZ (40)
Paw Flutters
2-way interaction: Sex x
Drug tx
Main effect: Sex
Main effect: Drug tx
Planned Comparisons:
Oxy-Veh vs Sal-Veh
Oxy-Veh vs Oxy-Oxy (75)
Oxy-Veh vs Oxy-ZCZ (5)
Oxy-Veh vs Oxy-ZCZ (10)
Oxy-Veh vs Oxy-ZCZ (20)
Oxy-Veh vs Oxy-ZCZ (40)
Head Shakes
2-way interaction: Sex x
Drug tx
Main effect: Sex

F Statistic, P value

Dunnett’s

Fisher

—
—
—
—
—
—

—
—
—
—
—
—

P < 0.0001****
P < 0.0001****
P > 0.99
P > 0.99
P = 0.083
P < 0.0001****

F (6, 90) = 0.413, p = 0.87

—

—

F (1, 90) = 2.05, p = 0.16
F (6, 90) = 11.3, p < 0.0001****

—
—

—
—

—
—
—
—
—
—

P < 0.0001****
P < 0.0001****
P = 0.90
P = 0.13
P = 0.098
P < 0.0001****

—
—
—
—
—
—

F (6, 88) = 1.17, p = 0.33

—

—

F (1, 88) = 9.49, p = 0.0028**
F (6, 88) = 4.64, p = 0.0004***

—
—

—
—

—
—
—
—
—
—

P = 0.0045**
P = 0.0004***
P = 0.78
P = 0.96
P = 0.87
P = 0.44

—
—
—
—
—
—

F (6, 88) = 0.535, p = 0.78

—

—

F (1, 88) = 0.964, p = 0.33
F (6, 88) = 21.7, p < 0.0001****

—
—

—
—

—
—
—
—
—
—

P < 0.0001****
P < 0.0001****
P = 0.99
P = 0.85
P = 0.0006***
P = 0.0002***

—
—
—
—
—
—

F (6, 88) = 1.14, p = 0.35

—

—

F (1, 88) = 0.899, p = 0.35

—

—
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Main effect: Drug tx
Planned Comparisons:
Oxy-Veh vs Sal-Veh
Oxy-Veh vs Oxy-Oxy (75)
Oxy-Veh vs Oxy-ZCZ (5)
Oxy-Veh vs Oxy-ZCZ (10)
Oxy-Veh vs Oxy-ZCZ (20)
Oxy-Veh vs Oxy-ZCZ (40)

F (6, 88) = 7.39, p < 0.0001****

—

—

—
—
—
—
—
—

P = 0.0004***
P < 0.0001****
P = 0.61
P = 0.24
P = 0.025*
P = 0.0004***

—
—
—
—
—
—
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2.3.6.

Rimonabant, not SR144528, reverses the anti-withdrawal effects of ZCZ011
A pharmacological approach was used to discern which cannabinoid receptors mediate the anti-

withdrawal effects of ZCZ011. Mice administered rimonabant, the CB1 receptor inverse
agonist/antagonist, SR144528, the CB2 receptor antagonist, or vehicle prior to vehicle or 40 mg/kg
ZCZ011 were evaluated for naloxone-precipitated withdrawal signs. Table 7 summarizes Fisher exact test
results for naloxone-precipitated diarrhea and three-way ANOVAs (Sex x CB antagonist x ZCZ011
treatment) for each of the other withdrawal signs. A schematic of treatment conditions for this experiment
is shown in Fig. 6A. As shown in Fig. 6B, oxycodone-dependent vehicle-ZCZ011-treated (4 of 16) mice
and SR144528-ZCZ011-treated (3 of 15) mice exhibited a lower incidence of naloxone-precipitated
diarrhea than oxycodone-dependent vehicle-vehicle-treated (15 of 15) mice and oxycodone-dependent
SR144528-vehicle-treated (15 of 16) mice, respectively. Moreover, rimonabant, but not SR144528,
blocked the protective effects of ZCZ011 on naloxone-precipitated body weight loss suggesting a CB1mediated effect. Again, ZCZ011 did not significantly affect naloxone-precipitated jumps (Fig. 6D);
though, a main effect of sex revealed male mice averaged 84 jumps whereas female mice averaged 46
jumps. Significant main effects were found for ZCZ011 treatment and sex for naloxone-precipitated paw
fluttering behavior (Fig. 6E). As seen in the figure, mice in the vehicle-ZCZ011 group averaged 27 paw
flutters, whereas mice in the vehicle-vehicle group averaged 46 paw flutters. Moreover, male mice
averaged 34 paw flutters whereas female mice averaged 44 paw flutters. However, no significant
interactions of cannabinoid antagonists and ZCZ011 treatment were found, suggesting lack of CB1 or CB2
receptor involvement. Finally, neither ZCZ011 nor the cannabinoid receptor antagonists produced
significant effects on naloxone-precipitated head shakes (Fig. 6F). On the contrary, a significant main
effect of sex was found in which male mice averaged 5 head shakes whereas female mice averaged 3 head
shakes.
The anti-withdrawal effects of ZCZ011 are absent in CB1 (-/-) mice
Constitutive CB1 (+/+) and (-/-) oxycodone-dependent male and female mice were used to
investigate the attenuation of naloxone-precipitated withdrawal signs by ZCZ011. Table 8 summarizes
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Fisher exact test results for naloxone-precipitated diarrhea and three-way ANOVAs (Sex x Genotype x
ZCZ011 treatment) for each of the other withdrawal signs. A schematic of treatment conditions for this
experiment is shown in Fig. 7A. As shown in Fig. 7B, CB1 deletion annihilated the effects of ZCZ011 in
reducing the incidence of naloxone-precipitated diarrhea in oxycodone-dependent mice. Specifically, 0 of
16 CB1 (+/+)-ZCZ011-treated oxycodone-dependent mice elicited a lower incidence of naloxoneprecipitated diarrhea than 10 of 16 CB1 (+/+)-vehicle-treated oxycodone-dependent mice and 13 of
15 CB1 (-/-)-ZCZ011-treated oxycodone-dependent mice. A significant 2-way interaction between
genotype and ZCZ011 treatment on naloxone-precipitated body weight loss indicates that CB1 receptors
mediate the protective effects of ZCZ011 for this measure (Fig. 7C). Specifically, CB1 (+/+)-ZCZ011treated mice elicited less body weight loss than CB1 (-/-)-ZCZ011-treated mice. ZCZ011 did not affect
naloxone-precipitated jumping behavior, though a significant main effect for genotype revealed that CB1
(+/+) mice jumped significantly more than CB1 (-/-) mice, which respectively averaged 69 and 37 jumps
(Fig. 7D). As shown in Fig. 7E, a significant 2-way interaction between genotype and ZCZ011 treatment
for naloxone-precipitated paw fluttering behavior revealed CB1 (+/+)-ZCZ011-treated mice elicited little
to no paw flutters compared to CB1 (+/+)-vehicle-treated mice. Furthermore, regardless of treatment, CB1
(-/-) mice elicited less paw flutters than CB1 (+/+)-vehicle-treated mice. Notably, no difference was
observed between CB1 (+/+)-ZCZ011-treated and CB1 (-/-)-ZCZ011-treated mice signifying a lack of a
CB1 receptor mediated effects. Lastly, Fig. 7F illustrates no 3-way interaction, relevant 2-way
interactions, or main effects for naloxone-precipitated head shakes.

68

A

B
####

Oxycodone
(9, 17.8, 23.7
33 mg/kg)

Oxycodone
(33 mg/kg)

Day 1-8

Day 9: 0 min

Vehicle,
Vehicle,
SR1, or SR2 or ZCZ011
(3 mg/kg) (40 mg/kg)

Naloxone
(1 mg/kg)
Acclimate

35 min 45 min

90 min

Observation
120 min

150 min

% Mice with Diarrhea

100

Vehicle
ZCZ011

75
50

****

25
15

4

****
16

16

15

3

0
Vehicle

C

D
Vehicle
3

****

##

ZCZ011

*
1
0

# of Jumps  SD

% Decrease in
Body Weight  SD

5

SR1

SR2

Antagonist Treatment
350
250
250

Vehicle
ZCZ011

150

50
0

-1
Vehicle

SR1

SR2

Vehicle

Antagonist Treatment

E

SR2

F
*

25

80
80

Vehicle
ZCZ011

60
40
20
0
Vehicle

SR1

# of Head Shakes  SD

120

# of Paw Flutters  SD

SR1

Antagonist Treatment

Vehicle

20

ZCZ011
15
10
5
0
Vehicle

SR2

SR1

SR2

Antagonist Treatment

Antagonist Treatment

Figure 6. Rimonabant (SR1; 3mg/kg i.p.), but not SR144528 (SR2; 3 mg/kg i.p.), reversed the antiwithdrawal effects of ZCZ011 (40 mg/kg i.p.) in oxycodone-dependent male and female mice undergoing
naloxone-precipitated withdrawal. Panel A illustrates the timeline of treatments mice received prior to
naloxone-precipitated withdrawal. The withdrawal signs measured include the occurrence of diarrhea (B),
body weight loss (C), number of jumps (D), number of paw flutters (E), and number of head shakes (F).
Data are expressed as percentage scores for panel B and individual data points with mean ± SD for panels
C-F. Numbers at the bottom of bar graphs in panel B indicate the number of mice that presented with
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diarrhea. Fisher exact test was used to analyze the occurrence of diarrhea (B). Between-measures threeway ANOVA and Tukey’s post hoc test was used to analyze all other withdrawal signs (C, D, E, and F).
A pre-planned comparison Student’s unpaired t-test was used to analyze whether ZCZ011 reliably
attenuated paw flutters (E). *, p < 0.05; ***, p < 0.001; ****, p < 0.0001 vehicle-ZCZ011 or SR144528ZCZ011 mice versus vehicle-vehicle or SR144528-vehicle mice, respectively. ##, p < 0.01; ####, p <
0.0001 vehicle-ZCZ011 mice versus rimonabant-ZCZ011 mice. n = 15-16 mice/group (n = 7-8 male and
n = 8 female mice/group due to an incorrect injection).
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Table 7
Summary of statistical results from Fisher exact tests and three-way ANOVA analyses for Figure 6
Withdrawal Signs
Diarrhea
Veh-Veh vs Veh-ZCZ
SR1-Veh vs SR1-ZCZ
SR2-Veh vs SR2-ZCZ
Veh-ZCZ vs SR1-ZCZ
Veh-ZCZ vs SR2-ZCZ
Body Weight Loss
3-way interaction: Sex x
CB Ant x ZCZ tx
2-way interaction: CB Ant x

F Statistic, P value

Tukey’s

Fisher

—
—
—
—
—

—
—
—
—
—

P < 0.0001****
P > 0.99
P < 0.0001****
P < 0.0001****
P > 0.99

F (2, 82) = 0.219, p = 0.80

—

—

F (2, 82) = 3.57, p = 0.033*

—

—

—
—
—
—
—
F (1, 82) = 0.280, p = 0.60

P < 0.0001****
P = 0.63
P = 0.018*
P = 0.0040**
P = 0.98
—

—
—
—
—
—
—

F (2, 82) = 0.338, p = 0.71

—

—

F (1, 82) = 0.447, p = 0.51
F (2, 82) = 12.5, p < 0.0001****
F (1, 82) = 33.6, p < 0.0001****

—
—
—

—
—
—

F (2, 82) = 0.219, p = 0.80

—

—

F (2, 82) = 3.45, p = 0.036*

—

—

—
—
—
—
—
F (1, 82) = 3.26, p = 0.074

P = 0.96
P = 0.67
P = 0.37
P = 0.84
P = 0.71
—

—
—
—
—
—
—

F (2, 82) = 3.45, p = 0.036*

—

—

F (1, 82) = 10.2, p = 0.0020**
F (2, 82) = 1.17, p = 0.3147
F (1, 82) = 0.735, p = 0.39

—
—
—

—
—
—

F (2, 82) = 0.545, p = 0.58

—

—

ZCZ tx

Planned Comparisons:
Veh-Veh vs Veh-ZCZ
SR1-Veh vs SR1-ZCZ
SR2-Veh vs SR2-ZCZ
Veh-ZCZ vs SR1-ZCZ
Veh-ZCZ vs SR2-ZCZ
2-way interaction: Sex x
ZCZ tx
2-way interaction: Sex x
CB Ant
Main Effect: Sex
Main Effect: CB Ant
Main Effect: ZCZ tx
Jumps
3-way interaction: Sex x
CB Ant x ZCZ tx
2-way interaction: CB Ant x
ZCZ tx

Planned Comparisons:
Veh-Veh vs Veh-ZCZ
SR1-Veh vs SR1-ZCZ
SR2-Veh vs SR2-ZCZ
Veh-ZCZ vs SR1-ZCZ
Veh-ZCZ vs SR2-ZCZ
2-way interaction: Sex x
ZCZ tx
2-way interaction: Sex x
CB Ant
Main Effect: Sex
Main Effect: CB Ant
Main Effect: ZCZ tx
Paw Flutters
3-way interaction: Sex x
CB Ant x ZCZ tx
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2-way interaction: CB Ant x

F (2, 82) = 1.06, p = 0.35

—

—

F (1, 82) = 0.135, p = 0.71

—

—

F (2, 82) = 0.943, p = 0.39

—

—

F (1, 82) = 4.19, p = 0.044*
F (2, 82) = 5.09, p = 0.0083**
F (1, 82) = 6.04, p = 0.016*

—
—
—

—
—
—

F (2, 82) = 0.403, p = 0.67

—

—

F (2, 82) = 0.489, p = 0.61

—

—

F (1, 82) = 1.56, p = 0.21

—

—

F (2, 82) = 0.0834, p = 0.92

—

—

F (1, 82) = 4.82, p = 0.031*
F (2, 82) = 2.73, p = 0.071
F (1, 82) = 2.73, p = 0.10

—
—
—

—
—
—

ZCZ tx

2-way interaction: Sex x
ZCZ tx
2-way interaction: Sex x
CB Ant
Main Effect: Sex
Main Effect: CB Ant
Main Effect: ZCZ tx
Head Shakes
3-way interaction: Sex x
CB Ant x ZCZ tx
2-way interaction: CB Ant x
ZCZ tx

2-way interaction: Sex x
ZCZ tx
2-way interaction: Sex x
CB Ant
Main Effect: Sex
Main Effect: CB Ant
Main Effect: ZCZ tx
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Figure 7. The anti-withdrawal effects of ZCZ011 (40 mg/kg i.p.) were absent in oxycodone-dependent
male and female CB1 (-/-) mice undergoing naloxone-precipitated withdrawal. Panel A illustrates the
timeline of treatments mice received prior to naloxone-precipitated withdrawal. The withdrawal signs
measured include the occurrence of diarrhea (B), body weight loss (C), number of jumps (D), number of
paw flutters (E), and number of head shakes (F). Data are expressed as percentage scores for panel B and
individual data points with mean ± SD for panels C-F. Numbers at the bottom of bar graphs in panel B
indicate the number of mice that presented with diarrhea. Between-measures three-way ANOVA and
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Tukey’s post hoc test was used to analyze all other withdrawal signs (C, D, E, and F). *, p < 0.05; **, p <
0.01; ***, p < 0.001 CB1 (+/+)-vehicle mice versus CB1 (+/+)-ZCZ011, CB1 (-/-)-vehicle, or CB1 (-/-)ZCZ011 mice. ##, p < 0.01; ####, p < 0.0001 CB1 (+/+)-ZCZ011 mice versus CB1 (-/-)-ZCZ011 mice.
The $$$ indicates a main effect of genotype for jumping behavior between CB1 (+/+) mice versus CB1 (/-) mice. n = 15-16 mice/group (n = 8 male and n = 7-8 female mice/group due to one death during
repeated oxycodone administration).
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Table 8
Summary of statistical results from Fisher exact tests and three-way ANOVA analyses for Figure 7
Withdrawal Signs
Diarrhea
CB1(+/+)-Veh vs CB1(+/+)-ZCZ
CB1(-/-)-Veh vs CB1(-/-)-ZCZ
CB1(+/+)-ZCZ vs CB1(-/-)-ZCZ
Body Weight Loss
3-way ANOVA: Sex x Geno x
ZCZ tx
2-way Interaction: Geno x ZCZ
tx
Planned Comparisons:
CB1(+/+)-Veh vs CB1(+/+)-ZCZ
CB1(-/-)-Veh vs CB1(-/-)-ZCZ
CB1(+/+)-ZCZ vs CB1(-/-)-ZCZ
2-way Interaction: Sex x ZCZ tx
2-way Interaction: Sex x Geno
Main Effect: Sex
Main Effect: Genotype
Main Effect: ZCZ tx
Jumps
3-way ANOVA: Sex x Geno x
ZCZ tx
2-way Interaction: Geno x ZCZ
tx
2-way Interaction: Sex x ZCZ tx
2-way Interaction: Sex x Geno
Main Effect: Sex
Main Effect: Genotype
Main Effect: ZCZ tx
Paw Flutters
3-way ANOVA: Sex x Geno x
ZCZ tx
2-way Interaction: Geno x ZCZ
tx
Planned Comparisons:
CB1(+/+)-Veh vs CB1(+/+)-ZCZ
CB1(+/+)-Veh vs CB1(-/-)-Veh
CB1(+/+)-Veh vs CB1(-/-)-ZCZ
CB1(-/-)-Veh vs CB1(-/-)-ZCZ
CB1(+/+)-ZCZ vs CB1(-/-)-ZCZ
2-way Interaction: Sex x ZCZ tx
2-way Interaction: Sex x Geno
Main Effect: Sex
Main Effect: Genotype

F Statistic, P value

Tukey’s

Fisher

—
—
—

—
—
—

P < 0.0001****
P > 0.99
P < 0.0001****

F (1, 55) = 0.0866, p = 0.77

—

—

F (1, 55) = 6.16, p = 0.016*

—

—

—
—
—
F (1, 55) = 1.27, p = 0.27
F (1, 55) = 0.215, p = 0.64
F (1, 55) = 1.04, p = 0.31
F (1, 55) = 9.40, p = 0.0034**
F (1, 55) = 5.31, p = 0.025*

P = 0.0055**
P = 0.99
P = 0.0013**
—
—
—
—
—

—
—
—
—
—
—
—
—

F (1, 55) = 0.894, p = 0.35

—

—

F (1, 55) = 0.464, p = 0.50

—

—

F (1, 55) = 0.464, p = 0.50
F (1, 55) = 0.0307, p = 0.86
F (1, 55) = 0.0833, p = 0.77
F (1, 55) = 15.1, p =
0.0003***
F (1, 55) = 0.0422, p = 0.84

—
—
—
—

—
—
—
—

—

—

F (1, 55) = 0.00293, p = 0.96

—

—

F (1, 55) = 9.63, p = 0.0030**

—

—

—

P=
0.0002***
P = 0.020*
P = 0.017*
P = 0.99
P = 0.51
—
—
—
—

—

—
—
—
—
F (1, 55) = 1.12, p = 0.30
F (1, 55) = 1.65, p = 0.20
F (1, 55) = 0.0150, p = 0.90
F (1, 55) = 1.13, p = 0.29
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—
—
—
—
—
—
—
—

Main Effect: ZCZ tx
Head Shakes
3-way ANOVA: Sex x Geno x
ZCZ tx
2-way Interaction: Geno x ZCZ
tx
2-way Interaction: Sex x ZCZ tx
2-way Interaction: Sex x Geno
Main Effect: Sex
Main Effect: Genotype
Main Effect: ZCZ tx

F (1, 55) = 9.99, p = 0.0026**

—

—

F (1, 55) = 1.67, p = 0.20

—

—

F (1, 55) = 1.34, p = 0.25

—

—

F (1, 55) = 0.0755, p = 0.78
F (1, 55) = 4.18, p = 0.046*
F (1, 55) = 0.246, p = 0.62
F (1, 55) = 0.0152, p = 0.90
F (1, 55) = 0.102, p = 0.75

—
—
—
—
—

—
—
—
—
—
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2.4. Discussion
Here we report that the CB1 receptor PAM, ZCZ011, attenuates a subset of naloxone-precipitated
withdrawal signs in oxycodone-dependent mice. Notably, ZCZ011 fully blocked withdrawal-induced
diarrhea and weight loss and attenuated paw flutters. In contrast, ZCZ011 did not impact naloxoneprecipitated jumping in oxycodone-dependent mice and its attenuation of naloxone-precipitated head
shakes was inconsistent. The anti-diarrheal and anti-weight loss effects of ZCZ011 occurred
predominantly through a CB1 receptor dependent mechanism in both male and female mice. Thus, a CB1
receptor PAM reduces a subset of withdrawal signs in both male and female opioid-dependent mice.
Complementary pharmacological and genetic approaches used to elucidate cannabinoid receptor
mediation of the anti-withdrawal effects of ZCZ011 demonstrate that ZCZ011 attenuates diarrhea and
body weight loss through CB1, not CB2, receptors. However, it is difficult to draw conclusions about CB1
receptor involvement in the paw flutters measure because rimonabant did not significantly block the
reduction of paw flutters produced by ZCZ011, and since CB1 (-/-) mice exhibited an overall lower
frequency of paw flutters than CB1 (+/+) mice regardless of drug treatment, determining CB1 receptor
involvement was hindered. The unreliability of ZCZ011 to reduce naloxone-precipitated head shakes in
oxycodone-dependent mice precluded discerning the role of CB1 receptors in this measure. Consistent
with previous reports (Ledent et al., 1999; Lichtman et al., 2001; Maldonado et al., 2002), CB1 (-/-) mice
showed less jumps and paw flutters compared to (+/+) mice. Nonetheless, both genetic and
pharmacological data reveal that ZCZ011 attenuates naloxone-precipitated diarrhea and weight loss in
oxycodone-dependent mice through CB1 receptors.
CB1 receptor orthosteric agonists and endocannabinoid catabolic enzyme inhibitors effectively
attenuate opioid withdrawal; however, they also produce unwanted cannabimimetic effects, and
antinociceptive tolerance and dependence upon repeated administration, which limits their potential
clinical utility. Moreover, while clonidine has shown to reduce the frequency of withdrawal-induced
jumps, paw flutters, and weight loss (Carper et al., 2021), its hypotensive effects limit its clinical use
(Kuhlman et al., 1998; Stolbach and Hoffman, 2020). In contrast to combined FAAH/MAGL blockade,
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which substitutes for THC in the drug discrimination paradigm (Long, Nomura, et al., 2009), ZCZ011
does not substitute for CB1 receptor orthosteric agonists (Ignatowska-Jankowska, Baillie, et al., 2015),
indicating that CB1 receptor PAMs do not elicit cannabimimetic subjective effects. Thus, CB1 receptor
PAMs may offer a favorable strategy to target CB1 receptors for therapeutic gain, with a reduced side
effect profile, compared with orthosteric CB1 receptor agonists or combined FAAH/MAGL blockade.
Repeated administration of THC or MAGL inhibitors leads to antinociceptive tolerance, whereas repeated
administration of ZCZ011 or GAT211 produces sustained antinociceptive effects in mouse models of
inflammatory and neuropathic pain (Ignatowska-Jankowska, Baillie, et al., 2015; Slivicki et al., 2017).
Finally, repeated administration of THC or MAGL inhibitors leads to cannabinoid dependence
(Schlosburg et al., 2014; Trexler et al., 2019); which is not seen with repeated administration of GAT211
(Slivicki et al., 2017). It is also noteworthy that ZCZ011 alone does not produce a conditioned place
preference (CPP) (Ignatowska-Jankowska, Baillie, et al., 2015; Trexler et al., 2019), suggesting that it
lacks rewarding effects. The present study showing that ZCZ011 attenuates oxycodone withdrawal signs
and other work showing that it attenuates rimonabant-precipitated and spontaneous withdrawal signs in
THC-dependent mice (Trexler et al., 2019) without cannabimimetic side effects or tolerance supports the
possibility that CB1 receptor PAMs may offer a novel strategy to treat opioid and cannabinoid
dependence.
The present study employed two strains (i.e., ICR and CB1 (+/+) and (-/-) mice on a C57BL/6J
background) of male and female mice, and showed that ZCZ011 reliably diminished naloxoneprecipitated diarrhea and weight loss in oxycodone-dependent mice regardless of strain or sex. While
female Wistar rats self-administer more oxycodone than males (Kimbrough et al., 2020), we did not
observe withdrawal sex differences with respect to drug treatment. However, independent of sex, we
found strain differences in which the variability in jumps and paw flutters was high in ICR mice
compared with CB1 (+/+) mice or the C57BL/6J mice used in the study done by Carper and colleagues
(2021). Additionally CB1 (+/+) and (-/-) mice on a C57BL/6J background show less weight loss than the
C57BL/6J mice used in the Carper and colleagues (2021) study. This solitary difference in the magnitude
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of weight loss is likely due to procedural differences between the studies. For example, the mice in the
present study were exposed to the withdrawal chambers for an additional 30 min acclimation period
before naloxone challenge, while the mice in the study by Carper et al. (2021) were placed in the chamber
immediately after naloxone administration.
In contrast to the present study in which ZCZ011 modestly lowered the frequency of paw flutters,
Slivicki and colleagues (2020) found that GAT211 did not attenuate naloxone-precipitated paw flutters in
morphine-dependent mice. They also found that GAT211 did not reduce naloxone-precipitated jumps;
however, they did not report other measures of withdrawal. Thus, it will be of value to evaluate multiple
CB1 receptor PAMs on a full complement of withdrawal signs in several rodent models of opioid
dependence.
ZCZ011 and related compounds (i.e., GAT211) show mixed allosteric agonistic and PAM
properties, which have been termed CB1 ago-PAMs (Kenakin, 2013). These compounds enhance the
effects of CB1 receptor orthosteric agonists (i.e., CP55,940, WIN55,212-2, or AEA) in a variety of
functional assays, including [35S] GTPγS-binding, β-arrestin recruitment and, inhibition of cAMP
production, but also activate β-arrestin recruitment and inhibit cAMP production in the absence of CB1
receptor orthosteric agonists (Ignatowska-Jankowska, Baillie, et al., 2015; Laprairie et al., 2017; Saleh et
al., 2018; Tseng et al., 2019; Garai et al., 2021). Thus, additional studies (e.g., site directed mutagenesis)
will be required to address the receptor mechanism(s) by which ZCZ011 ameliorates withdrawal signs in
opioid-dependent mice.
The differential effectiveness of ZCZ011 in ameliorating diarrhea and weight loss compared with
withdrawal-induced jumps, paw flutters, and head shakes merits consideration of CNS- and peripherallymediated processes. Withdrawal-induced jumping, paw fluttering, and head shaking behavior in opioiddependent mice have been mapped to various brain regions (Koob et al., 1992; Maldonado et al., 1992,
1996) including the locus coeruleus (LC; Maldonado and Koob, 1993) the periaqueductal grey (PAG;
Laschka et al., 1976), and the medial habenula (MHb; Boulos et al., 2019). It would be of value to
examine whether CB1 receptors expressed in the LC, PAG, and MHb play a role in the attenuation of
79

withdrawal-induced jumps, paw flutters, and/or head shakes by drugs targeting the endocannabinoid
system, such as CB1 receptor PAMs (Kenakin, 2013). Withdrawal-induced weight loss results from a
combination of diarrhea and increased micturition. Thus, activation of CB1 receptors, which are expressed
in the kidneys (Shire et al., 1995; Silva et al., 2013; Lin et al., 2014) and throughout the enteric nervous
system (Massa et al., 2005), particularly on neurons in the myenteric and submucosal plexuses (Storr et
al., 2010; Trautmann and Sharkey, 2015; Hasenoehrl et al., 2016), may prevent withdrawal-induced
weight loss. Notably, cannabinoid receptor agonists evoke diuresis (Sofia et al., 1977). Interestingly, CB1
receptor agonists produce biphasic effects on diuresis in which low doses increase urine output, while
high doses decrease urine output (Chopda et al., 2013). Lastly, naloxone-precipitated diarrhea is heavily
associated with the ileum of the small intestine (Maguma et al., 2010), where the coordination of motility
and secretion occur (Ramesh et al., 2011, 2013; Smith et al., 2012), and CB1 receptor activation leads to
decreased motility and secretion (Storr et al., 2010; Ramesh et al., 2011, 2013; Hasenoehrl et al., 2016).
Accordingly, ZCZ011 may prevent withdrawal-induced diarrhea and weight loss through CB1 receptor
activation in peripheral organs mediating gastrointestinal motility and secretion as well as urine output.
Current medications (i.e., methadone and buprenorphine) employed to treat opioid withdrawal
symptoms (Bell and Strang, 2020) possess abuse liability (Cicero and Inciardi, 2005) and do not
effectively ameliorate all withdrawal symptoms. Alternative adjunct medications offer benefit such as
clonidine for anxiety and loperamide for diarrhea and stomach cramps (Stolbach and Hoffman, 2020) yet
also exhibit hypotension and abuse liability, respectively (Miller et al., 2017; Wu and Juurlink, 2017;
Toce et al., 2018). As such, a need exists to identify alternative medications to treat the most severe
withdrawal symptoms, such as diarrhea (Stolbach and Hoffman, 2020). The finding that ZCZ011 fully
attenuates naloxone-precipitated diarrhea to a similar extent as 75 mg/kg oxycodone (figure 2), suggests
that a CB1 receptor PAM may serve as a potential alternative to substitution therapy.
In conclusion, the CB1 receptor PAM, ZCZ011, attenuates a subset of naloxone-precipitated withdrawal
signs in oxycodone-dependent male and female mice through a CB1 receptor-dependent mechanism. As
diarrhea is a severe withdrawal symptom in opioid-dependent humans and current medications possess
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side effect profiles, future directions will explore the antidiarrheal mechanisms of ZCZ011. Additionally,
it would be of interest to investigate ZCZ011 in other preclinical models of bowel dysfunction. Overall,
the results of the present study suggest that CB1 receptor PAMs may represent an alternative strategy to
treat selective and severe opioid withdrawal effects.
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Chapter 3: The CB1 Receptor Positive Allosteric Modulator, ZCZ011, Inhibits Small Intestinal
Transit in Oxycodone-Dependent Mice Undergoing Precipitated Withdrawal and in Naïve Mice
3.1. Introduction
Severe physical (i.e., diarrhea and vomiting) and psychological (i.e., insomnia, depression,
anxiety) opioid withdrawal symptoms are major drivers for ongoing opioid use (Koob, 2019). While
death from opioid withdrawal is uncommon, vomiting and diarrhea lead to dehydration, hypernatremia,
and ultimately heart failure, which often occurs in jails where suboptimal management programs are
prevalent (Mitchell et al., 2009; Darke et al., 2017). Although opioid-based (i.e., buprenorphine,
methadone) and non-opioid-based (i.e., lofexidine) FDA-approved withdrawal medications are available
for OUD, they are respectively limited by their abuse liability (Cicero and Inciardi, 2005) and postural
hypotension (Lobmaier et al., 2010). Additionally, when diarrhea management cannot be supervised,
individuals use the over-the-counter (OTC) peripherally-restricted opioid agonist, loperamide (Stolbach
and Hoffman, 2020). Unfortunately, reports of loperamide abuse and cardiotoxicity are beginning to
increase since 2005 (Daniulaityte et al., 2013; Vakkalanka et al., 2017) since individuals can take
extremely high doses to bypass the blood-brain-barrier and seek a euphoric high. Therefore, the
development of alternative medications to treat withdrawal-induced diarrhea are needed.
The endocannabinoid system plays an important role in regulating the gastrointestinal (GI) tract.
Many pre-clinical studies demonstrate that THC, synthetic cannabinoid receptor agonists, and MAGL and
FAAH inhibitors elicit inhibitory effects on GI transit in intact animals (i.e., delayed gastric emptying,
and small intestine and large intestine inhibition) and motility in isolated tissue (Chesher et al., 1973;
Calignano et al., 1997; Colombo et al., 1998; Izzo, Mascolo, et al., 1999; Izzo et al., 2000; Capasso et al.,
2005; Taschler et al., 2015), as well as inhibition of secretion (i.e., both in whole animals and isolated
tissue) through the activation of CB1 receptors (Izzo et al., 2003; Coruzzi et al., 2006; Izzo and Capasso,
2006; Borrelli, 2007). Conversely, the selective CB1 inverse agonist/antagonist, rimonabant, enhances
small intestinal transit in a dose-dependent manner (Calignano et al., 1997; Colombo et al., 1998; Izzo,
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Mascolo, et al., 1999; Izzo et al., 2000; Carai et al., 2006) thereby suggesting two possible explanations,
(1) endocannabinoid tone is actively regulating small intestinal transit or (2) CB1 receptors are
constitutively signaling readily and the presence of rimonabant elicits decreased constitutive activity
which implies inverse agonism. With respect to withdrawal-induced diarrhea in rodents, THC and the
MAGL inhibitor, JZL184, completely blocked naloxone-precipitated diarrhea through the activation of
CB1, but not CB2, receptors, whereas the FAAH inhibitor, PF-3845, failed to reduce diarrhea (Ramesh et
al., 2011). Notably, the dose of JZL184 (40 mg/kg) that produces anti-withdrawal effects also elicits
cannabinoid dependence, antinociceptive tolerance, and CB1 receptor downregulation and desensitization
following repeated administration (Long, Li, et al., 2009; Schlosburg et al., 2010, 2014). A follow-up
study by Ramesh et al. (2013) combined a low-dose of JZL184 (4 mg/kg) which retains antinociceptive
effects without producing cannabinoid dependence following repeated administration (Kinsey et al.,
2013) and a high-dose of PF-3845 (10 mg/kg) which did not reduce diarrhea, as well as SA-57 (full
inhibiter of FAAH and partial inhibiter of MAGL), to discern whether this would be a more optimal
strategy to reduce withdrawal signs. The results were that the combination of JZL184 and PF-3845 and
SA-57 attenuated naloxone-precipitated and spontaneous diarrhea in mice without producing untoward
cannabimimetic effects and to a greater extent than either JZL184 or PF-3845 treatment alone (Ramesh et
al., 2013). While these approaches produce a myriad of antinociceptive effects and anti-withdrawal
effects, THC, synthetic cannabinoids, and MAGL inhibitors produce acute cannabimimetic effects,
antinociceptive tolerance and physical dependence upon repeated administration, as well as a
discriminative stimuli indicating the potential for abuse liability (Lichtman et al., 2001; Wiley and
Martin, 2003; Vann et al., 2009; Long, Li, et al., 2009; Schlosburg et al., 2010, 2014; Kinsey and Cole,
2013; Wakley et al., 2014; Grim, Morales, et al., 2016; Owens et al., 2017; Slivicki et al., 2017; Trexler
et al., 2018, 2019), which may limit their clinical development.
CB1 receptor positive allosteric modulators (PAMs) offer a selective approach to elicit therapeutic
effects with little to no side effects (Nguyen et al., 2016). Two of the most studied CB1 receptor PAMs in
vivo, ZCZ011 and GAT211, produce antinociceptive effects in rodent pain models without undergoing
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antinociceptive tolerance (Ignatowska-Jankowska, Baillie, et al., 2015; Slivicki et al., 2017, 2020) or
physical dependence following repeated administration (Slivicki et al., 2017). Furthermore, ZCZ011
attenuates rimonabant-precipitated withdrawal signs in THC-dependent mice (Trexler et al., 2019) and
naloxone-precipitated diarrhea and weight loss in oxycodone-dependent mice (Dodu et al., 2021).
Therefore, after modeling enhanced transit and fecal output related processes of diarrhea, we
hypothesized the CB1 receptor PAM, ZCZ011, inhibits naloxone-enhanced small intestinal transit and
naloxone-precipitated fecal output in oxycodone-dependent male and female mice by activating CB1
receptors.
Here we determined whether ZCZ011 attenuates naloxone-enhanced small intestinal transit and
naloxone-precipitated fecal output and diarrhea in male and female mice. Because rimonabant has been
shown to enhance small intestinal transit (Colombo et al., 1998; Carai et al., 2006), a dose-response
relationship was conducted to identify a sub-threshold dose to be used in subsequent studies examining
whether CB1 receptors mediate the pharmacological effects of ZCZ011. Specifically, we employed doses
of rimonabant and SR144528, the CB2 antagonist, that do not affect small intestinal transit, and
constitutive CB1 (-/-) mice to discern cannabinoid receptor involvement of the anti-transit effects of
ZCZ011. In addition, we used non-dependent CB1 (-/-) mice to discern whether the finding that ZCZ011
inhibited small intestinal transit in non-dependent mice was mediated by CB1 receptors. Lastly, because
several studies demonstrated that the effects on small intestinal transit by CB1 receptor agonists and
rimonabant undergo tolerance following repeated administration (Anderson et al., 1975; Carai et al.,
2004; Abalo et al., 2009; Taschler et al., 2015), we examined the consequences of repeated ZCZ011
administration on small intestinal transit.
3.2. Methods
3.2.1.

Animals
Male and female ICR mice (minimum 8 weeks of age; Envigo, Indianapolis, IN, USA)

respectively weighing between 35-45 g and 30-40 g were used for these experiments. Animals continued
to be delivered at 7 weeks of age followed by one week of acclimation in VCU’s vivarium before testing
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began. Age-matched male and female CB1 (+/+) and CB1 (-/-) mice also served as subjects (Zimmer et
al., 1999). All mice were housed up to four mice per cage and in a light- (12 h light/dark cycle; lights on
at 0600), temperature- (20–22°C) and humidity-controlled (55% ± 10%) AAALAC-approved facility at
VCU. Food and water were available ad libitum except during the 30 min withdrawal observation period.
Moreover, water continued to be available ad libitum whereas mice were food deprived during the 4-hour
fasting period when measuring small intestinal transit. Animal protocols were approved by the
Institutional Animal Care and Use Committee at VCU and were in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals.
3.2.2.

Drugs
Oxycodone hydrochloride, naloxone hydrochloride, rimonabant, and SR144528 were obtained

from the National Institute on Drug Abuse drug supply program (Bethesda, MD). ZCZ011, the CB1
receptor PAM, was synthesized in the Lu laboratory based on the protocol recently described in Dodu and
colleagues (2021). ZCZ011, rimonabant (CB1 receptor inverse agonist/antagonist), and SR144528 (CB2
receptor antagonist) were dissolved in a vehicle solution consisting of ethanol, alkamuls-620 (SanofiAventis, Bridgewater, NJ), and saline (0.9% NaCl) in a 1:1:18 ratio. Oxycodone and naloxone were
dissolved in 0.9% saline and doses were calculated based on the weight of the salts. All injections were
administered in a volume of 10 ml/kg of body weight. Oxycodone and naloxone were administered via
subcutaneous (s.c.) injections, whereas ZCZ011, rimonabant, and SR144528 were given via
intraperitoneal (i.p.) injections.
3.2.3.

Measuring small intestinal transit in mice
Measurement of small intestinal transit in mice was adapted from a previously established

protocol (Ross et al., 2008) with modifications. On test day, mice were fasted (i.e., food deprived) for a 4hour period in single-housed cages with ad libitum access to water and did not contain any bedding.
Raised wire meshes were used to suspend the mice above the bottom of the cage to prevent them from
ingesting their own feces. A 4-hour fasting time period was chosen to deplete the small intestine of feces
to more easily visualize the charcoal solution, mitigate stress on the animals, and to avoid the need of
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maintaining caloric intake and potential development of hypoglycemia. Mice received an oral gavage
consisting of a 5% aqueous suspension of charcoal in 10% gum Arabic solution at a volume of 10 ml/kg
immediately before naloxone (or saline) administration and before they were placed back into the white
chambers used to record mice during the 30-min observation period as described in section 2.2.3. After
the 30-min observation period, mice were quickly euthanized by cervical dislocation and the small
intestine from the pyloric junction to the ileocecal junction was resected and placed on ice to stop
peristalsis. The distance traveled by the leading edge of the charcoal solution was measured relative to the
total length of the small intestine, and the percentage of intestinal transit for each animal was calculated as
percent intestinal transit (leading edge of charcoal distance)/(small intestinal length) × 100%. This is
referred as the small intestinal transit in the text and intestinal transit in the figures. Notably, mice were
separated by 15 min in their respective treatment schedule to ensure adequate time to euthanize and
measure small intestinal transit. An additional 15 min was given between every fourth mouse to clean
chambers between cohorts with 10% ethanol to mitigate odors between cohorts. A maximum of 12 mice
were tested per day to ensure testing was completed within a 6 h time frame. Collection of data was
performed by one experimenter (Julien Dodu). The timeline of the oral gavage and measurement of small
intestinal transit are indicated in panel A of each figure.
3.2.4.

Modified naloxone-precipitated oxycodone withdrawal model
Measurement of naloxone-precipitated oxycodone withdrawal signs was performed as described

in chapter 2 with adaptations to measure small intestinal transit concurrently. As outlined above in 3.2.3.,
a total of 12 mice were tested per day to ensure testing was completed within a 6 h time frame. Because
diarrhea is regarded as enhanced secretion and transit, we quantified the number of fecal pellets observed
at the end of the 30-min observation period as an additional surrogate measure to capture naloxoneprecipitated diarrhea in vivo.
Naloxone-precipitated withdrawal signs (i.e., diarrhea, jumps, paw flutters, and head shakes)
were scored as outlined in section 2.2.4.; however, body weight loss was not possible since mice
underwent a 4-hour fasting period. Moreover, the number of fecal pellets observed was quantified as an
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additional measure of gastrointestinal effects in mice as the number of pellets present in the chamber
following the 30-min test period. The primary observer (Julien Dodu) and a secondary observer (Aidan
Jones) scored separate videos of 23 oxycodone-dependent mice to establish inter-rater reliability for fecal
output. The primary observer scored withdrawal signs for all experiments.
3.2.5.

Treatment schedule for experiments
To establish whether naloxone enhances small intestinal transit in oxycodone-dependent male and

female mice, two groups of mice were injected with saline or the escalating dose procedure of oxycodone
(9.0, 17.8, 23.7, and 33.0 mg/kg s.c.) for eight days. On day 9, mice underwent a 4-hour fasting period at
0700 h (time = 0 min). 120 min later, mice received their final injection of saline or oxycodone (33 mg/kg
s.c.). 210 min later, mice were acclimated to their respective observation chambers. At 240 min, mice
received an oral gavage of the charcoal solution followed by an injection of 1 mg/kg s.c. naloxone to
precipitate withdrawal. Notably, the acclimation period was crucial because mice often produce several
fecal pellets when placed in a new environment; therefore, when mice underwent naloxone-precipitated
withdrawal, the increased fecal output observed was due to oxycodone-dependent mice undergoing
withdrawal and not due to the exposure of a new environment. After the 30-min observation period, mice
were immediately euthanized and their small intestines were dissected to determine small intestinal transit
using the leading edge of the charcoal solution.
In the experiment testing whether 40 mg/kg ZCZ011 inhibits naloxone-enhanced small intestinal
transit and naloxone-precipitated fecal output and diarrhea, counter-balanced groups of male and female
ICR mice repeatedly administered saline or escalating doses of oxycodone received an injection of
vehicle or ZCZ011 (40 mg/kg i.p.) 75 min before naloxone administration. In the experiment evaluating
the dose-response relationship of ZCZ011, counter-balanced groups of male and female oxycodonedependent ICR mice received ZCZ011 (5, 10, 20, or 40 mg/kg i.p.) or vehicle 75 min before naloxone.
Male and female ICR mice repeatedly administered saline received vehicle 75 min before naloxone
administration to serve as a negative control. The two experimental factors of repeated administration of
saline and escalating doses of oxycodone were collapsed and treated as a single statistical factor.
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As previous studies have shown that rimonabant dose-dependently enhances small intestinal
transit (Colombo et al., 1998; Izzo, Mascolo, et al., 1999; Izzo et al., 2000; Carai et al., 2006), we
similarly sought to determine the dose-response relationship of rimonabant in enhancing small intestinal
transit using our procedural conditions. Counter-balanced groups of naïve male and female ICR mice
underwent the 4-hour fasting period at 0700 h (time = 0 min). 155 min later, mice received one injection
of vehicle or their respective dose of rimonabant (0.1, 0.3, 1, 3 mg/kg i.p.). An additional group of mice
receiving one injection of the CB2 antagonist, SR144528 (3 mg/kg i.p.), was added to determine whether
small intestinal transit was impacted by a well-established dose that reverses CB2-mediated effects in
models of inflammatory and neuropathic pain (Kinsey et al., 2009; Kinsey, Mahadevan, et al., 2011;
Ignatowska-Jankowska, Wilkerson, et al., 2015).
To ascertain whether cannabinoid receptors mediate the anti-withdrawal effects of ZCZ011,
particularly on naloxone-enhanced small intestinal transit, we employed pharmacological and genetic
approaches. In the rimonabant experiment, counter-balanced groups of male and female oxycodonedependent ICR mice received two i.p. injections before naloxone administration. The first i.p. injection
consisted of vehicle, a subthreshold dose of rimonabant (0.3 mg/kg) that does not enhance small intestinal
transit, and a dose of SR144528 (3 mg/kg) that does not impact small intestinal transit followed by a
second i.p. injection that consisted of vehicle or ZCZ011 (40 mg/kg), with respective injections given 85
and 75 min before naloxone administration. In the experiment using CB1 (-/-) mice, age-matched (9-70
weeks of age) male and female oxycodone-dependent CB1 (+/+) and CB1 (-/-) mice were administered
one i.p. injection of vehicle or ZCZ011 (40 mg/kg) 75 min before naloxone administration.
The following experiment determined whether ZCZ011 inhibited small intestinal transit in nondependent and oxycodone-dependent mice in the absence of naloxone administration. Counter-balanced
groups of male and female ICR mice repeatedly administered saline or escalating doses of oxycodone
received an injection of vehicle or ZCZ011 (40 mg/kg i.p.) 75 min before saline administration.
Because 40 mg/kg ZCZ011 inhibited small intestinal transit regardless of mice being oxycodonedependent and whether they underwent naloxone-precipitated withdrawal, the remaining CB1 (-/-) mice
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available were used to determine whether CB1 receptors mediate the effects of ZCZ011 on small
intestinal transit in naïve mice. Counter-balanced naïve male and female CB1 (+/+) and CB1 (-/-) mice
were fasted for a 4-hour time period at 0700 h (time = 0 min) and 165 min later mice received one i.p.
injection of vehicle or ZCZ011 (40 mg/kg). At 210 min, mice were acclimated to their respective
chambers followed by an oral gavage at 240 min whereby mice were investigated for small intestinal
transit at 270 min.
The final experiment examined the consequences of repeated ZCZ011 administration on small
intestinal transit. Three groups of male and female ICR mice were administered two i.p. injections for 5
days (at 0900 h and 1600 h) followed by a final injection on day 6 at 0900 h (i.e., a total of 11 injections).
Group 1 was repeatedly administered vehicle for all 11 injections, group 2 received vehicle for 5 days
(i.e., a total of 10 injections) followed by 40 mg/kg ZCZ011 for the final injection, and group 3 received
40 mg/kg ZCZ011 for all 11 injections over the course of the 6-day procedure. Each figure contains
schematics outlining the timeline of treatments for each experiment.
3.2.6.

Statistical Analyses
All data are reported as mean ± standard deviation (SD). Small intestinal transit is presented as

the precent of transit from the leading edge of the charcoal solution relative to the total length of the small
intestine. The number of fecal pellets was quantified as the number of pellets counted following the 30min observation period. The occurrence of diarrhea was scored as a quantal measure following the 30-min
observation period. A power analysis (G*Power 3.1) of Fig. 10 indicated that a sample size of 12 mice
per group was adequate to detect significant effects of ZCZ011 on naloxone-enhanced small intestinal
transit. Experiments using CB1 (-/-) mice did not incorporate sex as a statistical variable because of the
small sample of CB1 (-/-) mice available. The Fisher exact test was used to analyze occurrence of
diarrhea. Two- and three-way between-measures ANOVAs and Student’s t-test (for pre-planned
comparisons when main effects of oxycodone and ZCZ011 treatment were observed without a significant
interaction) were used to analyze small intestinal transit and fecal output. Dunnett’s post-hoc test was
used to compare ZCZ011 treatments to oxycodone-dependent vehicle-treated mice or naïve mice
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receiving a vehicle injection and Tukey’s post-hoc test was used to compare between various treatments.
To determine the strength of the inter-rater reliability, a Pearson correlation was used with a minimum of
r = 0.9 or greater to ensure reliable scoring was conducted. The criterion of significance for all statistical
tests was p < 0.05.
3.3. Results
3.3.1.

Naloxone enhances small intestinal transit and precipitates fecal output and diarrhea in
oxycodone-dependent male and female mice
The goal of this study was to determine whether naloxone enhances small intestinal transit and

precipitates fecal output in oxycodone-dependent male and female ICR mice undergoing naloxoneprecipitated withdrawal. Fisher exact test was used to analyze diarrhea and Student’s t-tests were used to
analyze small intestinal transit and fecal output. A schematic of treatment conditions for this experiment
is shown in Fig. 8A. Indeed, naloxone enhanced small intestinal transit (p = 0.025; Fig. 8B) and
precipitated fecal output (p = 0.0050; Fig. 8C) and diarrhea (p = 0.048; Fig. 8D).
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Figure 8. Naloxone (1 mg/kg s.c.) enhances small intestinal transit and precipitates fecal output and
diarrhea in oxycodone-dependent male and female mice. Panel A illustrates the timeline of treatments
mice received prior to naloxone-precipitated withdrawal. The withdrawal signs measured include small
intestinal transit (B), fecal output (C), and the occurrence of diarrhea (D). Data are expressed as mean ±
SD for panels B-C and percentage scores for panel D. Numbers at the bottom of bar graphs in panel D
indicate number of mice that presented with diarrhea. Student’s unpaired t-test was used to analyze small
intestinal transit and fecal output (B and C). Fisher exact test was used to analyze the occurrence of
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diarrhea (D). *, p < 0.05; **, p < 0.01 versus mice repeatedly administered saline. Sample size was n = 5
mice/group (n = 3 male and n = 2 female mice/group).
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3.3.2.

Withdrawal scoring between observers
Two trained observers blinded to treatment conditions scored the experiment investigating

whether 40 mg/kg ZCZ011 attenuated naloxone-precipitated fecal output (Fig. 10). Both observes scored
the 23 videos of 23 oxycodone-dependent mice and demonstrated strong Pearson correlations for
naloxone-precipitated fecal output (r = 0.9927; p < 0.0001; Fig. 9).
3.3.3.

The CB1 receptor PAM, ZCZ011, inhibits naloxone-enhanced small intestinal transit in
saline-treated and oxycodone-dependent male and female mice
In this experiment we tested whether ZCZ011 (40 mg/kg i.p.) attenuates naloxone-enhanced

small intestinal transit and naloxone-precipitated fecal output and diarrhea in oxycodone-dependent male
and female ICR mice. Table 9 summarizes Fisher exact test results for naloxone-precipitated diarrhea and
three-way ANOVAs (Sex x Oxycodone treatment x ZCZ011 treatment) for each of the other withdrawal
signs. A schematic of treatment conditions for this experiment is shown in Fig. 10A. In Fig. 10B, while
no two-way interaction was observed, a main effect of oxycodone treatment demonstrates that
oxycodone-dependent mice continue to show enhanced small intestinal transit following naloxone
administration compared to saline-treated mice. Furthermore, a main effect of ZCZ011 was also found,
which revealed that ZCZ011 inhibited naloxone-enhanced small intestinal transit in both saline-treated
and oxycodone-dependent mice. With respect to fecal output (Fig. 10C), ZCZ011 elicited a lowered
frequency of naloxone-precipitated fecal output than oxycodone-dependent vehicle-treated mice. Notably,
a main effect of sex was observed, but no significant difference existed between male and female mice
producing fecal output (p = 0.24). Lastly, in Fig. 10D, 40 mg/kg ZCZ011 lowered the incidence of
naloxone-precipitated diarrhea (1 of 12 mice) compared to oxycodone-dependent vehicle-treated mice (9
of 10 mice). No differences were observed in mice receiving ZCZ011 and repeatedly administered saline
in any withdrawal sign measured. Because no interaction of sex by ZCZ011 treatment or other relevant
drug treatments were observed throughout subsequent experiments, the variable of sex was collapsed for
subsequent experiments.
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Figure 9. Two trained observers that were blind to treatment conditions displayed high inter-rater
reliability for naloxone-precipitated fecal output. Observers used the 23 videos of oxycodone-dependent
mice in figure 10 to determine inter-rater reliability. Pearson correlations were used to determine the
correlation between each observer and the dotted line represents the line of best fit.
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Figure 10. The CB1 receptor PAM, ZCZ011 (40 mg/kg i.p.), inhibits small intestinal transit in salinetreated and oxycodone-dependent male and female mice and attenuates naloxone-precipitated fecal output
and diarrhea in oxycodone-dependent male and female mice. Panel A illustrates the timeline of treatments
mice received prior to naloxone-precipitated withdrawal. The withdrawal signs measured include small
intestinal transit (B), fecal output (C), and the occurrence of diarrhea (D). Data are expressed as mean ±
SD for panels B-C and percentage scores for panel D. Numbers at the bottom of bar graphs in panel D
indicate number of mice that presented with diarrhea. Between-measures three-way ANOVAs were used
to analyze small intestinal transit and fecal output (B and C). Fisher exact test was used to analyze the
occurrence of diarrhea (D). ***, p < 0.001 versus oxycodone-vehicle mice. $$$$, p < 0.0001 main effect
of oxycodone treatment. &&&&, p < 0.0001 main effect of ZCZ011 treatment. Sample size was n = 1012 mice/group (n = 4-6 male and n = 6 female mice/group due to incorrect injections).
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Table 9
Summary of statistical results from Fisher exact tests and three-way ANOVA analyses for Figure 10

Withdrawal Signs
Intestinal Transit
3-way interaction: Sex x
Oxy tx x ZCZ tx
2-way interaction: Oxy tx x
ZCZ tx
2-way interaction: Sex x
ZCZ tx
2-way interaction: Sex x
Oxy tx
Main Effect: Sex
Main Effect: Oxy tx
Main Effect: ZCZ tx
Fecal Output
3-way interaction: Sex x
Oxy tx x ZCZ tx
2-way interaction: Oxy tx x
ZCZ tx
Planned Comparisons:
Sal-Veh vs Sal-ZCZ
Sal-Veh vs Oxy-Veh
Oxy-Veh vs Oxy-ZCZ
2-way interaction: Sex x
ZCZ tx
2-way interaction: Sex x
Oxy tx
Main Effect: Sex
Main Effect: Oxy tx
Main Effect: ZCZ tx
Diarrhea
Sal-Veh vs Sal-ZCZ
Sal-Veh vs Oxy-Veh
Oxy-Veh vs Oxy-ZCZ

F Statistic, P value

Tukey’s

Fisher’s

F (1, 37) = 0.00205, p = 0.96

—

—

F (1, 37) = 0.695, p = 0.41

—

—

F (1, 37) = 0.238, p = 0.63

—

—

F (1, 37) = 0.290, p = 0.59

—

—

F (1, 37) = 1.27, p = 0.27
F (1, 37) = 25.0, p < 0.0001****
F (1, 37) = 43.6, p < 0.0001****

—
—
—

—
—
—

F (1, 37) = 1.98, p = 0.17

—

—

F (1, 37) = 14.0, p = 0.0006***

—

—

—
—
—
F (1, 37) = 3.96, p = 0.054

P = 0.98
P < 0.0001****
P = 0.0003***
—

—
—
—
—

F (1, 37) = 3.96, p = 0.054

—

—

F (1, 37) = 6.61, p = 0.014*
F (1, 37) = 39.2, p < 0.0001****
F (1, 37) = 18.7, p = 0.00011***

—
—
—

—
—
—

—
—
—

—
—
—

P > 0.99
P < 0.0001****
P = 0.00012***
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3.3.4.

ZCZ011 dose-dependently inhibits naloxone-enhanced small intestinal transit in oxycodonedependent mice
Multiple doses of ZCZ011 (5, 10, 20, 40 mg/kg i.p.) were tested to determine whether the

inhibition of naloxone-enhanced small intestinal transit and attenuation of naloxone-precipitated fecal
output and diarrhea produced dose-dependent effects in oxycodone-dependent male and female mice.
Table 10 summarizes Fisher exact test results for naloxone-precipitated diarrhea and two-way ANOVAs
(Sex x ZCZ011 treatment) for each of the other withdrawal signs. A schematic of treatment conditions for
this experiment is shown in Fig. 11A. As shown in Fig. 11B, 40 mg/kg ZCZ011 completely inhibited
naloxone-enhanced small intestinal transit compared to oxycodone-dependent vehicle-treated mice and
the average transit was similar to the saline-treated (non-dependent) group. Additionally, 20 mg/kg
ZCZ011 inhibited naloxone-enhanced small intestinal transit by approximately half compared to
oxycodone-dependent vehicle-treated mice and our saline-treated negative control group. With respect to
fecal output (Fig. 11C), 40 mg/kg ZCZ011 lowered the frequency of naloxone-precipitated fecal output
than oxycodone-dependent mice. Lastly, as illustrated in Fig. 11D, 40 mg/kg ZCZ011 completely lowered
the incidence of naloxone-precipitated diarrhea (0 of 12 mice) than oxycodone-dependent vehicle-treated
mice (12 of 12 mice), whereas 20 mg/kg ZCZ011 lowered the incidence by approximately half (5 of 12
mice).
3.3.5.

Rimonabant dose-dependently enhances small intestinal transit in naïve mice
The purpose of this experiment was to determine a subthreshold dose of the CB1 inverse agonist,

rimonabant, on small intestinal transit to use for subsequent experiments testing cannabinoid receptor
mechanism. An additional group of naïve ICR male and female mice were administered the CB2
antagonist, SR144528 (3 mg/kg), to determine whether this dose impacts small intestinal transit. Table 11
summarizes two-way ANOVAs (Sex x CB antagonist treatment) for small intestinal transit and fecal
output. A schematic of treatment conditions for this experiment is shown in Fig. 12A. With respect to
small intestinal transit (Fig. 12B), 1 mg/kg and 3 mg/kg rimonabant significantly enhanced small
intestinal transit in naïve mice compared to vehicle-treated naïve mice whereas 3 mg/kg SR144528 did
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not impact small intestinal transit demonstrating that CB1 receptors, not CB2 receptors, enhance small
intestinal transit in a dose-dependent manner. As shown in Fig. 12C, these treatments did not elicit fecal
output differences. Notably, a statistically significant main effect of sex revealed male mice averaged 0.58
fecal pellets, whereas female mice averaged 0.17 fecal pellets (p = 0.044). Lastly, as illustrated in Fig.
12D, no diarrhea was observed; therefore, no analysis was completed for this measure.
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Figure 11. ZCZ011 inhibits naloxone-enhanced small intestinal transit and attenuates naloxoneprecipitated fecal output and diarrhea in oxycodone-dependent male and female mice in a dose-dependent
manner. Panel A illustrates the timeline of treatments mice received prior to naloxone-precipitated
withdrawal. The withdrawal signs measured include small intestinal transit (B), fecal output (C), and the
occurrence of diarrhea (D). Data are expressed as mean ± SD for panels B-C and percentage scores for
panel D. Numbers at the bottom of bar graphs in panel D indicate number of mice that presented with
diarrhea. Between-measures three-way ANOVAs were used to analyze small intestinal transit and fecal
output (B and C). Fisher exact test was used to analyze the occurrence of diarrhea (D). **, p < 0.01; ***,
p < 0.001; ****, p < 0.0001 versus oxycodone-vehicle mice. Sample size was n = 12 mice/group (n = 6
male and n = 6 female mice/group).

99

Table 10
Summary of statistical results from Fisher exact tests and two-way ANOVA analyses for Figure 11

Withdrawal Signs
Intestinal Transit
2-way interaction: Sex x
ZCZ tx
Main Effect: Sex
Main Effect: ZCZ tx
Planned Comparisons:
Oxy-Veh vs Sal-Veh
Oxy-Veh vs Oxy-ZCZ (5)
Oxy-Veh vs Oxy-ZCZ (10)
Oxy-Veh vs Oxy-ZCZ (20)
Oxy-Veh vs Oxy-ZCZ (40)
Fecal Output
2-way interaction: Sex x
ZCZ tx
Main Effect: Sex
Main Effect: ZCZ tx
Planned Comparisons:
Oxy-Veh vs Sal-Veh
Oxy-Veh vs Oxy-ZCZ (5)
Oxy-Veh vs Oxy-ZCZ (10)
Oxy-Veh vs Oxy-ZCZ (20)
Oxy-Veh vs Oxy-ZCZ (40)
Diarrhea
Oxy-Veh vs Sal-Veh
Oxy-Veh vs Oxy-ZCZ (5)
Oxy-Veh vs Oxy-ZCZ (10)
Oxy-Veh vs Oxy-ZCZ (20)
Oxy-Veh vs Oxy-ZCZ (40)

F Statistic, P value

Dunnett’s

Fisher’s

F (5, 60) = 0.162, p = 0.98

—

—

F (1, 60) = 0.116, p = 0.73
F (5, 60) = 19.3, p < 0.0001****

—
—

—
—

—
—
—
—
—

P < 0.0001****
P = 0.58
P = 0.44
P = 0.0010***
P < 0.0001****

—
—
—
—
—

F (5, 60) = 0.227, p = 0.95

—

—

F (1, 60) = 1.74, p = 0.19
F (5, 60) = 9.09, p < 0.0001****

—
—

—
—

—
—
—
—
—

P < 0.0001****
P = 0.99
P = 0.66
P = 0.47
P = 0.00010***

—
—
—
—
—

—
—
—
—
—

—
—
—
—
—

P < 0.0001****
P > 0.99
P > 0.99
P = 0.0046**
P < 0.0001****
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Figure 12. The CB1 inverse agonist/antagonist, rimonabant, dose-dependently enhances small intestinal
transit in naïve male and female mice. Panel A illustrates the timeline of treatments mice received prior to
small intestinal transit measurement. The measurements include small intestinal transit (B), fecal output
(C1 and C2), and the occurrence of diarrhea (D). Data are expressed as mean ± SD for panels B-C and
percentage scores for panel D. Between-measures two-way ANOVAs were used to analyze small
intestinal transit and fecal output (B and C1). Students t-test was used to analyze fecal output between
male and female mice (C2). ****, p < 0.0001 versus naïve mice treated with vehicle. Sample size was n
= 12 mice/group (n = 6 male and n = 6 female mice/group).
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Table 11
Summary of statistical results from two-way ANOVA analyses for Figure 12
Measurements Observed
F Statistic, P value
Intestinal Transit
2-way interaction: Sex x CB ant tx
F (5, 60) = 0.976, p = 0.44
Main Effect: Sex
F (1, 60) = 1.19, p = 0.28
Main Effect: CB ant tx
F (5, 60) = 15.0, p < 0.0001****
Planned Comparisons:
Veh vs SR2 (3)
—
Veh vs SR1 (0.1)
—
Veh vs SR1 (0.3)
—
Veh vs SR1 (1)
—
Veh vs SR1 (3)
—
Fecal Output
2-way interaction: Sex x CB ant tx
F (5, 60) = 0.724, p = 0.61
Main Effect: Sex
F (1, 60) = 4.31, p = 0.042*
Main Effect: CB ant tx
F (5, 60) = 1.55, p = 0.19
No Diarrhea observed; therefore, no analysis was conducted
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Dunnett’s
—
—
—
P = 0.93
P = 0.95
P = 0.71
P < 0.0001****
P < 0.0001****
—
—
—

3.3.6.

The inhibition of naloxone-enhanced small intestinal transit and naloxone-precipitated
diarrhea by ZCZ011 is mediated by CB1, not CB2, receptors
The purpose of this experiment was to determine whether cannabinoid receptors mediate the

inhibition of small intestinal transit by ZCZ011 in oxycodone-dependent mice undergoing naloxoneprecipitated withdrawal. Accordingly, we selected doses of rimonabant (0.3 mg/kg) and SR144528 (3
mg/kg) that do not influence small intestinal transit (Fig. 12). Table 12 summarizes Fisher exact test
results for naloxone-precipitated diarrhea and three-way ANOVAs (Sex x CB antagonist treatment x
ZCZ011 treatment) for each of the other withdrawal signs. A schematic of treatment conditions for this
experiment is shown in Fig. 13A. With respect to small intestinal transit (Fig. 13B), 40 mg/kg ZCZ011
inhibited naloxone-enhanced small intestinal transit in mice pre-treated with vehicle and SR144528
compared to their respective control groups. In contrast, a dose of rimonabant that does not enhance small
intestinal transit reversed the inhibition of naloxone-enhanced small intestinal transit by ZCZ011
suggesting that CB1 receptors, not CB2 receptors, mediate this anti-transit effect. In Fig. 13C, an
unforeseen three-way interaction between sex, CB antagonist, and ZCZ011 treatment was found where
two statistical differences were observed, (1) female-vehicle-ZCZ011 versus male-rimonabant-vehicle
treated mice (p = 0.029); and (2) male-rimonabant-vehicle versus male-SR144528-ZCZ011 treated mice
(p = 0.037). However, no other relevant significant differences between groups of interest were observed.
No two-way interactions or main effect of sex were observed. Notably, there was a main effect of
ZCZ011 treatment demonstrating that indeed ZCZ011 did reduce naloxone-precipitated fecal output,
however, the lack of a ZCZ011 by CB antagonist treatment two-way interaction illustrates that
cannabinoid receptor involvement remains unknown. Lastly, 40 mg/kg ZCZ011 elicited a lower incidence
of naloxone-precipitated diarrhea in oxycodone-dependent mice pre-treated with vehicle (1 of 11 mice) or
SR144528 (1 of 11 mice) than oxycodone-dependent mice pre-treated with either vehicle (12 of 12 mice)
or SR144528 (11 of 12 mice), respectively. On the contrary, 0.3 mg/kg rimonabant prevented the
reduction of naloxone-precipitated diarrhea by ZCZ011 (12 of 12 mice). These findings suggest that CB1
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receptors, not CB2 receptors, mediate the anti-transit and anti-diarrheal effects of ZCZ011 and corroborate
with results in chapter 2, Fig. 6B.
3.3.7.

The inhibition of naloxone-enhanced small intestinal transit by ZCZ011 in oxycodonedependent mice requires CB1 receptor activation
Constitutive CB1 (+/+) and (-/-) oxycodone-dependent male and female mice were used to

investigate whether the inhibition of naloxone-enhanced small intestinal transit by ZCZ011 requires CB1
receptors. Table 13 summarizes Fisher exact test results for naloxone-precipitated diarrhea and two-way
ANOVAs (Genotype x ZCZ011 treatment) for each of the other withdrawal signs. Sex was not
incorporated as an experimental factor because of the small sample of CB1 (-/-) mice available and the
fact that sex was not detected as a factor in previous experiments. A schematic of treatment conditions for
this experiment is shown in Fig. 14A. In Fig. 14B, 40 mg/kg ZCZ011 inhibited naloxone-enhanced small
intestinal transit in oxycodone-dependent CB1 (+/+) mice whereas the anti-transit effect was abolished in
oxycodone-dependent CB1 (-/-) mice. Importantly, ZCZ011-treated CB1 (+/+) mice demonstrated
significantly less transit than ZCZ011-treated CB1 (-/-) mice indicating that CB1 receptors mediate the
anti-transit effects of ZCZ011. With respect to naloxone-precipitated fecal output (Fig. 14C), mice
excreted small amounts of fecal pellets regardless of treatment and may be explained by the fasting period
in that is may affect CB1 (+/+) and (-/-) more than ICR mice. Thus, it was inconclusive whether CB1
receptors mediate the effects of ZCZ011 on naloxone-precipitated fecal output. As illustrated in Fig. 14D,
ZCZ011 fully blocked naloxone-precipitated diarrhea in oxycodone-dependent CB1 (+/+) mice (0 of 6
mice) compared to oxycodone-dependent CB1 (+/+) mice not receiving ZCZ011 (5 of 6 mice). In
contrast, no difference was observed between oxycodone-dependent vehicle-treated CB1 (-/-) mice (4 of 5
mice) and oxycodone-dependent ZCZ011-treated CB1 (-/-) mice (5 of 6 mice). In addition, ZCZ011treated CB1 (+/+) mice did not elicit naloxone-precipitated diarrhea whatsoever compared to ZCZ011treated CB1 (-/-) mice demonstrating that once again ZCZ011 attenuates naloxone-precipitated diarrhea
through CB1 receptors.
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Figure 13. A subthreshold dose of rimonabant (0.3 mg/kg i.p.), but not SR144528 (3 mg/kg i.p.),
reversed the inhibition of ZCZ011 (40 mg/kg i.p.) on naloxone-enhanced small intestinal transit and
naloxone-precipitated diarrhea in oxycodone-dependent male and female mice. Panel A illustrates the
timeline of treatments mice received prior to naloxone-precipitated withdrawal. The withdrawal signs
measured include small intestinal transit (B), fecal output (C), and the occurrence of diarrhea (D). Data
are expressed as mean ± SD for panels B-C and percentage scores for panel D. Numbers at the bottom of
bar graphs in panel D indicate number of mice that presented with diarrhea. Between-measures three-way
ANOVAs were used to analyze small intestinal transit and fecal output (B and C). Fisher exact test was
used to analyze the occurrence of diarrhea (D). ***, p < 0.001; ****, p < 0.0001 versus vehicle-vehicle or
SR144528-vehicle mice. ####, p < 0.0001 versus vehicle-ZCZ011 mice. Sample size was n = 12
mice/group (n = 6 male and n = 6 female mice/group).
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Table 12
Summary of statistical results from Fisher exact tests and three-way ANOVA analyses for Figure 13
Withdrawal Signs
Intestinal Transit
3-way interaction: Sex x
CB ant tx x ZCZ tx
2-way interaction: CB ant
tx x ZCZ tx
Planned Comparisons:
Veh-Veh vs Veh-ZCZ
SR1-Veh vs SR1-ZCZ
SR2-Veh vs SR2-ZCZ
Veh-ZCZ vs SR1-ZCZ
Veh-ZCZ vs SR2-ZCZ
2-way interaction: Sex x
ZCZ tx
2-way interaction: Sex x
CB ant tx
Main Effect: Sex
Main Effect: CB ant tx
Main Effect: ZCZ tx
Fecal Output
3-way interaction: Sex x
CB ant tx x ZCZ tx
2-way interaction: CB ant
tx x ZCZ tx
2-way interaction: Sex x
ZCZ tx
2-way interaction: Sex x
CB ant tx
Main Effect: Sex
Main Effect: CB ant tx
Main Effect: ZCZ tx
Diarrhea
Veh-Veh vs Veh-ZCZ
SR1-Veh vs SR1-ZCZ
SR2-Veh vs SR2-ZCZ
Veh-ZCZ vs SR1-ZCZ
Veh-ZCZ vs SR2-ZCZ

F Statistic, P value

Tukey’s

Fisher’s

F (2, 60) = 0.0706, p = 0.93

—

—

F (2, 60) = 8.50, p =
0.0006***

—

—

—
—
—
—
—
F (1, 60) = 1.21, p = 0.28

P < 0.0001****
P = 0.26
P < 0.0001****
P < 0.0001****
P = 0.89
—

—
—
—
—
—
—

F (2, 60) = 0.134, p = 0.87

—

—

F (1, 60) = 1.08, p = 0.30
F (2, 60) = 25.8, p <
0.0001****
F (1, 60) = 84.2, p <
0.0001****

—
—

—
—

—

—

F (2, 60) = 4.36, p = 0.017*

—

—

F (2, 60) = 0.387, p = 0.68

—

—

F (1, 60) = 0.314, p = 0.58

—

—

F (2, 60) = 1.18, p = 0.31

—

—

F (1, 60) = 0.240, p = 0.63
F (2, 60) = 5.92, p = 0.0045**
F (1, 60) = 9.06, p = 0.0038**

—
—
—

—
—
—

—
—
—
—
—

—
—
—
—
—

P < 0.0001****
P > 0.99
P = 0.00011***
P < 0.0001****
P > 0.99
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Figure 14. The inhibition of ZCZ011 (40 mg/kg i.p.) on naloxone-enhanced small intestinal transit and
the attenuation on naloxone-precipitated diarrhea was absent in CB1 (-/-) oxycodone-dependent male and
female mice. Panel A illustrates the timeline of treatments mice received prior to naloxone-precipitated
withdrawal. The withdrawal signs measured include small intestinal transit (B), fecal output (C), and the
occurrence of diarrhea (D). Data are expressed as mean ± SD for panels B-C and percentage scores for
panel D. Numbers at the bottom of bar graphs in panel D indicate number of mice that presented with
diarrhea. Between-measures two-way ANOVAs were used to analyze small intestinal transit and fecal
output (B and C). Fisher exact test was used to analyze the occurrence of diarrhea (D). *, p < 0.05; ***, p
< 0.001 versus CB1 (+/+)-vehicle mice. #, p < 0.05; ###, p < 0.001 versus CB1 (+/+)-ZCZ011 mice.
Sample size was n = 5-6 mice/group (n = 2-3 male and n = 3 female mice/group).
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Table 13
Summary of statistical results from Fisher exact tests and two-way ANOVA analyses for Figure 14
Withdrawal Signs
Intestinal Transit
2-way interaction: Geno x ZCZ tx
Planned Comparisons:
CB1(+/+)-Veh vs CB1(+/+)-ZCZ
CB1(-/-)-Veh vs CB1(-/-)-ZCZ
CB1(+/+)-ZCZ vs CB1(-/-)-ZCZ
Main Effect: Geno
Main Effect: ZCZ tx
Fecal Output
2-way interaction: Geno x ZCZ tx
Main Effect: CB ant tx
Main Effect: ZCZ tx
Diarrhea
CB1(+/+)-Veh vs CB1(+/+)-ZCZ
CB1(-/-)-Veh vs CB1(-/-)-ZCZ
CB1(+/+)-ZCZ vs CB1(-/-)-ZCZ

F Statistic, P value

Tukey’s

Fisher’s

F (1, 19) = 9.120, p =
0.0070**

—

—

—
—
—
F (1, 19) = 12.5, p =
0.0022**
F (1, 19) = 19.2, p =
0.0003***

P = 0.0002***
P = 0.79
P = 0.0007***
—

—
—
—
—

—

—

F (1, 19) = 0.160, p = 0.69
F (1, 19) = 0.363, p = 0.36
F (1, 19) = 0.363, p = 0.36

—
—
—

—
—
—

—
—
—

—
—
—

P = 0.015*
P > 0.99
P = 0.015*
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3.3.8.

ZCZ011 inhibits small intestinal transit in saline-treated and oxycodone-dependent mice in
the absence of naloxone.
To investigate the finding of ZCZ011 inhibition on small intestinal transit irrespective of

naloxone (Fig. 10B), we used saline-treated and oxycodone-dependent male and female ICR mice in the
absence of naloxone. Table 14 summarizes three-way ANOVAs (sex x oxycodone treatment x ZCZ011
treatment) for small intestinal transit and fecal output. A schematic of treatment conditions for this
experiment is shown in Fig. 15A. In Fig. 15B, a main effect of ZCZ011 treatment was present without
interactions between sex or oxycodone treatment suggesting that ZCZ011 inhibits small intestinal transit
in saline-treated and oxycodone-dependent mice. With respect to fecal output (Fig. 15C), a significant
two-way interaction was observed between sex and oxycodone treatment, but no post-hoc analyses
demonstrated differences between groups. The explanation for this interaction is likely due to the
observation that a small number of fecal pellets were observed specifically in saline-treated female mice
and oxycodone-dependent male mice, thus producing a two-way interaction, but with no significant
differences between groups. In Fig. 15D, no observable diarrhea was present; therefore, no analysis was
performed.
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Figure 15. ZCZ011 (40 mg/kg i.p.) inhibits small intestinal transit in saline-treated and oxycodonedependent male and female mice in the absence of naloxone administration. Panel A illustrates the
timeline of treatments mice received prior to the 30-min observation period. The measurements include
small intestinal transit (B), fecal output (C1 and C2), and the occurrence of diarrhea (D). Data are
expressed as mean ± SD for panels B-C and percentage scores for panel D. Between-measures three-way
ANOVAs were used to analyze small intestinal transit and fecal output (B and C1). Between-measures
two-way ANOVA was used to analyze fecal output between sex and oxycodone treatment (C2). $$$$, p <
0.0001 main effect of oxycodone treatment. &&&&, p < 0.0001 main effect of ZCZ011 treatment.
Sample size was n = 12 mice/group (n = 6 male and n = 6 female mice/group).
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Table 14
Summary of statistical results from two-way ANOVA analyses for Figure 15
Measurements Observed
F Statistic, P value
Intestinal Transit
3-way interaction: Sex x Oxy tx x ZCZ tx
F (1, 40) = 0.046, p = 0.83
2-way interaction: Oxy tx x ZCZ tx
F (1, 40) = 0.272, p = 0.61
2-way interaction: Sex x Oxy tx
F (1, 40) = 3.67, p = 0.063
2-way interaction: Sex x ZCZ tx
F (1, 40) = 0.340, p = 0.56
Main Effect: Sex
F (1, 40) = 0.0949, p = 0.76
Main Effect: Oxy tx
F (1, 40) = 45.5, p < 0.0001****
Main Effect: ZCZ tx
F (1, 40) = 16.9, p = 0.0002***
Fecal Output
3-way interaction: Sex x Oxy tx x ZCZ tx
F (1, 40) = 1.32, p = 0.26
2-way interaction: Oxy tx x ZCZ tx
F (1, 40) = 1.32, p = 0.26
2-way interaction: Sex x Oxy tx
F (1, 40) = 7.21, p = 0.011*
Planned Comparisons:
Male-Sal vs Female-Sal
—
Male-Oxy vs Female -Oxy
—
Male-Sal vs Male-Oxy
—
Male-Sal vs Female-Oxy
—
Female-Sal vs Male-Oxy
—
Female-Sal vs Female-Oxy
—
2-way interaction: Sex x ZCZ tx
F (1, 40) = 1.32, p = 0.26
Main Effect: Sex
F (1, 40) = 0.147, p = 0.70
Main Effect: Oxy tx
F (1, 40) = 0.147, p = 0.70
Main Effect: ZCZ tx
F (1, 40) = 1.32, p = 0.26
No Diarrhea observed; therefore, no analysis was conducted

111

Tukey’s
—
—
—
—
—
—
—
—
—
—
P = 0.16
P = 0.39
P = 0.39
P > 0.99
P = 0.95
P = 0.16
—
—
—
—

3.3.9.

The inhibition of small intestinal transit by ZCZ011 was absent in naïve CB1 (-/-) mice
This experiment examined the consequences of ZCZ011 on small intestinal transit in CB1 (-/-)

male and female naïve mice. Sex was not incorporated as an experimental factor because of the small
sample of CB1 (-/-) mice available and the fact that virtually no sex effects were found throughout these
studies. A schematic of treatment conditions for this experiment is shown in Fig. 16A. In Fig. 16B, no
two-way interaction [F (1, 19) = 3.95; p = 0.062] was observed for small intestinal transit; however, main
effects of genotype [F (1, 19) = 8.21; p = 0.0099] and ZCZ011 treatment [F (1, 19) = 9.80; p = 0.0055]
were present. As described above, planned comparisons revealed that 40 mg/kg ZCZ011 inhibited small
intestinal transit in naïve CB1 (+/+) mice (p = 0.0033) but not CB1 (-/-) mice (p = 0.46) suggesting that the
inhibition of small intestinal transit by ZCZ011 is mediated by CB1 receptors. With respect to fecal output
(Fig. 16C) and diarrhea (Fig. 16D), no differences were quantified because little to no fecal pellets or
observable diarrhea were present.
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Figure 16. The inhibition of small intestinal transit by ZCZ011 (40 mg/kg i.p.) was absent in CB1 (-/-)
naïve male and female mice. Panel A illustrates the timeline of treatments mice received prior to
measuring small intestinal transit. The measurements include small intestinal transit (B), fecal output (C),
and the occurrence of diarrhea (D). Data are expressed as mean ± SD for panels B-C and percentage
scores for panel D. Pre-planned multiple comparisons were performed on small intestinal transit (B)
because we were underpowered to observe a significant interaction since we had an insufficient number
of female CB1 (-/-)-vehicle mice (n = 2). ##, p < 0.01 versus CB1 (+/+)-vehicle mice. Sample size was n =
5-6 mice/group (n = 3 male and n = 2-3 female mice/group due to insufficient number of CB1 (-/-) mice).
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Table 15
Summary of statistical results from two-way ANOVA analyses for Figure 16
Measurements Observed
F Statistic, P value
Intestinal Transit
2-way interaction: Geno x ZCZ tx
F (1, 19) = 3.95, p = 0.062
Main Effect: Geno
F (1, 19) = 8.21, p = 0.0099**
Main Effect: ZCZ tx
F (1, 19) = 9.80, p = 0.0055**
Planned Comparisons:
CB1(+/+)-Veh vs CB1(+/+)-ZCZ
—
CB1(-/-)-Veh vs CB1(-/-)-ZCZ
—
Fecal Output
2-way interaction: Geno x ZCZ tx
F (1, 19) = 1.23, p = 0.28
Main Effect: Geno
F (1, 19) = 0.0102, p = 0.92
Main Effect: ZCZ tx
F (1, 19) = 0.823, p = 0.38
No Diarrhea observed; therefore, no analysis was conducted
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Student’s t-test
—
—
—
P = 0.0033**
P = 0.46
—
—
—

3.3.10. The inhibition of small intestinal transit by ZCZ011 undergoes tolerance following repeated
administration
The final experiment investigated whether the inhibition of small intestinal transit by ZCZ011 in
non-dependent male and female ICR mice would undergo tolerance following repeated administration.
Table 16 summarizes two-way ANOVAs (Sex x ZCZ011 treatment) for small intestinal transit and fecal
output. A schematic of treatment conditions for this experiment is shown in Fig. 17A. In Fig. 17B, mice
that received one injection of ZCZ011 on day six demonstrated inhibition of small intestinal transit
compared to mice repeatedly treated with vehicle. In contrast, repeated administration of ZCZ011 led to
tolerance of its inhibitory effects on small intestinal transit. With respect to fecal output (Fig. 17C) and
diarrhea (Fig. 17D), no differences were quantified because little to no fecal pellets or diarrhea were
observed.
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Figure 17. The inhibition of small intestinal transit by ZCZ011 (40 mg/kg i.p.) in naïve male and female
mice undergoes tolerance following repeated administration. Mice received two injections per day on
days 1-5 separated by approximately 7 hours followed by one final injection on day 6 before measuring
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small intestinal transit. Acute ZCZ011 mice received one exposure to ZCZ011 on day 6 to serve as a
control. Panel A illustrates the timeline of treatments mice received prior to measuring small intestinal
transit. The measurements include small intestinal transit (B), fecal output (C), and the occurrence of
diarrhea (D). Data are expressed as mean ± SD for panels B-C and percentage scores for panel D.
Between-measures two-way ANOVAs were used to analyze small intestinal transit and fecal output (B
and C). ****, p < 0.0001 versus mice repeatedly administered vehicle. ####, p < 0.0001 versus mice
repeatedly administered vehicle followed by ZCZ011 on the final day. Sample size was n = 12
mice/group (n = 6 male and n = 6 female mice/group).
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Table 16
Summary of statistical results from two-way ANOVA analyses for Figure 17
Measurements Observed
F Statistic, P value
Intestinal Transit
2-way interaction: Sex x ZCZ tx
F (2, 30) = 1.46, p = 0.25
Main Effect: Sex
F (1, 30) = 0.0353, p = 0.85
Main Effect: ZCZ tx
F (2, 30) = 27.6, p < 0.0001****
Planned Comparisons:
Veh vs Acute ZCZ
—
Veh vs Repeated ZCZ
—
Acute ZCZ vs Repeated ZCZ
—
Fecal Output
2-way interaction: Sex x ZCZ tx
F (2, 30) = 1.00, p = 0.38
Main Effect: Sex
F (1, 30) = 1.00, p = 0.33
Main Effect: ZCZ tx
F (2, 30) = 1.00, p = 0.38
No Diarrhea observed; therefore, no analysis was conducted
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Tukey’s
—
—
—
P < 0.0001****
P = 0.18
P < 0.0001****
—
—
—

3.4. Discussion
The experiments reported in this chapter tested whether the CB1 receptor PAM, ZCZ011, inhibits
naloxone-enhanced small intestinal transit and naloxone-precipitated fecal output and diarrhea in
oxycodone-dependent mice. Initial findings demonstrated ZCZ011 completely attenuated naloxoneprecipitated fecal output and diarrhea; however, ZCZ011 inhibited small intestinal transit in both nondependent and oxycodone-dependent mice administered naloxone. Subsequently, one major finding was
that rimonabant dose-dependently enhanced small intestinal transit in naïve mice, whereas SR144528 did
not affect transit, suggesting constitutive CB1 receptor activity and/or an active endocannabinoid tone
within the GI tract under normal physiological conditions. In addition, a subthreshold dose of rimonabant
(0.3 mg/kg), but not SR144528 (3 mg/kg), blocked the anti-transit and anti-diarrheal effects of ZCZ011 in
oxycodone-dependent male and female mice undergoing naloxone-precipitated withdrawal demonstrating
CB1, not CB2, receptors are required for these anti-withdrawal effects. Additionally, the anti-transit and
anti-diarrheal effects of ZCZ011 were absent in oxycodone-dependent CB1 (-/-) mice undergoing
naloxone-precipitated withdrawal providing supporting evidence that CB1 receptors mediate these antiwithdrawal effects. In contrast, the initial findings that ZCZ011 inhibited naloxone-precipitated fecal
output was inconsistent and may be explained by the impact the 4-hour fasting period had on mice in
subsequent pharmacological and genetic mechanistic studies. Another major finding was that ZCZ011
also inhibited small intestinal transit in non-dependent and oxycodone-dependent mice in the absence of
naloxone, which suggests that ZCZ011 plays a broader role in modulating transit than during precipitated
opioid withdrawal. Subsequently, the inhibition of small intestinal transit by ZCZ011 in naïve mice was
absent in CB1 (-/-) mice revealing a CB1 receptor dependent mechanism. Lastly, the inhibition of small
intestinal transit by ZCZ011 in naïve mice underwent tolerance following repeated administration.
The aim of the current chapter was to explore the anti-diarrheal effects of ZCZ011 on small
intestinal transit and fecal output as associated measures of naloxone-precipitated diarrhea. We
determined that ZCZ011 inhibits naloxone-enhanced small intestinal transit and naloxone-precipitated
fecal output and diarrhea in a dose-dependent manner (Fig. 11). Before evaluating cannabinoid receptor
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involvement using a pharmacological approach, previous studies demonstrate that rimonabant, the CB1
inverse agonist/antagonist, can enhance small intestinal transit in naïve mice in the same charcoal transit
procedure (Calignano et al., 1997; Colombo et al., 1998; Izzo, Mascolo, et al., 1999; Izzo et al., 2000;
Carai et al., 2006). As illustrated in Fig. 12B, rimonabant elicited a dose-dependent (1 and 3 mg/kg)
enhancement of small intestinal transit in naïve ICR mice, whereas a dose of SR144528 (3 mg/kg) readily
used to reveal CB2 receptor-mediated effects did not impact transit. Accordingly, doses of rimonabant
(0.3 mg/kg i.p.) and SR144528 (3 mg/kg) that do not affect transit revealed that rimonabant, not
SR144528, completely reversed the anti-transit and anti-diarrheal effects of ZCZ011 suggesting a CB1,
not CB2, receptor mechanism of action. Moreover, the anti-transit and anti-diarrheal effects of ZCZ011
were absent in CB1 (-/-) mice, which is consistent with the pharmacological approach that CB1 receptors
mediate these anti-withdrawal effects of ZCZ011. While ZCZ011 attenuated naloxone-precipitated fecal
output, cannabinoid receptor involvement was inconclusive and may be explained in part by the impact
the 4-hour fasting period had on these mice and they may have excreted more fecal content during their
fasting period than previous experiments. Nonetheless, genetic and pharmacological approaches
demonstrate CB1 receptors mediate the anti-transit and anti-diarrheal effects of ZCZ011.
CB1 receptor orthosteric agonists and MAGL inhibitors effectively attenuate withdrawal-induced
diarrhea; however, their use is hindered because they elicit a discriminative stimulus in mice. THC (5 and
10 mg/kg) (Hine, Friedman, et al., 1975) and the MAGL inhibitor, JZL184 (16 and 40 mg/kg), dosedependently attenuate naloxone-precipitated diarrhea through the activation of CB1, not CB2, receptors
(Ramesh et al., 2011). On the contrary, the FAAH inhibitor, PF-3845 (10 mg/kg), did not attenuate
naloxone-precipitated diarrhea. In addition, the combination of a low-dose of JZL184 (4 mg/kg) that does
not elicit cannabinoid dependence (Kinsey et al., 2013) with a high-dose of PF-3845 (10 mg/kg) that did
not attenuate diarrhea was found to attenuate spontaneous and naloxone-precipitated withdrawal signs,
including diarrhea, to a greater extent than either inhibitor alone (Ramesh et al., 2013). Moreover, the
dual partial MAGL and full FAAH inhibitor, SA-57, also reduced the occurrence of spontaneous
withdrawal-induced diarrhea in morphine dependent mice (Ramesh et al., 2013). Therefore, elevation of
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2-AG or a combination of elevating 2-AG and AEA are needed to elicit anti-diarrheal effects in both
naloxone-precipitated and spontaneous withdrawal models. However, the drug discrimination paradigm
has shown the MAGL inhibitor, MJN110, and the dual MAGL/FAAH inhibitor, SA-57, induces a
discriminative stimulus in mice where the highly potent pan CB1/CB2 receptor agonist, CP55,940,
demonstrates full substitution for both inhibitors (Owens et al., 2016, 2017). These findings suggest that
full MAGL inhibition or partial MAGL and full FAAH inhibition resembles intrinsic subjective effects
similar to highly potent pan CB1/CB2 receptor agonists. In contrast, ZCZ011 does not substitute for
CP55,940 in C57BL/6J mice or AEA in FAAH (-/-) mice (Ignatowska-Jankowska, Baillie, et al., 2015).
Moreover, the CB1 receptor PAM, GAT211, produces synergistic antinociceptive effects with the MAGL
inhibitor, JZL184, in a paclitaxel-induced neuropathic pain model (Slivicki et al., 2017). Thus, future
studies may examine the combination of CB1 receptor PAMs with low doses of MAGL inhibitors, e.g., 4
mg/kg JZL184, or high doses of FAAH inhibitors, e.g., 10 mg/kg PF-3845, in models of opioid
withdrawal to discern whether the combination produces enhanced anti-withdrawal effect compared with
either approach alone. Another approach may be the combination of CB1 receptor PAMs with opioids.
For example, combination of GAT211 and morphine elicited synergistic antinociceptive effects in a
paclitaxel-induced neuropathic pain model (Slivicki et al., 2020). Thus, future studies may examine the
combination of CB1 receptor PAMs and opioids used for substitution as a strategy to reduce the opioid
dose needed to ameliorate withdrawal signs.
Two additional major findings were that ZCZ011 inhibits small intestinal transit regardless of
treatment conditions and that rimonabant enhances small intestinal transit in naïve mice. As shown in
Figures 10B, 15B, 16B, and 17B, an acute injection of ZCZ011 elicits inhibitory effects on small
intestinal transit in non-dependent mice, and Figure 12B shows that rimonabant enhances small intestinal
transit in naïve mice in a dose-dependent manner. Likewise, CB1 receptor orthosteric agonists (i.e., THC,
AEA, or WIN55,212-2) elicit inhibitory effects on small intestinal transit in mice (Jackson et al., 1976;
Colombo et al., 1998; Izzo, Mascolo, et al., 1999; Izzo et al., 2000), whereas mice treated with
rimonabant elicit enhanced small intestinal transit (Colombo et al., 1998; Izzo, Mascolo, et al., 1999; Izzo
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et al., 2000; Carai et al., 2006). This pattern of findings suggests the following: (1) the GI system
demonstrates a tonically active endocannabinoid tone; or (2) CB1 receptors are constitutively active in the
absence of orthosteric agonists in which rimonabant acts as an inverse agonist. The first notion is
supported on the evidence that DAGL, MAGL, and FAAH are expressed within the myenteric plexus
(Capasso et al., 2005; Bashashati et al., 2015; Taschler et al., 2015) and 2-AG and AEA is present
throughout the small and large intestine (Ramesh et al., 2011; Taschler et al., 2015). On the other hand,
the FAAH inhibiter, AM3506, does not alter small intestinal transit in naïve mice (Bashashati et al.,
2012) and the MAGL inhibitor, JZL184, does not alter whole gut transit in naïve mice, though MAGL (-/) mice display delayed whole gut transit (Taschler et al., 2015). Thus, temporarily elevating 2-AG and
AEA does not inhibit GI transit, which is inconsistent with the notion of a tonically active
endocannabinoid tone in the GI tract. Because ZCZ011 enhances the effects of AEA in vivo (IgnatowskaJankowska, Baillie, et al., 2015), it may augment the endocannabinoid tone present in the gut, which
supports the first notion. However, ZCZ011 also acts as an allosteric agonist by activating downstream
signaling pathways of CB1 receptors in the absence of orthosteric ligands (see table 2) and the evidence
that temporarily elevating 2-AG and AEA does not inhibit transit leaves the possibility open that ZCZ011
may stimulate constitutively active CB1 receptors to inhibit small intestinal transit without 2-AG or AEA
being present. Additional experiments are needed to test these opposing hypotheses. One means is by
comparing and contrasting other CB1 receptor PAMs, such as the “pure” PAM, GAT229 (see table 2),
which may act to enhance endocannabinoids without activating the CB1 receptor on its own and may
contrast the inhibitory effects of ZCZ011.
Because small intestinal transit was measured in whole animals, the neurobiological mechanisms
of activating CB1 receptors may occur through central and/or peripheral mechanisms. CB1 receptor
expression is well-known to localize to the myenteric plexus of the small intestine and colon where it is
readily expressed on motor, inter-neuronal, and sensory neurons that produce the primary excitatory
neurotransmitter of the enteric nervous system, acetylcholine (ACh), and a lesser extent on neurons
expressing substance P (SP) and calcitonin gene-related peptide (CGRP) (Coutts et al., 2002). Similarly
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to CB1, CB2 receptors are localized to myenteric neurons (Duncan et al., 2008). Regarding central
mechanisms, the dorsal motor nucleus of the vagus (DMV) in the brain stem (Berthoud et al., 1991)
releases ACh to activate postganglionic neurons which subsequently project to the stomach and small
intestine where regulation of GI transit occurs through two main pathways: (1) an excitatory cholinergic
pathway and (2) an inhibitory non-adrenergic non-cholinergic (NANC) pathway (Browning and Travagli,
2014). The DMV is highly innervated by GABAergic and glutamatergic neurons that reside in the nucleus
tractus solitarii (NTS) of the midbrain where axonal terminals express CB1 receptors (Derbenev et al.,
2004). Considering ZCZ011 distributes in the brain following a 75-min pre-treatment time, as used in
these studies, (Poklis et al., 2015) central mechanisms of activating CB1 receptors cannot be ruled out.
Izzo et al. (2000) conducted a series of experiments that revealed central and peripheral CB1 receptormediated effects on small intestinal transit. They determined that administering WIN55,212-2 and
rimonabant by intracerebroventricular (i.c.v.) and intraperitoneal (i.p.) injections respectively inhibits and
enhances small intestinal transit. Furthermore, rimonabant completely blocked the inhibitory effects of
WIN55,212-2 indicating CB1 receptor involvement. The major findings were revealed when using the
ganglionic blocker, hexamethonium. Hexamethonium completely abolished the inhibitory transit effects
of WIN55,212-2 and the enhanced transit effects of rimonabant when administered i.c.v., but when given
i.p. the modulation of transit was still present. This implies that CB1 receptors modulate small intestinal
transit through both central and peripheral mechanisms of action. Therefore, it is likely that ZCZ011 is
concomitantly acting on both peripheral CB1 receptors found in the myenteric plexus and central CB1
receptors found on nerve terminals of the NTS. An additional explanation for the inhibitory transit effects
of ZCZ011 can be through delayed gastric emptying since the oral gavage of charcoal solution is
administered into the stomach of mice. In fact, one study examining the effects of WIN55,212-2 on
isolated mouse gastric preparations found that both CB1 and CB2 receptor activation leads to inhibition of
the cholinergic excitatory pathway without affecting the NANC inhibitory transmission (Mulè et al.,
2007). Thus, future studies may delineate the centrally- versus peripherally-mediated transit effects of
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ZCZ011 using hexamethonium and various isolated small intestinal and gastric tissue models (see Fig.
18).
Another novel finding was that the inhibitory transit effects of ZCZ011 undergo tolerance
following repeated administration. The inhibitory transit effects of CB1 receptor orthosteric agonists in the
small intestine readily undergo tolerance following repeated administration (Anderson et al., 1975; Abalo
et al., 2009). Moreover, rimonabant-induced enhancement of small intestinal transit also undergoes
tolerance (Carai et al., 2004). Although acute inhibition of small intestinal transit by ZCZ011 may
suggest a “constipating” effect similar to opioids, opioid constipation has been shown to be associated
with the colon and not the small intestine, i.e., the ileum, in mice (Ross et al., 2008; Kang et al., 2012).
Indeed, these studies demonstrate that morphine undergoes tolerance to its inhibitory effects in the small
intestine, whereas the colon is resistant to tolerance and seems to be mediated through a β-arrestin2dependent mechanism (Ross et al., 2008; Kang et al., 2012). Therefore, future research should examine
the effects of ZCZ011 on colonic propulsion by using commonly used bead expulsion assays (Hornby and
Prouty, 2004). More importantly, because the inhibitory transit effect of ZCZ011 undergoes tolerance, it
is imperative to test whether the anti-transit, and more generally the anti-withdrawal, effects of ZCZ011
under conditions of opioid withdrawal are diminished because this would limit the potential of CB1
receptor PAMs to be used in opioid withdrawal. Alternatively, if the anti-withdrawal effects of ZCZ011
are maintained following repeated administration, this signifies key differences of using ZCZ011 in states
of physiological and pathophysiological conditions. Therefore, future studies should examine whether
repeated administration of ZCZ011 continues to elicit inhibitory transit effects under opioid withdrawal
conditions to determine whether it still holds therapeutic potential to treat withdrawal-induced diarrhea.
These studies employed two strains (i.e., ICR mice and CB1 (+/+) and (-/-) mice on a C57BL/6J
background) of male and female mice, and showed that ZCZ011 inhibits naloxone-enhanced small
intestinal transit and naloxone-precipitated diarrhea and fecal output regardless of strain or sex. The lack
of sex differences here corroborates our previous findings that ZCZ011 attenuates a subset of naloxoneprecipitated withdrawal signs in oxycodone-dependent mice irrespective of sex (see chapter 2) (Dodu et
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al., 2021). Regarding strain differences, ICR mice and CB1 (+/+) and (-/-) mice display similar naloxoneenhanced small intestinal transit, whereas ICR mice seem to display more naloxone-precipitated fecal
output and diarrhea than CB1 (+/+) and (-/-) mice, which may suggest that the outbred strain undergoes
more severe opioid dependence than CB1 (+/+) and (-/-) mice on a C57BL/6J background.
In sum, the CB1 receptor PAM, ZCZ011, inhibits naloxone-enhanced small intestinal transit and
naloxone-precipitated diarrhea through the activation of CB1 receptors. However, the finding that the
inhibition of small intestinal transit by ZCZ011 undergoes tolerance may limit its therapeutic potential
and future studies need to examine whether the anti-withdrawal effects of repeatedly administered
ZCZ011 under conditions of opioid withdrawal are maintained or diminished. In conclusion, CB1 receptor
PAMs may represent an alternative strategy to treat withdrawal-induced diarrhea in opioid-dependent
individuals, but there are potential limitations (i.e., potential diminished anti-transit and anti-withdrawal
effects under conditions of opioid withdrawal) that need to be addressed in future research.

125

Chapter 4: Discussion
4.1. Summary
Although the FDA approved opioid-based (i.e., methadone and buprenorphine) and non-opioidbased (i.e., lofexidine and clonidine) medications to treat acute opioid withdrawal, these approaches
respectively elicit abuse potential (Cicero and Inciardi, 2005) and postural hypotension and sedation
(Lobmaier et al., 2010) and they are not always effective in alleviating withdrawal symptoms (Dyer et al.,
1999). One of the more severe physical withdrawal symptoms, i.e., diarrhea, can lead to extreme
dehydration, hypernatremia, and ultimately death if not managed well. When diarrhea management
cannot be supervised, the over-the-counter peripherally-restricted opioid agonist, loperamide, is often
used (Stolbach and Hoffman, 2020). However, loperamide abuse and cardiotoxicity have also been
reported (Daniulaityte et al., 2013; Vakkalanka et al., 2017). Thus, a great need still exists to develop
alternative and adjunct medications to treat withdrawal symptoms, particularly diarrhea.
The endocannabinoid system has been implicated to treat opioid withdrawal as early as 1889
(Birch, 1889). Two double-blind placebo-controlled clinical trials have shown that dronabinol (30 mg)
demonstrated effectiveness in reducing acute withdrawal symptoms in opioid dependent individuals
(Bisaga et al., 2015; Lofwall et al., 2016). Bisaga et al. (2015) reported that participants showed modest
improvement of acute opioid withdrawal scores when administered 30 mg of dronabinol from days 2-5 of
the 8-day inpatient phase, whereas no differences were observed regarding retention rates of extended
release naltrexone therapy during the subsequent 8-week outpatient phase. Lofwall et al. (2016) reported
participants taking 30 mg of dronabinol reduced several withdrawal symptoms, including backaches,
feeling of being sick, lacrimation, rhinorrhea, yawning, and muscular tension. However, reported adverse
effects of 30 mg of dronabinol include increased risk of tachycardia, psychoactive effects, slower reaction
times, and somnolence (Jicha et al., 2015), which hinders its application to treat opioid dependence.
Pre-clinical animal models have established that cannabinoid receptor orthosteric agonists (i.e.,
THC and HU-210) reduce naloxone-precipitated withdrawal signs in morphine-dependent rodents (Hine,
Friedman, et al., 1975; Bhargava, 1976b; Vela et al., 1995; Yamaguchi et al., 2001). However, CB1
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receptor activation using orthosteric ligands elicits cannabimimetic side effects, i.e., impaired locomotion,
catalepsy, and hypothermia, in rodents (Wiley and Martin, 2003; Varvel et al., 2005). Moreover, mice
learn to discriminate CB1 receptor agonists, i.e., THC, CP55,940, and WIN55,212-2, in nose poking and
lever pressing procedures and CP55,940 and WIN55,212-2 fully substitutes for THC. thereby suggesting
intrinsic subjective effects associated with THC (Compton et al., 1993; Wiley et al., 1995, 2017, 2018;
Vann et al., 2009; Gatch and Forster, 2018). Inhibition of MAGL and FAAH also attenuate withdrawal
signs in opioid dependent mice with MAGL inhibition attenuating many withdrawal signs, whereas
complete FAAH blockade reduced a subset of withdrawal measures (i.e., jumping and paw flutters)
(Ramesh et al., 2011). A subsequent study found that a dual MAGL/FAAH inhibitor, SA-57, and a low
dose of the MAGL inhibitor, JZL184, and a high dose of the FAAH inhibitor, PF-3845, in combination
fully attenuate spontaneous withdrawal in opioid dependent mice without eliciting cannabimimetic effects
(i.e., hypomotility, catalepsy, and hypothermia) at the doses tested (Ramesh et al., 2013). However, SA57 and the MAGL inhibitor, MJN110 produce a discriminative stimulus on their own and substitute for
the full CB1/CB2 receptor agonist, CP55,940, in C57BL/6J mice (Owens et al., 2016, 2017).
CB1 receptor positive allosteric modulators (PAMs) offer a targeted approach to activate CB1
receptor by binding to a topographically distinct site, i.e., an allosteric site, that does not overlap but is
conformationally linked to the orthosteric site where exogenous, e.g., THC, CP55,940, and WIN55,212-2,
and endogenous, e.g., 2-AG and AEA, cannabinoids bind. The CB1 receptor PAM, ZCZ011, has been
shown to attenuate rimonabant-precipitated and spontaneous withdrawal signs in THC-dependent mice
(Trexler et al., 2019) without substituting for CP55,940 in C57BL/6J mice or AEA in FAAH (-/-) mice in
the drug discrimination paradigm (Ignatowska-Jankowska, Baillie, et al., 2015). We hypothesized that
CB1 receptor PAMs attenuate naloxone-precipitated withdrawal signs in opioid dependent mice through
the activation of CB1 receptors.
While morphine is often used in rodent models of dependence, we used a recently developed
model of naloxone-precipitated withdrawal in oxycodone-dependent mice (Enga et al., 2016; Carper et
al., 2021). It is important to study various opioids used in the clinic today considering physicians often
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use multiple variations of opioids to treat patients. We observed that ZCZ011 reliably reduces naloxoneprecipitated diarrhea, weight loss, and paw flutters with high efficacy on attenuating diarrhea and weight
loss in oxycodone dependent mice. Subsequent studies revealed that CB1, not CB2, receptors attenuate the
anti-withdrawal effects of ZCZ011 on naloxone-precipitated diarrhea and weight loss. This profound antidiarrheal effect of ZCZ011 parallels the work that THC, full MAGL inhibition and dual MAGL/FAAH
inhibition elicit complete blockade of withdrawal-induced diarrhea in rodents (Hine, Friedman, et al.,
1975; Ramesh et al., 2011, 2013). Also, because diarrhea is a severe opioid withdrawal symptom in
humans that in rare instances can lead to death through extreme dehydration (Darke et al., 2017), the aim
of chapter 3 was to investigate one of the two predominant antecedents of diarrhea, enhanced
gastrointestinal (GI) transit. Therefore, we established naloxone-enhanced small intestinal transit and
naloxone-precipitated fecal output as physiological and behavioral measures of withdrawal-enhanced GI
effects. We revealed that ZCZ011 attenuates naloxone-enhanced small intestinal transit and naloxoneprecipitated diarrhea through a CB1 receptor dependent mechanism. Major additional findings were that
ZCZ011 inhibited small intestinal transit in non-dependent mice and oxycodone-dependent mice in the
presence and absence of naloxone administration which parallels previous literature showing that CB1
receptor orthosteric agonists inhibit small intestinal transit in rodents (Calignano et al., 1997; Colombo et
al., 1998; Capasso et al., 2005; Taschler et al., 2015). Lastly, we found that this acute inhibition of small
intestinal transit by ZCZ011 underwent tolerance following repeated administration which corroborated
with previous studies examining CB1 receptor agonists (Anderson et al., 1975; Abalo et al., 2009).
4.2. Anti-weight loss mechanisms of ZCZ011
Naloxone-precipitated weight loss in oxycodone-dependent mice results from increased fecal
matter and fluid from diarrhea and increased micturition in their respective withdrawal chambers.
Because the mechanisms of diarrhea are discussed below, here we focus on the role of CB1 receptors in
micturition. CB1 receptors have been shown to be expressed on nerve endings in the muscular layer of the
bladder wall (Walczak et al., 2009) and in proximal tubule cells of nephrons (Jenkin et al., 2015), which
can provide insight into the potential inhibition of urination during opioid withdrawal. An early study
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found that THC (20 mg/kg) increases urine output in rats by excreting Na+ and K+, but not Cl- (Sofia et
al., 1977). Additionally, when rats received a hypophysectomy or adrenalectomy, the diuretic effect of
THC was abolished, implicating both central and peripheral sites of action, respectively. Moreover,
another study confirmed these early findings in rats where THC (1, 3, and 10 mg/kg) and WIN55,212-2 (3
and 10 mg/kg) increased urine output through a CB1 receptor dependent mechanism (Paronis et al., 2013).
However, a mouse study demonstrated biphasic effects of THC, WIN55,212-2, and two structurally
distinct cannabinoid agonists, AM7418 and AM4054 on diuresis. Lower doses of THC (1, 3, and 10
mg/kg), WIN55,212-2 (0.3, 1, and 3 mg/kg), AM7418 (0.03, 0.1, and 0.3 mg/kg), and AM4054 (0.01,
0.03, and 0.1 mg/kg) increased urine output whereas higher doses of THC (30 and 100 mg/kg),
WIN55,212-2 (10 mg/kg), AM7418 (1 mg/kg), and AM4054 (0.3 and 1 mg/kg) decreased urine output
(Chopda et al., 2013). Furthermore, cannabinoid receptor involvement of AM4054 was characterized by
using the selective CB1 receptor antagonist, rimonabant, a peripherally-restricted selective CB1 receptor
antagonist, AM6545, and the selective CB2 receptor antagonist, AM630. Rimonabant produced a
rightward shift of the biphasic response curve of AM4054 on diuresis, whereas AM630 did not affect the
curve whatsoever, implicating CB1 receptor involvement. What was interesting was that the peripherallyrestricted CB1 receptor antagonist, AM6545, did not affect the ascending limb of AM4054 effect on
increased diuresis, but produced a rightward shift of the descending limb of AM4054 effect on decreased
diuresis. Therefore, the authors concluded that the increase of urine output occurs by actions of CB1
receptors within the central nervous system, while decreases of urine output may be involved through
peripheral CB1 receptors. Further studies are warranted to test higher doses, e.g., 30 mg/kg or more of
THC, in rats to potentially reveal a biphasic response curve on urine output. With respect to the current
studies, considering that ZCZ011 produced a dose-dependent attenuation of naloxone-precipitated weight
loss, it is possible that the high dose of ZCZ011 (40 mg/kg) may have decreased urine output similar to
the biphasic response observed in the Chopda et al. (2013) study. However, we did not directly measure
urine output, it was simply an observation that substantial micturition was observed in their respective
withdrawal chambers. Similarly to how Chopda et al. (2013) measured urine output, future studies
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examining the effects of CB1 receptor PAMs on naloxone-precipitated weight loss can be quantified by
placing individual absorbent pads in each withdrawal chamber and weighing the pads (in grams) before
and after the 30-min withdrawal period. The difference in pad weight can be calculated to determine how
much urine output was observed.
4.3. Anti-transit and anti-diarrheal mechanisms of ZCZ011
4.3.1.

Possible peripheral mechanisms of anti-diarrheal and anti-transit effects
The peripheral mechanisms by which ZCZ011 attenuates naloxone-precipitated diarrhea and

naloxone-enhanced small intestinal transit may be interpreted by previous literature. Cellular expression
of CB1 receptor mRNA can be found throughout the myenteric and submucosal plexuses (Buckley et al.,
1998). Coutts et al. thoroughly characterized the neuronal subpopulations of CB1 receptor expression in
the myenteric plexus of guinea pig ileum and proximal colon and rat ileum (Coutts et al., 2002) where
they found CB1 receptor protein co-localized with choline acetyltransferase (ChAT)-positive motor, interneuronal, and sensory neurons. Additional co-localization of CB1 receptors with substance P and
calcitonin gene-related peptide (CGRP) producing neurons was present, but not to the extent as
acetylcholine (ACh) producing neurons. They demonstrated that the presence of CB1 receptors is virtually
on all cholinergic neurons in the myenteric plexus of rat and guinea pig ileum and guinea pig proximal
colon. Moreover, Coutts et al. (2002) tested whether the pan CB1/CB2 receptor agonist, WIN55,212-2,
inhibited electrically evoked isometric responses on longitudinal muscle-myenteric plexus (LMMP)
guinea pig ileum in the presence of the ganglionic blocker, hexamethonium. They found that the
inhibitory effects of WIN55,212-2 on LMMP contractions were still observed in the presence of
hexamethonium which implicates the site of action on local myenteric neurons. This was an important
finding because ACh functions as the excitatory neurotransmitter at ganglionic synapses and at
neuromuscular junctions of myenteric neurons that innervate longitudinal and circular muscles. (Coutts et
al., 2002) also demonstrated that rimonabant reversed these inhibitory effects suggesting that CB1
receptors inhibit motility by inhibiting the release of ACh on local motor, inter-neuronal, and sensory
neurons without the involvement of ganglionic nerve innervations (Coutts et al., 2002). The caveat of this
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study was that it was conducted under normal physiological conditions, and it may be helpful to measure
CB1 receptor distribution associated with underlying pathology. Another study aimed to investigate
whether repeated exposure of opioid (i.e., DAMGO) and cannabinoid (i.e., WIN55,212-2) receptor
agonists change MOR and CB1 receptor protein abundance in the LMMP of guinea pigs (Maguma et al.,
2010). Guinea pigs were injected with morphine s.c. for seven days b.i.d. of escalating doses (10-80
mg/kg) or WIN55,212-2 for five daily injections of 6 mg/kg s.c. before they were decapitated and
harvested for their LMMP. Maguma et al. (2010) found that repeated treatment of WIN55,212-2 lowered
CB1 receptor protein levels in the LMMP, whereas MOR expression was unaffected. On the contrary,
repeated morphine exposure did not influence MOR or CB1 receptor protein expression in the LMMP.
These findings suggest that repeated exposure of an opioid does not influence the expression of CB1
receptors in the myenteric plexus. Additional major findings were that CB1 receptors and MORs readily
co-localize in a whole mount preparation of the guinea pig LMMP under naïve, repeated WIN55,212-2,
and repeated morphine treatment conditions. Moreover, it seems that under repeated drug conditions that
co-localization slightly increases from approximately 20% of neurons to 50% suggesting a morphological
cross-talk between these receptors. This potentially suggests that both receptors interact with each other
through downstream intra-cellular signaling pathways, for instance the cAMP pathway (Levitt et al.,
2011). However, several caveats must be addressed in future research. First, these studies were conducted
with guinea pigs (Maguma et al., 2010) and not mice (current work). Second, these studies measured CB1
receptors and MORs under conditions of antinociceptive tolerance, whereas a different expression pattern
may be observed during naloxone-precipitated withdrawal. And third, morphine was used and not
oxycodone and it may be that oxycodone could influence CB1 receptor protein expression in the
myenteric plexus. Regardless this work provides some insight into a common downstream signaling
pathway where CB1 receptor activation may modulate downstream intra-cellular signaling pathways in
the myenteric plexus.
To date, no study has examined the cellular mechanisms associated with withdrawal-induced
diarrhea. However, one study does suggest a cellular downstream signaling event that is not associated
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with a naloxone-precipitated phenotype in ileal neurons from adult opioid-dependent mice (Smith et al.,
2014). Morphine exposure to enteric neurons acutely decreases neurotransmitter release (Paton, 1957) and
decreases firing rates of myenteric neurons (North and Tonini, 1977). Studies revealed that two major
classes of enteric neurons have been characterized; (1) afterhyperpolarization (AHP) and (2) synaptic (S)
neurons (Hirst et al., 1974). AHP neurons produce a large afterhyperpolarization following an action
potential and morphologically have multiple long axonal projections and are characterized as sensory
neurons (Clerc et al., 1997). S neurons feature only one long axon and are either motor neurons or
interneurons (Nurgali et al., 2004). A previous publication identified two subtypes of AHP neurons; (1)
AHP-positive and (2) AHP-negative neurons in primary cultured adult mouse ileal neurons and found that
morphine reduced excitability in AHP-positive, but not AHP-negative neurons (Smith et al., 2012).
Excitability is characterized as reductions in the threshold at which an action potential (AP) fires, a
decrease in the number of APs elicited, and a decrease in the AP amplitude observed. Smith et al. (2014)
aimed to determine whether dependence develops when administering naloxone to isolated AHP-positive
neurons from the ileum and colon treated overnight with morphine or from morphine pelleted (75 mg)
mice. In current-clamp mode, acute morphine decreases the height of the AP, increases the rheobase (a
measure of membrane potential excitability), and inhibits the ileal (Smith et al., 2012) and colonic (Smith
et al., 2014) neuron from firing multiple APs. In voltage-clamp mode, acute morphine reduces the inward
current density of ileal (Smith et al., 2012) and colonic (Smith et al., 2014) neurons which drives Na+
channels into an inactive state but not the sustained outward K+ currents. In contrast, ileal neurons from
morphine pelleted mice display tolerance to these electrophysiological properties, in that they fire
multiple APs at a low rheobase, and following naloxone administration produce a hyperexcitable
phenotype characterized by a significantly increased frequency of APs and an increase in input resistance.
However, no changes were observed in the threshold at which an AP was initiated, the height of an AP,
the duration of an AP, or the resting membrane potential. Notably, this naloxone precipitated
hyperexcitability was only observed in AHP-positive neurons from morphine-dependent mice. On the
contrary, colonic enteric neurons isolated from morphine pelleted mice did not survive in culture;
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therefore, Smith et al. (2014) isolated colonic neurons from naïve mice and incubated them with
morphine overnight to test for dependence. They investigated the same paradigm in ileal neurons exposed
to morphine overnight and found the same naloxone-precipitated hyperexcitability phenotype that was
observed in ileal neurons isolated from morphine pelleted mice, but colonic neurons failed to elicit this
hyperexcitability phenotype. It was shown, though, that colonic neurons isolated from β-arrestin2 (-/-)
mice revealed a naloxone precipitated hyperexcitability profile when exposed to morphine overnight
where the number of APs fired increased, whereas ileal neurons were unaffected by the absence of βarrestin2 and continued to elicit a naloxone precipitated hyperexcitability. These findings suggest that βarrestin2 is integral in preventing colonic neurons to develop opioid dependence (Kang et al., 2012). As
such, more studies are needed to investigate the downstream signaling mechanisms during opioid
withdrawal in myenteric neurons. One well-known and possible alternative pathway is the wellcharacterized overactivation of the cAMP pathway during opioid withdrawal in the locus coeruleus
(Guitart et al., 1992; Lane-Ladd et al., 1997).
When activating the CB1 receptor during opioid withdrawal, studies have shown the pan CB1/CB2
orthosteric agonist, WIN55,212-2, the MAGL inhibitor, JZL184, and the FAAH inhibitor, PF-3845, can
inhibit naloxone-precipitated contractions in morphine-treated mouse ileal tissue (Ramesh et al., 2011;
Szymaszkiewicz et al., 2021). Szymaszkiewicz et al. (2021) also examined a dual opioid receptor and
CB1 receptor agonist, PR-38, which inhibited naloxone-precipitated contractions in morphine-treated
mouse ileal tissue where the selective CB1 receptor antagonist, AM-251, reversed these effects indicating
CB1 receptors, but not opioid receptors, inhibit the naloxone-precipitated contractions of PR-38
(Szymaszkiewicz et al., 2021). In sum, the CB1 receptor-mediated inhibition of naloxone-enhanced small
intestinal transit by ZCZ011 may in part be explained by inhibiting ACh neurotransmitter release on
longitudinal and circular muscles of the myenteric plexus by mitigating a dysregulated shared
downstream signaling pathway of μ-receptors (e.g. the overactivation of the cAMP pathway) during
withdrawal. However, further studies need to elucidate whether CB1 receptor PAMs also inhibit
naloxone-precipitated contractions in opioid dependent ileal tissue. Moreover, the anti-diarrheal effects of
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ZCZ011 may also be explained by inhibiting hypersecretion considering it is another antecedent of
diarrhea.
As described above, CB1 receptors are also expressed in the submucosal plexus, which regulates
fluid secretion in the small intestine. Although CB1 receptor activation on fluid secretion is not as readily
studied as motility and transit effects, several studies do provide insight on hypersecretion induced by
opioid withdrawal and other means. In a model of cholera toxin-induced fluid hypersecretion, the nonselective CB1/CB2 receptor orthosteric agonist, CP55,940, and the selective CB1 receptor agonist, ACEA,
dose-dependently diminished fluid accumulation in the small intestine of mice (Izzo et al., 2003).
Moreover, the selective CB1 receptor inverse agonist/antagonist, rimonabant, but not the selective CB2
receptor antagonist, SR144528, dose-dependently increased fluid accumulation. However, a sub-threshold
dose of rimonabant, but not SR144528, completely blocked the inhibition of secretion by CP55,940,
indicating a CB1 receptor dependent mechanism. One study has shown that the MAGL inhibitor, JZL184,
and the FAAH inhibitor, PF-3845, elicit anti-secretory effects in a model of naloxone-precipitated
hypersecretion in morphine-treated small intestinal tissue (Ramesh et al., 2013). An in vitro model to
measure hypersecretion was developed by isolating small intestinal tissue and mounting them to Ussing
chambers. Ussing chambers are designed to measure transport of ions, nutrients, and drugs across
epithelial tissues. The primary measure used to assess secretion is the short-circuit current (Isc). Isc refers
to the current that is required to nullify the potential difference of the tissue and is the sum of all ionic
currents through the epithelium (Clarke, 2009). What Ramesh et al. (2013) found was that the MAGL
inhibitor, JZL184 (10 μM), attenuated the naloxone-precipitated hypersecretion (i.e., attenuation of the
increased Isc) in morphine-treated (20 min exposure) CB1 (+/+) small intestinal tissue, whereas the effect
was abolished in morphine-treated CB1 (-/-) small intestinal tissue, demonstrating a CB1 receptormediated effect. Furthermore, the FAAH inhibitor, PF-3845 (1 μM), attenuated naloxone-precipitated
hypersecretion in morphine-treated C57BL/6J small intestinal tissue as well. A fascinating observation is
that PF-3845 seems to be more potent in this assay than JZL184; however, some caveats exist here. One,
only one dose of each compound was studied. Two, they were conducted in different strains of mice. And
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three, cannabinoid receptor involvement for the anti-secretory effects of PF-3845 remain to be tested.
Thus, future research should examine whether this is a concentration-dependent response and whether
attenuation of hypersecretion by PF-3845 is CB1 receptor-mediated. Notably, it was described in the
methods that an ex vivo approach was conducted, but failed to establish enhanced secretion from mice
rendered morphine dependent with 75 mg pellets. This discrepancy was likely explained by the fact that
morphine was absent when tissues became isolated; therefore, it may mean that continually bathing the
small intestine tissue in morphine is necessary to maintain a morphine-dependent state. Alternatively, a
different prolonged opioid treatment schedule, such as the nine-day injection schedule of oxycodone used
in these studies, may produce a hypersecretory phenotype following naloxone challenge. Lastly, it would
be of great interest to determine whether CB1 receptor PAMs inhibit hypersecretion in opioid-treated
small intestine to discern additional mechanisms behind its anti-diarrheal effects. In sum, there are several
peripheral mechanisms that describe the anti-transit and anti-diarrheal effects of ZCZ011, but central
mechanisms may also be considered.
4.3.2.

Possible central mechanisms of anti-diarrheal and anti-transit effects
While the GI tract has the capacity to work autonomously without extrinsic inputs on functions

such as transit and motility, digestion, nutrient absorption, and elimination of waste, particularly in the
small and large intestines, the central nervous system can regulate, modulate, and control these functions.
The sympathetic nervous system is the predominant system to produce a homeostatic tone that exerts
inhibitory effects on the GI muscle and mucosal secretion whereas the parasympathetic nervous system
(PaNS) exerts both excitatory and inhibitory functions to modulate the homeostatic GI tone. More
specifically, the PaNS motor-neurons that heavily innervate the stomach, small intestine, and proximal
colon originate from the dorsal motor nucleus of the vagus (DMV) found in the brain stem (Berthoud et
al., 1991; Altschuler et al., 1993; Browning and Travagli, 2014). The DMV can fine tune the homeostatic
GI tone through two main pathways, (1) a cholinergic excitatory pathway and (2) a non-adrenergic noncholinergic (NANC) inhibitory pathway. DMV preganglionic neuronal fibers release ACh to bind and
activate nicotinic receptors found on postganglionic neurons. Postganglionic ACh neurons (i.e., with
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respect to the excitatory cholinergic pathway) are then depolarized and subsequently produce an
excitatory effect on the stomach, small intestine, or proximal colon by releasing ACh and activating
muscarinic receptors on smooth muscles thereby leading to contractions and an overall increase in GI
tone (Holmes et al., 2013). In contrast, postganglionic NANC neurons release nitric oxide (NO) and
induce gastric and intestinal smooth muscle relaxation via a cGMP pathway that activates cGMPdependent protein kinase (PKG) which leads to reduced intracellular calcium concentrations through a
variety of cellular mechanisms (Grange et al., 2001). Moreover, the nucleus tractus solitarii (NTS) can
modulate DMV neurons since it projects both glutamatergic and GABAergic neurons which ultimately
can fine tune the activation of ACh-producing neurons found in the DMV (Holmes et al., 2013).
The CB1 receptor is readily found in the central nervous system and studies reveal that CB1
receptors are also expressed on axonal terminals of the NTS which innervate the DMV (Derbenev et al.,
2004) and the CB1/CB2 receptor agonist, WIN55,212-2, has shown to inhibit DMV neurons through the
activation of CB1 receptors (Derbenev et al., 2004; Roux et al., 2009). One particular study examined the
effects of central and peripheral CB1 receptor modulation on small intestinal transit by administering
WIN55,212-2, the phytocannabinoid, cannabinol, and the CB1 receptor inverse agonist/antagonist,
rimonabant, by intracerebroventricular (i.c.v.) and intraperitoneal (i.p.) routes of administration (Izzo et
al., 2000). Izzo et al. (2000) aimed to determine two objectives: (1) to compare the effect of cannabinoid
drugs on small intestinal transit after i.c.v. and i.p. administration and (2) to evaluate the effect of
cannabinoid agonists on small intestinal transit during experimental diarrhea. In order to induce diarrhea,
they used croton oil, a known cathartic agent (Pol et al., 1996). The effects of WIN55,212-2 and
cannabinol were investigated in naïve mice initially. When given i.c.v. and i.p., both produce dosedependent inhibition of small intestinal transit. Furthermore, rimonabant given i.c.v. and i.p. demonstrated
a dose-dependent enhancement of small intestinal transit and a sub-threshold dose of rimonabant,
reversing the anti-transit effects of WIN55,212-2, and cannabinol, demonstrating a CB1 receptor-mediated
effect. While routes of administration do not conclusively provide evidence for central and peripheral
mechanisms, ganglionic blockers, such as hexamethonium, are reliable tools that help suggest central
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versus peripheral effects. Hexamethonium inhibited the effects of WIN55,212-2 and cannabinol when
administered i.c.v., but did not block the inhibitory effects when they were administered i.p. This suggests
that CB1 receptor activation leads to inhibition of small intestinal transit through both central and
peripheral mechanisms, but if compounds are administered through an i.p. route, the cannabinoid
compound may act through peripheral CB1 receptors to modulate small intestinal transit. However, some
caveats may need to be addressed. For one, if the test drug is not restricted to the periphery, then it may
still cross the blood-brain barrier to induce concomitant central and peripheral-mediated modulation of
small intestinal transit. For instance, ZCZ011 has shown to cross the blood-brain-barrier at the pretreatment time of 75 min used in these studies (Poklis et al., 2015). Moreover, direct infusion of drugs in
specific brain regions that modulate small intestinal transit, such as the DMV and NTS, may help narrow
down the central mechanisms involved compared to infusion in the intracerebroventricular area. This does
not provide a good basis for a druggable target, and so currently, ZCZ011, may not be a good standalone
drug considering it has multiple mechanisms of action. Moreover, under conditions of croton-oil-induced
diarrhea, cannabinol and WIN55,212-2 inhibited croton-oil-enhanced small intestinal transit and
rimonabant, not SR144528, reversed these effects suggesting a CB1, not CB2, receptor mechanism. Thus,
it is plausible that ZCZ011 is concomitantly attenuating naloxone-enhanced small intestinal transit and
naloxone-precipitated diarrhea through central and peripheral mechanisms by activating CB1 receptors on
axonal terminals innervating the DMV and inhibiting excitatory local ACh-producing neurons in the
myenteric and submucosal plexuses, respectively (as described in section 4.3.1.) (see Fig. 18 for an
illustration of the potential central and peripheral anti-transit and anti-diarrheal mechanisms of ZCZ011);
however, future studies are needed to test these predictions.
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Fig. 18. Potential anti-transit and anti-diarrheal mechanism of action of the CB1 PAM, ZCZ011 in the
small intestine. (Bottom) Cross-section of the small intestine. Outer-inner layers; serosa, longitudinal
muscle, myenteric plexus, circular muscle, submucosal plexus, submucosa, and mucosa. (Left) Potential
central mechanism where ZCZ011 activates CB1 receptors in the nucleus tractus solitarii (NTS) to inhibit
release of neurotransmitters on neurons of the dorsal motor nucleus of the vagus (DMV) subsequently
inhibiting the release of acetylcholine (ACh) on postganglionic neurons and ultimately inhibiting release
of neurotransmitters on neuromuscular junctions of the circular and longitudinal muscles of the small
intestine. (Right) Potential peripheral mechanism where ZCZ011 activates CB1 receptors to inhibit the
release of ACh in neurons of the myenteric plexus. Figure was created with BioRender.com.
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4.4. Sex differences in models of opioid dependence
Because these studies investigated whether ZCZ011 attenuates naloxone-precipitated withdrawal
in both male and female mice, discussions of potential sex differences in models of opioid dependence are
warranted. These studies found some evidence of sex differences in Figures 5D, 6D, and 7F, where male
mice elicit a higher number of jumps and head shakes than female mice, whereas Fig. 6E demonstrates
female mice elicit more paw flutters than male mice. Moreover, tables 6 and 7 are in agreeance of sex
differences based on relevant main effects. It seems that the expression of withdrawal-induced jumping,
paw fluttering, and head shaking behavior in female mice produce varying severity compared with male
mice. On the contrary, no differences between sex were observed when examining withdrawal-induced
diarrhea, weight loss, small intestinal transit, or fecal output. With the NIH mandate to include both sexes
in animal studies (National Institutes of Health, 2015) and the observation that the studies summarized in
table 3 outlining cannabinoid agonists on opioid withdrawal show no use of male and female animals,
future studies should include sex as a biological variable to discern potential differences. In contrast, other
work has shown relevant sex differences in opioid self-administration models. Female rodents seem to
acquire morphine, heroin, and fentanyl self-administration and show higher motivation (i.e. higher break
point in a progressive ratio procedure) to self-administer opioids than male rodents (Lynch and Carroll,
1999; Cicero et al., 2003; Roth et al., 2004; Towers et al., 2019; Townsend et al., 2021). Moreover, a
recent study examined oxycodone self-administration in female and male rats and found that female rats
escalate oxycodone intake faster than male rats (Kimbrough et al., 2020). Thus, it may be plausible that
sex differences associated with opioid dependence may only be revealed when the opioid used is selfadministered versus experimenter-administered (as in this dissertation), but future studies are greatly
needed to decipher relevant sex differences.
4.5. Advantages of CB1 receptor positive allosteric modulation
CB1 receptor positive allosteric modulators (PAMs) offer several advantages over orthosteric
ligands. First, PAMs bind to an allosteric site which is not as conserved as the orthosteric site (Conn et
al., 2009). For instance, the nucleotide sequence homology between CB1 and CB2 receptors is reported to
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be 44% and 68% within the residues of the transmembrane domain where the orthosteric site lies (Munro
et al., 1993). This suggests that CB1 receptor PAMs can selectively the CB1 receptor subtype without
potentially binding to CB2 receptors. Second, PAMs may enhance orthosteric ligands (i.e., 2-AG and
AEA) only when both are bound simultaneously. Third, PAMs may signal in a bias manner to produce
therapeutic effects with diminished side effects whereas an orthosteric ligand often activates multiple
pathways. For example, one of the first allosteric modulators of the CB1 receptor, ORG27569, displays
biased effects by blocking cAMP inhibition while having little to no effect on ERK1/2 phosphorylation
(Khajehali et al., 2015). In addition, CB1 PAMs can produce probe dependence where they may modulate
one orthosteric modulator more than another. Lipoxin A4 seems to exhibit these effects by enhancing
CP55,940 binding greater than WIN55,212-2 and will enhance the potency of AEA and simultaneously
reduce the efficacy of 2-AG on [35S]GTPγS binding (see table 1 and 2) (Pamplona et al., 2012). Lastly,
CB1 receptor PAMs may elicit downstream signaling in the absence of CB1 receptor orthosteric ligands
where they can show unique pharmacological properties not observed with traditional activation of the
orthosteric site and may be classified as positive allosteric agonists (Kenakin, 2013). Overall, CB1 PAMs
offer a potentially selective approach of targeting CB1 receptors and may potentially fine tune the
pharmacological effects of activating CB1 receptors that make for a favorable strategy for potential
therapeutic effects.
In preclinical studies, CB1 receptor PAMs produce a plethora of potentially beneficial effects
without producing cannabimimetic effects or tolerance and cannabinoid dependence upon repeated
administration (Ignatowska-Jankowska, Baillie, et al., 2015; Slivicki et al., 2017; Trexler et al., 2019;
Tseng et al., 2019; Thapa et al., 2020). Moreover, Slivicki et al. (2017) and Trexler et al. (2019)
respectively demonstrate improved antinociceptive effects and gastroprotective effects when in
combination with the MAGL inhibitor, JZL184. Additionally, GAT211 produces synergistic
antinociceptive effects with morphine in a neuropathic pain model and minimizes the development of
tolerance to the antinociceptive effects of morphine (Slivicki et al., 2020). Considering Ramesh et al.
(2013) demonstrated additive effects when using combinations of MAGL and FAAH inhibitors in
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naloxone-precipitated and spontaneous withdrawal signs, future studies that combine ZCZ011 with CB1
receptor orthosteric agonists or other opioids may produce enhanced anti-withdrawal effects with no
untoward side effects.
4.6. Implications of CB1 receptor positive allosteric modulation in other models of developing
diarrhea and gastrointestinal disorders and diseases
The finding that ZCZ011 inhibits small intestinal transit in non-dependent mice suggests that it
may be effective in reducing diarrhea in other models and potentially other GI disorders and diseases.
This finding suggests that it may be limiting its potential clinical utility for withdrawal, but the
subsequent finding that the inhibitory small intestinal effects of ZCZ011 undergoes tolerance mitigates
this limitation. On the contrary, it remains to be determined whether the anti-transit, and more generally
the anti-withdrawal, effects of repeatedly administered ZCZ011 are maintained or diminished during
opioid withdrawal; thus, further research is needed. However, CB1 receptor orthosteric agonists decrease
small intestinal transit in an inflammatory croton oil-induced diarrhea model (Izzo et al., 2000) and
reduce secretion associated with cholera toxin-induced small intestinal fluid accumulation (Izzo et al.,
2003). In fact, Cannabis was indicated for the treatment of diarrhea a century ago in the USA by the US
Pharmacopeia and anecdotal evidence reported Cannabis helped treat dysentery and cholera toxicity
(Carlo and Izzo, 2003; Hornby and Prouty, 2004). Regarding other GI disorders and diseases, two
promising therapeutic applications of targeting the CB1 receptor are to alleviate irritable bowel syndrome
(IBS) and inflammatory bowel disease (IBD). IBS is a multifactorial disease that includes symptoms of
abdominal pain, bloating, and altered bowel movements and secretion and has three forms, (1) IBS-C
(constipation predominant), IBS-D (diarrhea predominant), mixed, and un-subtyped. IBS-D patients
exhibit enhanced propagated contractions and accelerated colonic transit (Chey et al., 2001). A recent
clinical trial was conducted testing dronabinol in patients with IBS-D and revealed inhibitory effects on
fasting colonic motility (Wong et al., 2012). As outlined above, CB1 receptors are expressed throughout
the enteric nervous system and in areas of the central nervous system that regulate GI transit and
secretion. Therefore, future studies examining the role of CB1 receptor PAMs in models of IBS-D may be
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promising. In regards to IBD, ulcerative colitis (UC) and Crohn’s disease (CD) are common subcategories
of IBD where the primary difference is that UC is limited to the colon whereas CD can occur anywhere
along the GI tract from the mouth to the anus. The defining characteristic is that both involve proinflammatory states which readily lead to abdominal pain and diarrhea. A placebo-controlled study
showed that ∆9-THC decreased CD activity index scores of 10 out of the 11 CD patients (Naftali et al.,
2013). Pre-clinically, activation of CB1 or CB2 receptor agonists produce a protective effect in various
models of experimental colitis (Kimball et al., 2006; Storr et al., 2009; Singh et al., 2012). Thus, future
studies testing CB1 receptor PAMs in models of IBD, particularly on colonic propulsion and
inflammation are warranted.
4.7. Overall conclusions and future directions
The studies in this dissertation demonstrate that the CB1 receptor positive allosteric modulator
ZCZ011 attenuates a subset of naloxone-precipitated withdrawal signs in oxycodone-dependent mice with
profound anti-diarrheal and anti-transit effects. Currently, FDA-approved opioid-based (i.e., methadone
and buprenorphine) medications are readily used to treat opioid withdrawal, but their abuse liability
(Cicero and Inciardi, 2005) and inability to easily access them because they can only be prescribed,
hinders their potential. Moreover, the non-opioid-based medication, lofexidine/clonidine, that was
recently FDA-approved in 2018 can also be used to treat high blood pressure and heart rate, they too can
elicit hypotension, sedation, and cognitive impairment (Lobmaier et al., 2010) thereby limiting their
clinical use, also. Moreover, withdrawal-induced diarrhea can be deadly due to extreme dehydration
where suboptimal management programs are prevalent in jails (Mitchell et al., 2009; Darke et al., 2017)of
withdrawal in and loperamide is often used as an over-the-counter medication when access to prescription
medications are limited; however, abuse and toxicity of loperamide have been on the rise (Miller et al.,
2017; Vakkalanka et al., 2017). Thus, alternative withdrawal medications are needed with reduced side
effect profiles. CB1 receptor PAMs offer a potential alternative treatment for withdrawal-induced
diarrhea.
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Future studies, however, need to determine whether CB1 receptor PAMs attenuate spontaneous
withdrawal (Ramesh et al., 2013) or other aspects of withdrawal such as affective withdrawal which
measures psychological withdrawal symptoms, such as motivational components assessed in the
conditioned place aversion paradigm (Gamage et al., 2015). Furthermore, future studies should
investigate whether ZCZ011 influences withdrawal-induced secretion and motility in isolated tissue
models and the discern the underlying downstream cellular signaling mechanisms. In addition, because
combinations of MAGL and FAAH inhibitors produce additive anti-withdrawal effects (Ramesh et al.,
2013), ZCZ011 and MAGL inhibition produce enhanced gastroprotective effects (Trexler et al., 2019),
and GAT211 synergizes with MAGL inhibitors and morphine to produce antinociceptive effects (Slivicki
et al., 2017, 2020), further research can focus on combining CB1 receptor PAMs with MAGL and FAAH
inhibitors, as well as opioids, in precipitated and spontaneous withdrawal models. Moreover, while CB1
receptor PAMs are unlikely to replace opioid-based anti-withdrawal medications, they may be a
promising adjunct medication to buprenorphine, methadone, and/or lofexidine because CB1 receptor
PAMs elicit minimal pre-clinical side effects. The finding that inhibition of small intestinal transit by
ZCZ011 develops tolerance drives future research to investigate whether anti-transit/anti-withdrawal
effects are diminished or maintained during opioid withdrawal. In conclusion, the activation of CB1
receptors using CB1 receptor PAMs may be a potentially effective strategy to attenuate opioid withdrawal
signs with a reduced side effect profile, but further studies to determine whether tolerance develops
during opioid withdrawal is needed.
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